阅读说明：本技术 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子 (Bispecific antigen binding molecules comprising lipocalin muteins ) 是由 C·克劳斯 C·费拉拉·科勒 C.克雷恩 P·尤马纳 于 2020-04-08 设计创作，主要内容包括：本发明涉及能够二价结合到4-1BB并单价结合到靶细胞抗原的双特异性抗原结合分子及其在治疗癌症或感染性疾病中的用途,所述双特异性抗原结合分子包含两个(两种)能够特异性结合到4-1BB的脂质运载蛋白突变蛋白。(The present invention relates to bispecific antigen binding molecules capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising two (two) lipocalin muteins capable of specific binding to 4-1BB, and their use in the treatment of cancer or infectious diseases.)

1. A bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising

(a) An antigen binding domain capable of specifically binding to a target cell antigen,

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of said lipocalin muteins is fused to the C-terminus of said first subunit of said Fc domain and the other is fused to the C-terminus of said second subunit of said Fc domain.

2. The bispecific antigen-binding molecule of claim 1, wherein each of the lipocalin muteins capable of specifically binding to 4-1BB is derived from mature human neutrophil gelatinase-associated lipocalin (hunGAL) of SEQ ID NO: 1.

3. The bispecific antigen binding molecule of claim 1 or 2, wherein each of the lipocalin muteins capable of specifically binding to 4-1BB comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2, wherein one or more of the following amino acids are mutated as follows:

(a) Q at position 20 is replaced by R, or

(b) N at position 25 is replaced by Y or D, or

(c) H at position 28 is replaced by Q, or

(d) Q at position 36 is replaced by M, or

(e) I at position 40 is replaced by N, or

(f) R at position 41 is replaced by L or K, or

(g) E at position 44 is replaced by V or D, or

(h) K at position 46 is replaced by S and the amino acids at positions 47 to 49 are deleted, or

(i) I at position 49 is replaced by H, N, V or S, or

(j) M at position 52 is replaced by S or G, or

(k) K at position 59 is replaced by N, or

(l) D at position 65 is replaced by N, or

(M) M at position 68 is replaced by D, G or A, or

(n) K at position 70 is replaced by M, T, A or S, or

(o) F at position 71 is replaced by L, or

(p) D at position 72 is replaced by L, or

(q) M at position 77 is replaced by Q, H, T, R or N, or

(s) D at position 79 is replaced by I or A, or

(t) I at position 80 is replaced by N, or

(u) W at position 81 is replaced by Q, S or M, or

(v) T at position 82 is replaced by P, or

(w) F at position 83 is replaced by L, or

(y) F at position 92 is replaced by L or S, or

L at (z) position 94 is replaced by F, or

K at (za) position 96 is replaced by F, or

(zb) F at position 100 is replaced by D, or

(zc) replacement of P by L at position 101, or

(zd) replacement of H at position 103 by P, or

S at (ze) position 106 is replaced by Y, or

(zf) F at position 122 is replaced by Y, or

(zg) F at position 125 is replaced by S, or

(zh) F at position 127 is replaced by I, or

E at (zi) position 132 is replaced by W, or

(zj) Y at position 134 is replaced by G.

4. The bispecific antigen binding molecule of any one of claims 1 to 3, wherein each of the lipocalin muteins capable of specifically binding to 4-1BB comprises an amino acid sequence selected from the group consisting of: SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18, SEQ ID NO 19 and SEQ ID NO 20.

5. The bispecific antigen binding molecule of any one of claims 1 to 4, wherein each of the lipocalin muteins capable of specifically binding to 4-1BB comprises the amino acid sequence of SEQ ID NO 2.

6. The bispecific antigen binding molecule of any one of claims 1 to 5, wherein the Fc domain comprises a knob and hole modification that facilitates association of the first and second subunits of the Fc domain.

7. The bispecific antigen binding molecule of any one of claims 1 to 6, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor, particularly to an Fcyreceptor.

8. The bispecific antigen binding molecule of any one of claims 1 to 7, wherein the Fc domain is an IgG1 Fc domain comprising the amino acid substitutions L234A, L235A and P329G (EU numbering according to Kabat).

9. The bispecific antigen binding molecule of any one of claims 1 to 8, wherein the antigen binding domain capable of specifically binding to a target cell antigen is a Fab fragment capable of specifically binding to a target cell antigen.

10. The bispecific antigen binding molecule of any one of claims 1 to 9, wherein the Fab fragment capable of specifically binding to a target cell antigen is a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP).

11. The bispecific antigen binding molecule of any one of claims 1 to 10, wherein the Fab fragment capable of specific binding to Fibroblast Activation Protein (FAP) comprises:

(a) heavy chain variable region (V) _HFAP) comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 23; and light chain variable region (V)_LFAP) comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 26; or

(b) Heavy chain variable region (V)_HFAP) comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 31; and light chain variable region (V)_LFAP) comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 34.

12. The bispecific antigen binding molecule of any one of claims 1 to 11, wherein the Fab fragment capable of specific binding to Fibroblast Activation Protein (FAP) comprises:

(a) heavy chain variable region (V)_HFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 27; and light chain variable region (V) _LFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 28; or

(b) Heavy chain variable region (V)_HFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 35; and light chain variable region (V)_LFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 36.

13. The bispecific antigen binding molecule of any one of claims 1 to 12, comprising:

a first heavy chain of SEQ ID NO 37, a second heavy chain of SEQ ID NO 38 and a light chain of SEQ ID NO 39.

14. The bispecific antigen binding molecule of any one of claims 1 to 9, wherein the Fab fragment capable of specifically binding to a target cell antigen is a Fab fragment capable of specifically binding to HER 2.

15. The bispecific antigen binding molecule of any one of claims 1 to 9 or claim 14, wherein the Fab fragment capable of specific binding to HER2 comprises:

(a) a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:40, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:41, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 42; and a VL domain comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:43, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:44, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 45; or

(b) A VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:48, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:49, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 50; and a VL domain comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:51, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:52, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 53; or

(c) A VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:56, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:57, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 58; and a VL domain comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:59, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:60, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 61.

16. The bispecific antigen binding molecule of any one of claims 1 to 9 or claim 14 or 15, wherein the Fab fragment capable of specific binding to HER2 comprises:

(a) heavy chain variable region (V)_HHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 46; and light chain variable region (V) _LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 47; or

(b) Heavy chain variable region (V)_HHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 54; and light chain variable region (V)_LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 55; or

(c) Heavy chain variable region (V)_HHER2) comprising an amino acid sequence at least about 95%, 96%, 97% identical to that of SEQ ID NO 62(ii) an amino acid sequence that is% identical, 98%, 99% or 100%; and light chain variable region (V)_LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 63.

17. The bispecific antigen binding molecule of any one of claims 1 to 9 or 14 to 17, comprising a first heavy chain of SEQ ID No. 64, a second heavy chain of SEQ ID No. 65 and a light chain of SEQ ID No. 66.

18. An isolated nucleic acid encoding the bispecific antigen binding molecule of any one of claims 1 to 17.

19. A vector, in particular an expression vector, comprising the isolated nucleic acid according to claim 18.

20. A host cell comprising the nucleic acid of claim 18 or the vector of claim 19.

21. A method of producing the bispecific antigen binding molecule of any one of claims 1 to 17, comprising culturing the host cell of claim 19 under conditions suitable for expression of the bispecific antigen binding molecule.

22. The method of claim 21, further comprising recovering the bispecific antigen binding molecule from the host cell.

23. A pharmaceutical composition comprising the bispecific antigen binding molecule of any one of claims 1 to 17 and at least one pharmaceutically acceptable excipient.

24. The pharmaceutical composition of claim 23, further comprising an additional therapeutic agent.

25. The bispecific antigen binding molecule of any one of claims 1 to 17 or the pharmaceutical composition of claim 23 for use as a medicament.

26. The bispecific antigen binding molecule of any one of claims 1 to 17 or the pharmaceutical composition of claim 23 for use in the treatment of cancer or an infectious disease.

27. Use of the bispecific antigen binding molecule of any one of claims 1 to 17 for the manufacture of a medicament for the treatment of cancer or an infectious disease.

28. A method of treating an individual having cancer or an infectious disease, comprising administering to the individual an effective amount of the bispecific antigen binding molecule of any one of claims 1 to 17 or the pharmaceutical composition of claim 21.

29. A method of up-regulating or prolonging cytotoxic T cell activity in an individual having cancer comprising administering to the individual an effective amount of the bispecific antigen binding molecule of any one of claims 1 to 17 or the pharmaceutical composition of claim 23.

Technical Field

The present invention relates to bispecific antigen binding molecules capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising two (two) lipocalin muteins capable of specific binding to 4-1BB, and their use in the treatment of cancer or infectious diseases. The invention further relates to methods of producing these molecules and methods of using them.

Background

4-1BB (CD137) is a member of the TNF receptor superfamily, which was first identified as an inducible molecule expressed by T cell activation (Kwon and Weissman,1989, Proc Natl Acad Sci USA 86, 1963-. Subsequent studies have shown that many other immune cells also express 4-1BB, including NK cells, B cells, NKT cells, monocytes, neutrophils, mast cells, Dendritic Cells (DCs) and cells of non-hematopoietic origin, such as endothelial cells and smooth muscle cells (Vinay and Kwon,2011, Cell Mol Immunol 8, 281-. Expression of 4-1BB in different cell types is mostly inducible and driven by various stimulatory signals such as T Cell Receptor (TCR) or B cell receptor triggering and receptor-induced signaling by co-stimulatory molecules or pro-inflammatory cytokines (Diehl et al, 2002, J Immunol 168, 3755-2762; Zhang et al, 2010, Clin Cancer Res 13, 2758-2767).

4-1BB ligand (4-1BBL or CD137L) was identified in 1993 (Goodwin et al, 1993, Eur J Immunol 23, 2631-2641). Expression of 4-1BBL has been shown to be limited to professional Antigen Presenting Cells (APC) such as B cells, DCs and macrophages. Inducible expression of 4-1BBL is characteristic of T cells (including both. alpha. beta. and. gamma. delta. T cell subsets) and endothelial cells (Shao and Schwarz,2011, J Leukoc Biol 89, 21-29).

Activation of T cells (CD 4) by co-stimulation of the 4-1BB receptor (e.g., by 4-1BBL ligation)⁺And CD8⁺Both subgroups) within a plurality of messagesThe signal transduction cascade strongly enhances the activation of T cells (Bartkowiak and Curran,2015, Front Oncol 5,117). In combination with TCR triggering, agonistic 4-1 BB-specific antibodies enhance T cell proliferation, stimulate lymphokine secretion and reduce T lymphocyte sensitivity to activation-induced cell death (Snell et al, 2011, Immunol Rev 244, 197-217). This mechanism is further advanced as the first demonstration of cancer immunotherapy concept. Potent anti-tumor effects have been produced in preclinical models in which agonistic antibodies against 4-1BB are administered to tumor-bearing mice (Melero et al, 1997, Nat Med 3, 682-685). Later, there is increasing evidence that 4-1BB generally only shows its efficacy as an anti-tumor agent when administered in combination with other immunomodulatory compounds, chemotherapeutic agents, tumor-specific vaccination or radiotherapy (Bartkowiak and Curran,2015, Front Oncol 5,117).

The signaling of the TNFR superfamily requires cross-linking of trimeric ligands to engage with receptors, as does the 4-1BB agonistic antibodies that require wild-type Fc binding (Li and Ravetch,2011, Science333, 1030-1034). However, systemic administration of 4-1 BB-specific agonistic antibodies with functionally active Fc domains resulted in CD8 associated with hepatotoxicity⁺Influx of T cells (dublot et al, 2010, Cancer Immunol Immunother 59,1223-1233), which were attenuated or significantly improved in the absence of functional Fc receptors in mice. In the clinic, Fc competent 4-1BB agonistic Ab (BMS-663513) (NCT00612664) caused grade 4 hepatitis, leading to termination of the experiment (Simeone and Ascieto, 2012, J immunotoxin 9, 241-. Thus, there is a need for effective and safer 4-1BB agonists.

Human fibroblast activation protein (FAP; GenBank accession AAC51668), also known as Seprase, is an integrated membrane serine peptidase of 170kDa (EC 3.4.21. B28). FAP together with dipeptidyl peptidase IV (also known as CD 26; GenBank accession number P27487), a closely related cell surface enzyme, and other peptidases belongs to the family of dipeptidyl peptidases IV (Yu et al, FEBS J277, 1126-1144 (2010)). It is a homodimer containing two N-glycosylated subunits with a large C-terminal extracellular domain in which the catalytic domain of the enzyme is located (Scanlan et al, Proc Natl Acad Sci USA 91,5657-5661 (1994)). FAP is in its glycosylated form, having both post-prolyl dipeptidyl peptidase and gelatinase activities (Sun et al, Protein Expr Purif 24,274-281 (2002)). Due to its expression in many common cancers and its limited expression in normal tissues, FAP has been considered a promising antigenic target for imaging, diagnosis and treatment of a variety of cancers. Thus, a variety of monoclonal antibodies have been generated against FAP (raised) for research, diagnostic and therapeutic purposes.

Human epidermal growth factor receptor-2 (HER 2; ErbB2) is a receptor tyrosine kinase and is a member of the Epidermal Growth Factor Receptor (EGFR) family of transmembrane receptors. HER2 is overexpressed in a range of tumor types and is associated with the development and progression of disease. It is associated with poor prognosis. For example, overexpression of HER2 was observed in approximately 30% of human breast cancers and was associated with invasive growth and poor clinical outcome associated with these tumors (Slamon et al, (1987) Science 235: 177-182).

Humanized anti-HER 2 monoclonal antibody trastuzumab (CAS 180288-69-1, Ab. TM.),huMAb4D5-8, rhuMAb HER2, gene taxol) targeted the extracellular domain of HER2 (US 5677171; US 5821337; US 6054297; US 6165464; US 6339142; US 6407213; US 6639055; US 6719971; US 6800738; US 7074404; coissens et al, (1985) Science 230: 1132-9; slamon et al, (1989) Science 244: 707-12; slamon et al, (2001) New Engl. J. Med.344: 783-. Trastuzumab has been shown to inhibit the proliferation of human tumor cells that overexpress HER2 and is a mediator of antibody-dependent cellular cytotoxicity ADCC (Hudziak et al, (1989) Mol Cell Biol 9: 1165-72; Lewis et al, (1993) Cancer Immunol Immunother; 37: 255-63; Baselga et al, (1998) Cancer Res.58: 2825-2831; Hotaling et al, (1996) [ abstract ] ]Annular Meeting Am Assoc Cancer Res; 471 parts by weight; peg ram MD, et al, (1997) [ abstract ]]Proc Am Assoc Cancer Res; 38: 602; sliwkowski et al, (1999) sensiars in Oncology 26(4), Suppl 12: 60-70; yarden Y. and Sliwkowski, M. (2001) Nature Reviews: Molecular Cell Biology, Macmillan Magazines, Ltd., Vol.2: 127-.

Trastuzumab (Gentek. RTM.) was approved in 1998 for the treatment of patients with metastatic breast cancer overexpressing HER2 (Baselga et al, (1996) J.Clin.Oncol.14: 737-744). In 2006, FDA approvalAs part of a treatment regimen containing doxorubicin, cyclophosphamide and paclitaxel, for the adjuvant treatment of patients with HER2 positive, lymph node positive breast cancer.

Pertuzumab (also known as recombinant humanized monoclonal antibody 2C4, rhuMAb 2C4,Genentech, Inc, South San Francisco) is another antibody therapy targeting HER 2. Pertuzumab is a Her Dimerization Inhibitor (HDI) and functions to inhibit the ability of Her2 to form active heterodimers or homodimers with other Her receptors such as EGFR/HERl, Her2, Her3, and Her 4. See, e.g., Harari and Yarden Oncogene 19:6102-14 (2000); yarden and Sliwkowski. Nat Rev Mol Cell Biol 2:127-37 (2001); sliwkowski, Nat Struct Biol 10:158-9 (2003); cho et al, Nature 421:756-60 (2003); and Malik et al, Pro Am Soc Cancer Res 44:176-7 (2003); US 7560111. The first was approved in 2012 for the treatment of patients with advanced or late (metastatic) HER2 positive breast cancer in combination with trastuzumab and docetaxel. At the same time, combination therapy with trastuzumab and pertuzumab is also approved for neoadjuvant (pre-operative) treatment of HER2 positive, locally advanced, inflammatory or early breast cancer and adjuvant (post-operative) treatment of HER2 positive Early Breast Cancer (EBC) with high risk of recurrence. Perjethe mechanism of action of ta and Herceptin is thought to complement each other, as both bind to HER2 receptor, but bind to different places. The combination of Perjeta and Herceptin is believed to provide a more comprehensive dual block of the HER signaling pathway, thereby preventing tumor cell growth and survival.

Bispecific bivalent HER2 antibodies against domains II, III and IV of human ErbB2 are disclosed in WO 2012/143523. Bispecific HER-2 antibodies comprising optimized variants of the antibodies rhuMab 2C4 and hu4D5, called herceptin (herceptirg), have been described in WO 2015/091738. Although the therapeutic efficacy of trastuzumab in breast cancer is well documented, there are still many patients who cannot benefit from trastuzumab because of drug resistance. Given the lack of effective anti-HER 2 therapy in certain cancers that express low levels of HER2, resistance to current therapies, and the prevalence of HER 2-related cancers, new therapies are needed to treat such cancers.

The bispecific antigen binding molecules of the invention are characterized in that they bind to a target cell antigen, in particular a tumor target, such as FAP or HER2, and in that they bind specifically to 4-1 BB. The antigen binding domain capable of specifically binding to 4-1BB is represented by a lipocalin mutein. Lipocalin muteins (anticalins) are non-antibody scaffolds derived from native human lipocalins and offer several benefits, such as small size, stable folding and apparent target specificity (Rothe C, Skerra a., BioDrugs 2018,32, 233-. Lipocalin muteins specific for CD137(4-1BB) are described in WO 2016/177762 and WO 2018/087108. Fusion proteins comprising a binding specificity for CD137 and a binding specificity for HER2/neu are disclosed in WO 2016/177802. Based on their Fc domains, these fusion proteins form symmetric antibody-like dimers in which two valencies bind to CD137 and HER 2.

The binding antigen-binding molecules of the invention are characterized in that they provide monovalent binding to a target cell antigen and bivalent binding to 4-1 BB. Surprisingly, it has been found that a ratio of tumor target binding to effector cell target binding of 1:2 results in improved cross-linking of 4-1BB agonists on effector cells, stronger signaling downstream of the 4-1BB receptor, and thus improved therapeutic efficacy.

Disclosure of Invention

In one aspect, the invention provides a bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising

(a) An antigen binding domain capable of specifically binding to a target cell antigen,

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of said lipocalin muteins is fused to the C-terminus of said first subunit of an Fc domain and the other is fused to the C-terminus of said second subunit of said Fc domain.

In a particular aspect, the invention provides a bispecific antigen binding molecule, wherein each of the lipocalin muteins capable of specifically binding to 4-1BB is a lipocalin mutein derived from mature human neutrophil gelatinase-associated lipocalin (huNGAL) of SEQ ID NO: 1.

In a further aspect, the present invention provides a bispecific antigen binding molecule as defined above, wherein each of the lipocalin muteins capable of specifically binding to 4-1BB comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 wherein one or more of the following amino acids are mutated as follows:

(a) Q at position 20 is replaced by R, or

(b) N at position 25 is replaced by Y or D, or

(c) H at position 28 is replaced by Q, or

(d) Q at position 36 is replaced by M, or

(e) I at position 40 is replaced by N, or

(f) R at position 41 is replaced by L or K, or

(g) E at position 44 is replaced by V or D, or

(h) K at position 46 is replaced by S and the amino acids at positions 47 to 49 are deleted, or

(i) I at position 49 is replaced by H, N, V or S, or

(j) M at position 52 is replaced by S or G, or

(k) K at position 59 is replaced by N, or

(l) D at position 65 is replaced by N, or

(M) M at position 68 is replaced by D, G or A, or

(n) K at position 70 is replaced by M, T, A or S, or

(o) F at position 71 is replaced by L, or

(p) D at position 72 is replaced by L, or

(q) M at position 77 is replaced by Q, H, T, R or N, or

(s) D at position 79 is replaced by I or A, or

(t) I at position 80 is replaced by N, or

(u) W at position 81 is replaced by Q, S or M, or

(v) T at position 82 is replaced by P, or

(w) F at position 83 is replaced by L, or

(y) F at position 92 is replaced by L or S, or

L at (z) position 94 is replaced by F, or

K at (za) position 96 is replaced by F, or

(zb) F at position 100 is replaced by D, or

(zc) replacement of P by L at position 101, or

(zd) replacement of H at position 103 by P, or

S at (ze) position 106 is replaced by Y, or

(zf) F at position 122 is replaced by Y, or

(zg) F at position 125 is replaced by S, or

(zh) F at position 127 is replaced by I, or

E at (zi) position 132 is replaced by W, or

(zj) Y at position 134 is replaced by G.

In one aspect, a lipocalin mutein capable of specifically binding to 4-1BB comprises the amino acid sequence of SEQ ID NO 2, wherein 4 to 10 amino acids have been mutated as defined above. In one aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises an amino acid sequence selected from the group consisting of: SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18, SEQ ID NO 19 and SEQ ID NO 20. In one aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises an amino acid sequence selected from the group consisting of: 2, 3, 4, 5, 6, 7, 8, 9 and 10. In a further aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises an amino acid sequence selected from the group consisting of: 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20. In one aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises the amino acid sequence of SEQ ID NO. 2. In one aspect, the lipocalin muteins all comprise the same amino acid sequence.

In one aspect, the Fc domain is an IgG, in particular an IgG1 Fc domain or an IgG4 Fc domain. More specifically, the Fc domain is an IgG1 Fc domain. In a particular aspect, the Fc domain comprises a modification that facilitates association of the first subunit and the second subunit of the Fc domain. In a particular aspect, there is provided a bispecific antigen binding molecule, wherein the Fc domain comprises a knob-and-hole (knob-and-hole) modification that facilitates association of a first subunit and a second subunit of the Fc domain. In a particular aspect, there is provided a bispecific antigen binding molecule, wherein the first subunit of the Fc domain comprises amino acid substitutions S354C and T366W (EU numbering according to Kabat) and the second subunit of the Fc domain comprises amino acid substitutions Y349C, T366S, L368A and Y407V (EU numbering according to Kabat).

In another aspect, the present invention relates to a bispecific antigen binding molecule as defined herein above, comprising (b) an Fc domain comprising a first subunit and a second subunit capable of stable association, wherein said Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor, in particular to an fey receptor. In particular, the Fc domain comprises amino acid substitutions at positions 234 and 235 (EU numbering according to Kabat) and/or 329 (EU numbering according to Kabat) of the IgG heavy chain. In particular, a bispecific antigen binding molecule is provided wherein the Fc domain is a human IgG1 Fc domain comprising the amino acid substitutions L234A, L235A and P329G (EU numbering according to Kabat). In a further aspect, there is provided a bispecific antigen binding molecule, wherein the Fc domain is a human IgG4 Fc domain comprising one or more amino acid substitutions selected from the group consisting of: S228P, N297A, F234A and L235A (EU numbering according to Kabat), in particular amino acid substitutions S228P, F234A and L235A (EU numbering according to Kabat), more in particular amino acid substitution S228P (EU numbering according to Kabat).

In one aspect, the invention provides a bispecific antigen binding molecule comprising two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of the lipocalin muteins is fused via a peptide linker to the C-terminus of a first subunit of the Fc domain and the other is fused via a peptide linker to the C-terminus of a second subunit of the Fc domain. In one aspect, the peptide linker has an amino acid sequence selected from the group consisting of: SEQ ID NO 75, SEQ ID NO 76, SEQ ID NO 77, SEQ ID NO 78, SEQ ID NO 79, SEQ ID NO 80, SEQ ID NO 81, SEQ ID NO 82, SEQ ID NO 83, SEQ ID NO 84, SEQ ID NO 85, SEQ ID NO 86, SEQ ID NO 87, SEQ ID NO 88, SEQ ID NO 89, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 115, SEQ ID NO 116, SEQ ID NO 117, SEQ ID NO 118, SEQ ID NO 119, SEQ ID NO 120 and SEQ ID NO 121. In one aspect, the peptide linker has an amino acid sequence selected from the group consisting ofThe method comprises the following steps: SEQ ID NO 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88 and 89. Specifically, the peptide linker has the amino acid sequence of SEQ ID NO:78, i.e., (G) ₄S)₃。

In a particular aspect, the invention provides a bispecific antigen binding molecule capable of divalent binding to 4-1BB and monovalent binding to a target cell antigen, wherein the antigen binding domain capable of specific binding to the target cell antigen is a Fab fragment capable of specific binding to the target cell antigen. Accordingly, the present invention provides a bispecific antigen binding molecule comprising:

(a) a Fab fragment capable of specifically binding to a target cell antigen;

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of said lipocalin muteins is fused to the C-terminus of said first subunit of an Fc domain and the other is fused to the C-terminus of said second subunit of said Fc domain.

In one aspect, bispecific antigen binding molecules are provided that are capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, wherein the target cell antigen is Fibroblast Activation Protein (FAP). Accordingly, there is provided a bispecific antigen binding molecule as defined above, wherein the Fab fragment capable of specifically binding to a target cell antigen is a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP).

In one aspect, a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP) comprises: (a) heavy chain variable region (V)_HFAP) comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 23; and light chain variable region (V)_LFAP) comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 26; or (b) a heavy chain variable region (V)_HFAP) comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 31; and light chain variable region (V)_LFAP) comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 34. In particular, a Fab fragment capable of specifically binding to FAP comprises: heavy chain variable region (V)_HFAP) comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 23; and light chain variable region (V) _LFAP) comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 26.

In one aspect, a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP) comprises: (a) heavy chain variable region (V)_HFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 27; and light chain variable region (V)_LFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 28; or (b) a heavy chain variable region (V)_HFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 35; and light chain variable region (V)_LFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 36. In particular, a Fab fragment capable of specifically binding to FAP comprises: heavy chain variable region (V)_HFAP) comprising the amino acid sequence of SEQ ID NO 27 to And light chain variable region (V)_LFAP) comprising the amino acid sequence of SEQ ID NO 28; or (b) a heavy chain variable region (V)_HFAP) comprising the amino acid sequence of SEQ ID NO 35, and a light chain variable region (V)_LFAP) comprising the amino acid sequence of SEQ ID NO: 36. More specifically, a Fab fragment capable of specifically binding to FAP comprises: heavy chain variable region (V)_HFAP) comprising the amino acid sequence of SEQ ID NO 27; and light chain variable region (V)_LFAP) comprising the amino acid sequence of SEQ ID NO 28.

In one aspect, the invention provides a bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to FAP comprising a first heavy chain of SEQ ID No. 37, a second heavy chain of SEQ ID No. 38, and a heavy chain of SEQ ID NO: 39.

In another aspect, bispecific antigen binding molecules are provided that are capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, wherein the target cell antigen is HER 2. Accordingly, there is provided a bispecific antigen binding molecule as defined above, wherein the Fab fragment capable of specifically binding to a target cell antigen is a Fab fragment capable of specifically binding to HER 2.

In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: (a) a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:40, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:41, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 42; and a VL domain comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:43, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:44, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 45; or (b) a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:48, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:49, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 50; and a VL domain comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:51, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:52, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 53; or (c) a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:56, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:57, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 58; and a VL domain comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:59, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:60, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:40, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:41, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 42; and a VL domain comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:43, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:44, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 45. In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:48, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:49, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 50; and a VL domain comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:51, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:52, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 53.

In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: (a) heavy chain variable region (V)_HHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 46; and light chain variable region (V)_LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 47; or (b) a heavy chain variable region (V)_HHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 54; and light chain variable region (V)_LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 55;or (c) a heavy chain variable region (V)_HHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 62; and light chain variable region (V)_LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 63. In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: (a) heavy chain variable region (V) _HHER2) comprising the amino acid sequence of SEQ ID NO:46, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO:47, or (b) a heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:54, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO:55, or (c) a heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:62, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO: 63. In a particular aspect, a Fab fragment capable of specifically binding to HER2 comprises: heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:46, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO: 47. In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:54, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO: 55.

In one aspect, the invention provides a bispecific antigen binding molecule capable of divalent binding to 4-1BB and monovalent binding to HER2, comprising a first heavy chain of SEQ ID NO:64, a second heavy chain of SEQ ID NO:65, and a heavy chain of SEQ ID NO: 66, or a light chain of (b).

According to another aspect of the present invention there is provided an isolated nucleic acid encoding a bispecific antigen binding molecule as defined herein above. The present invention further provides a vector, in particular an expression vector, comprising an isolated nucleic acid of the present invention; and provides a host cell comprising the isolated nucleic acid or vector of the invention. In some embodiments, the host cell is a eukaryotic cell, particularly a mammalian cell.

In another aspect, a method for producing a bispecific antigen binding molecule of the invention is provided, comprising culturing a host cell of the invention under conditions suitable for expression of the bispecific antigen binding molecule, and further comprising recovering the bispecific antigen binding molecule from the host cell. The invention also encompasses bispecific antigen binding molecules produced by the methods of the invention.

Further provided are pharmaceutical compositions comprising the bispecific antigen binding molecules of the invention and at least one pharmaceutically acceptable excipient. In another aspect, a pharmaceutical composition is provided comprising a bispecific antigen binding molecule of the invention and at least one pharmaceutically acceptable excipient, further comprising an additional therapeutic agent, such as a chemotherapeutic agent and/or other agent for cancer immunotherapy.

The invention also encompasses a bispecific antigen binding molecule of the invention or a pharmaceutical composition of the invention for use as a medicament. In one aspect, there is provided a bispecific antigen binding molecule of the invention or a pharmaceutical composition of the invention for use in the treatment of a disease in an individual in need thereof. In a specific aspect, there is provided a bispecific antigen binding molecule of the invention or a pharmaceutical composition of the invention for use in the treatment of cancer or an infectious disease. In another aspect, there is provided a bispecific antigen binding molecule of the invention or a pharmaceutical composition of the invention for use in up-regulating or prolonging cytotoxic T cell activity.

Further, there is provided the use of a bispecific antigen binding molecule of the invention for the manufacture of a medicament for the treatment of a disease in an individual in need thereof, in particular for the treatment of cancer or an infectious disease, and a method of treating a disease in an individual comprising administering to said individual a therapeutically effective amount of a composition comprising a bispecific antigen binding molecule as disclosed herein, said composition being in a pharmaceutically acceptable form. In one aspect, the disease is a cancer or an infectious disease. In a particular aspect, the disease is cancer. Also provided is a method of up-regulating or prolonging cytotoxic T cell activity in an individual having cancer comprising administering to the individual an effective amount of a bispecific antigen binding molecule of the invention or a pharmaceutical composition of the invention. In any of the above embodiments, the individual is preferably a mammal, in particular a human.

Drawings

FIGS. 1A and 1B show a bispecific antigen binding molecule comprising two fusion proteins capable of specifically binding to 4-1BB, which is targeted to a Tumor Antigen (TA). In FIG. 1A, the bispecific antigen binding molecule is bivalent to both the tumor target antigen (TA1) and to 4-1BB, also referred to as the 2+2 format. In FIG. 1B, a bispecific antigen binding molecule of the invention is shown, which is monovalent for TA1 and bivalent for 4-1BB, also referred to as the 1+2 format. Both antigen binding molecules are in the huIgG 1P 329GLAL format.

Figure 2A shows the setup of SPR experiment for simultaneous binding to FAP targeting a bispecific antigen binding molecule comprising two fusion proteins capable of specific binding to 4-1BB (TA1 is FAP). In FIGS. 2B and 2C, the simultaneous binding of bispecific anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA antigen-binding molecule (analyte 1) with immobilized human 4-1BB and human FAP (analyte 2) is shown. The simultaneous binding of bispecific bivalent 2+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA (referred to as 2+2) is shown in fig. 2B. FIG. 2C shows the simultaneous binding of bispecific monovalent 1+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA (designated 1+2) to human 4-1BB and human FAP.

Figure 3A shows the setup of SPR experiments for simultaneous binding to HER2 targeting bispecific 4-1BB lipocalin (TA1 is HER 2). In FIG. 3B, the simultaneous binding of bispecific anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (analyte 1) in 2+2 and 1+2 formats to immobilized human 4-1BB and human HER2 (analyte 2) is shown.

Figure 4 shows binding of FAP-targeted 4-1BB lipocalin to FAP expressed on human FAP-expressing cell line NIH/3T3-huFAP clone 19 cells. Concentrations of bispecific bivalent 2+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA (designated FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 2+2, open downward triangles and dashed lines) or bispecific monovalent 1+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA (designated FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 1+2, filled black triangles and lines) or controls thereof were plotted against the geometric mean of fluorescence intensity (gMFI) of PE-conjugated secondary detection antibody. Baseline correction was performed for all values by subtracting baseline values for blank controls (e.g., no primary detection antibody, only secondary detection antibody included). Constructs containing only FAP binding domains, such as FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 2+2 (open downward triangles and dashed lines), FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 1+2 (filled black triangles and lines), FAP (4B9) x 4-1BB lipocalin huIgG4 SP 2+2 (half filled black circles and lines-dashed lines), or FAP (4B9) huIgG1 PG LALA antibody (grey stars and lines) bind efficiently to FAP expressing cells.

FIG. 5 shows the binding of FAP-targeted 4-1BB lipocalin to the reporter cell line Jurkat-hu4-1BB-NFkB-luc2 expressing human 4-1BB (CD 137). Concentrations of bispecific bivalent 2+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA (designated FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 2+2, open downward triangles and dashed lines) or bispecific monovalent 1+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA (designated FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA1+2, filled black triangles and lines) or controls thereof were plotted against the geometric mean of fluorescence intensity (gMFI) of PE-conjugated secondary detection antibody. Baseline correction was performed for all values by subtracting baseline values for blank controls (e.g., no primary detection antibody, only secondary detection antibody included). Anti-4-1 BB (20H4.9) x anti-FAP (4B9)2+ 1H 2H (black filled circles and lines) bound to 4-1BB similarly to its control anti-4-1 BB (20H4.9) huIgG 1P 329G LALA (grey stars and lines).

Activation of the NF-. kappa.B signaling pathway by NF-. kappa.B mediated luciferase activity in the reporter cell line was shown in FIGS. 6A to 6C by measuring Jurkat-hu4-1 BB-NF-. kappa.B-luc 2. To test the functionality of bispecific bivalent 2+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA (named FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 2+2, open downward black triangles and dashed lines) or bispecific monovalent 1+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA (named FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA1+2, solid black triangles and lines) or control molecules specific bivalent 2+2 anti-FAP, anti-4-1 BB lipocalin huIgG4 PGLALA (named FAP (4B9) x 4-1 solid lipocalin huIgG4 SP 2+2, semi-black hexamers (hexamers, hexagons) and line-dashed lines) or single specific control molecules, NIWM 4-266-1 BB lipocalin huIgG4 SP 2+2, NIWM-3619 or NIWM H3H 3619, incubate the reporter cell line Jurkat-hu4-1BB-NF kappa B-luc2 at various titers. In the absence of FAP-expressing cells, all molecules failed to activate 4-1BB signaling because no cross-linking occurred. In the presence of FAP-expressing cells, only bispecific molecules that bind FAP and 4-1BB can lead to NF κ B activation on the reporter cell line. The results in the absence of FAP + cells are shown in fig. 6A, in the presence of the human FAP expressing cell line WM-266-4, in fig. 6B, or in the presence of the human FAP expressing cell line NIH/3T3-huFAP clone 19, in fig. 6C.

Figures 7A and 7B show HER2 binding of 4-1BB lipocalin-targeted to HER2 expressed on the cell surface by the human gastric cancer cell line NCI-N87 (figure 7B) or the breast cancer cell line KPL4 (figure 7A). Concentrations of bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1 PGLALA (referred to as HER2(TRAS) x4-1BB lipocalin huIgG1 PG LALA 2+2, open black downward triangles, dashed lines) or bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1 PGLALA (referred to as HER2(TRAS) x4-1BB lipocalin huIgG1 PG LALA 1+2, black filled triangles and lines) or controls thereof were plotted against the geometric mean of fluorescence intensity (gMFI) of the PE-conjugated secondary detection antibody. Baseline correction was performed for all values by subtracting baseline values for blank controls (e.g., no primary detection antibody, only secondary detection antibody included). Constructs containing only HER2 binding domain, such as bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA (named HER2(TRAS) x4-1BB lipocalin huIgG1 PG LALA 2+2, open black downward triangles, dashed lines) or bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1 PGLALA (named HER2(TRAS) x4-1BB lipocalin huIgG1 PG LALA 1+2, black filled triangles and lines) or HER2(TRAS) huIgG1 PG LALA antibodies (stars and lines grey) or HER2(TRAS) x4-1BB lipocalin huIgG4 SP (black hemi-hexamers, black dashed lines) bound effectively to cells expressing HER 2.

FIG. 8 shows the binding of HER 2-targeted 4-1BB lipocalin to the reporter cell line Jurkat-hu4-1BB-NF κ B-luc2 expressing human 4-1BB (CD 137). Concentrations of bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1 PGLALA (designated HER2(TRAS) x 4-1BB lipocalin huIgG1 PG LALA 2+2, open downward triangles and dashed lines) or bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1 PGLALA (designated HER2(TRAS) x 4-1BB lipocalin huIgG1 PG LALA 1+2, filled black triangles and lines) or controls thereof were plotted against the geometric mean of fluorescence intensity (gMFI) of the PE-conjugated secondary detection antibody. Baseline correction was performed for all values by subtracting baseline values for blank controls (e.g., no primary detection antibody, only secondary detection antibody included).

Activation of the NF-. kappa.B signaling pathway by NF-. kappa.B-mediated luciferase activity in the reporter cell line was shown in FIGS. 9A to 9D by measuring Jurkat-hu4-1BB-NFkB-luc 2. To test the functionality of bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1 PG LALA (named HER2(TRAS) x 4-1BB lipocalin huIgG1 PG LALA 2+2, open black triangles and dashes downwards) or bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1 PGLALA (named HER2(TRAS) x 4-1BB lipocalin huIgG1 PG LALA 1+2, solid black triangles and lines) or control molecules bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB lipocalin huIgG4 SP (named HER2(TRAS) x 4-1BB lipocalin huIgG4 SP 2+2, half black hexamers and dashes) or control molecules SK, in the absence or presence of cell lines NCI-N87, KPL4 or Br-3 expressing HER2, incubate the reporter cell line Jurkat-hu4-1BB-NF kappa B-luc2 at various titers. In the absence of HER2 expressing cells, all molecules failed to activate 4-1BB signaling because no cross-linking occurred. In the presence of cells expressing HER2, only bispecific molecules that bind HER2 and 4-1BB resulted in NF κ B activation on the reporter cell line. The results in the absence of HER2+ cells are shown in figure 9A, in the presence of the HER2 expressing cell line SK-Br3 in figure 9B, in the presence of the HER2 expressing cell line KPL4 in figure 9C, or in the presence of the HER2 expressing cell line NCI-N87 in figure 9D.

Detailed Description

Definition of

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly used in the art to which this invention belongs. For the purpose of interpreting the specification, the following definitions will apply and, where appropriate, terms used in the singular will also include the plural and vice versa.

As used herein, the term "antigen binding molecule" refers in its broadest sense to a molecule that specifically binds to an antigenic determinant. Examples of antigen binding molecules are antibodies, antibody fragments and scaffold antigen binding proteins.

The term "antigen binding domain" refers to a portion of an antigen binding molecule that comprises a region that specifically binds to and is complementary to a portion or all of an antigen. In the case of large antigens, the antigen binding molecule may bind only to a specific part of the antigen, which part is called an epitope. The antigen binding domain may be provided by, for example, one or more variable domains (also referred to as variable regions). Preferably, the antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH), but it may also be provided by a scaffold antigen binding protein, in particular a lipocalin mutein.

As used herein, the term "antigen binding domain capable of specifically binding to a target cell antigen" or "moiety capable of specifically binding to a target cell antigen" refers to a polypeptide molecule that specifically binds to a target cell antigen. In one aspect, the antigen binding domain is capable of directing an entity attached thereto (e.g., a lipocalin mutein capable of specifically binding to 4-1 BB) to a target site, e.g., to a specific type of tumor cell carrying a target cell antigen. Antigen binding domains capable of specifically binding to a target cell antigen include antibodies and fragments thereof as further defined herein. In addition, moieties capable of specifically binding to a target cell antigen include scaffold antigen binding proteins as further defined herein. With respect to antibodies or fragments thereof, the term "antigen binding domain capable of specifically binding to a target cell antigen" includes antibody light chain variable regions (VL) and antibody heavy chain variable regions (VH).

As used herein, the term "Fab fragment capable of specifically binding to a target cell antigen" refers to a Fab molecule that specifically binds to a target cell antigen. In one aspect, the antigen binding portion is capable of activating signaling through its target cell antigen. In a particular aspect, the antigen binding portion is capable of directing the entity (e.g., lipocalin mutein) attached thereto to a target site, e.g., to a particular type of tumor cell or tumor stroma carrying the target cell antigen.

The term "antibody" herein is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen binding activity.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies (e.g., containing naturally occurring mutations or produced during the production of a monoclonal antibody preparation, such variants typically being present in minor amounts). In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed against a single determinant on the antigen.

As used herein, the term "monospecific" antibody refers to an antibody having one or more binding sites, each binding site binding to the same epitope of the same antigen. The term "bispecific" means that the antigen binding molecule is capable of specifically binding to at least two different antigenic determinants (targets). Typically, bispecific antigen binding molecules comprise two antigen binding sites, each of which is specific for a different antigenic determinant. In a particular aspect, a bispecific antigen binding molecule comprises three antigen binding sites, wherein two antigen binding sites have specificity for a first antigenic determinant and one antigen binding site has specificity for a second antigenic determinant. In certain embodiments, the bispecific antigen binding molecule is capable of binding two antigenic determinants simultaneously, particularly two antigenic determinants expressed on two distinct cells.

The term "valency" as used in this application denotes the presence of a specified number of binding sites in an antigen binding molecule. Thus, the terms "monovalent", "divalent", "tetravalent" and "hexavalent" indicate the presence of one binding site, two binding sites, four binding sites and six binding sites, respectively, in an antigen binding molecule.

The term "monovalent to an antigen" as used herein means that the antigen is present only in the antigen binding moleculeOne isA binding site. The term "monovalent to a target cell antigen" as used herein means that the only target cell antigen present in the antigen binding molecule isOne isA binding site.

The terms "full-length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure that is substantially similar to a native antibody structure. "Natural antibody" refers to a naturally occurring immunoglobulin molecule having a different structure. For example, a natural IgG class antibody is a heterotetrameric glycoprotein of about 150,000 daltons, consisting of two light chains and two heavy chains linked by disulfide bonds. From N-terminus to C-terminus, each heavy chain has a variable region (VH) (also known as the variable heavy chain domain or heavy chain variable domain) followed by three constant domains (CH1, CH2, and CH3) (also known as heavy chain constant regions). Similarly, from N-terminus to C-terminus, each light chain has a variable region (VL) (also known as a variable light chain domain or light chain variable domain) followed by a light chain constant domain (CL) (also known as a light chain constant region). The heavy chain of an antibody may be assigned to one of five types, referred to as α (IgA), δ (IgD), epsilon (IgE), γ (IgG), or μ (IgM), some of which may be further divided into subtypes such as γ 1(IgG1), γ 2(IgG2), γ 3(IgG3), γ 4(IgG4), α 1(IgA1), and α 2(IgA 2). The light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

An "antibody fragment" refers to a molecule other than a whole antibody that comprises a portion of a whole antibody that binds to an antigen to which the whole antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab '-SH, F (ab')₂(ii) a Diabodies, triabodies, tetrabodies, cross-Fab fragments; a linear antibody; single chain antibody molecules (e.g., scFv); and single domain antibodies. For a review of certain antibody fragments, see Hudson et al, Nat Med 9, 129-. For reviews of scFv fragments see, for example, Pl ü ckthun in The pharmacolgy of Monoclonal Antibodies, vol.113, Rosenburg and Moore eds., Springer-Verlag, New York, pp.269-315 (1994); see also WO 93/16185; and U.S. Pat. nos. 5,571,894 and 5,587,458. For a discussion of Fab fragments and F (ab')2 fragments that contain salvage receptor binding epitope residues and have increased half-life in vivo, see U.S. patent No. 5,869,046. Diabodies, which can be bivalent or bispecific, are antibody fragments with two antigen binding sites, see, e.g., EP 404,097; WO 1993/01161; hudson et al, Nat Med 9, 129-; and Hollinger et al, Proc Natl Acad Sci USA 90, 6444-. Trisomal and tetrasomal antibodies are also described in Hudson et al, Nat Med 9,129-134 (2003). A single domain antibody is an antibody fragment comprising all or part of a heavy chain variable domain or all or part of a light chain variable domain of an antibody. In certain embodiments, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Pat. No. 6,248,516B 1). The antibody fragment can be Preparation by a variety of techniques, including but not limited to proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., E.coli or phage), as described herein.

Papain digestion of whole antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each containing a heavy and light chain variable domain and a constant domain of the light chain and the first constant domain of the heavy chain (CH 1). Thus, as used herein, the term "Fab fragment" refers to an antibody fragment comprising a light chain fragment comprising a VL domain and a light chain constant domain (CL), and the VH domain and first constant domain (CH1) of the heavy chain. Fab 'fragments differ from Fab fragments in that the Fab' fragment has added to the carboxy terminus of the heavy chain CH1 domain residues that include one or more cysteines from the antibody hinge region. Fab '-SH is a Fab' fragment in which the cysteine residues of the constant domains have a free thiol group. Pepsin treatment to yield F (ab')₂A fragment having two antigen binding sites (two Fab fragments) and a portion of an Fc region.

The term "crossover Fab fragment" or "xFab fragment" or "crossover Fab fragment" refers to a Fab fragment in which the variable or constant regions of the heavy and light chains are exchanged. Two different chain compositions of the crossover Fab molecule are possible and are comprised in the bispecific antibody of the invention: in one aspect, the variable regions of the Fab heavy and light chains are exchanged, i.e., the exchanged Fab molecule comprises a peptide chain consisting of the light chain variable region (VL) and the heavy chain constant region (CH1), and a peptide chain consisting of the heavy chain variable region (VH) and the light chain constant region (CL). This exchanged Fab molecule is also called CrossFab _(VLVH). In another aspect, when the constant regions of the Fab heavy and light chains are exchanged, the exchanged Fab molecule comprises a peptide chain comprising a heavy chain variable region (VH) and a light chain constant region (CL), and a peptide chain comprising a light chain variable region (VL) and a heavy chain constant region (CH 1). This exchanged Fab molecule is also called CrossFab_(CLCH1). In one aspect, the term "Fab fragment" also includes cross Fab fragments.

"scaffold antigen binding proteins" are known in the artFor example fibronectin and designed ankyrin repeat proteins (DARPin) have been used as alternative scaffolds for antigen binding domains, see for example Gebauer and Skerra, Engineered protein scaffolds as next-generation antibodies therapeutics, curr Opin Chem Biol 13: 245-. In one aspect of the invention, the scaffold antigen binding protein is selected from the group consisting of: CTLA-4(Evibody), lipocalin (Anticalin), protein a-derived molecules such as the Z-domain of protein a (affibody), a-domain (Avimer/macroantibody), serum transferrin (trans-body); designed ankyrin repeat proteins (darpins), variable domains of antibody light or heavy chains (single domain antibodies, sdabs), variable domains of antibody heavy chains (nanobodies, aVH), V _NARFragments, fibronectin (AdNectin), C-type lectin domains (tetranectin); variable domain (V) of the neoantigen receptor beta-lactamase_NARFragments), human gamma-crystallin or ubiquitin protein (Affilin molecules); the kunitz-type domain of human protease inhibitors, minibodies (such as proteins from the knottin family), peptide aptamers, and fibronectin (adnectins). CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) is predominantly CD4⁺The CD28 family of receptors expressed on T cells. The extracellular domain has a variable domain-like Ig fold. The loops corresponding to the CDRs of the antibody can be substituted with heterologous sequences to confer different binding properties. CTLA-4 molecules engineered to have different binding specificities are also known as evibods (e.g., US7166697B 1). Evibody is about the same size as the isolated variable region of an antibody (e.g., a domain antibody). For further details, see Journal of Immunological Methods 248(1-2),31-45 (2001). Lipocalins are a family of extracellular proteins that transport small hydrophobic molecules, such as steroids, cholesterol, retinoids, and lipids. They have a rigid β -sheet secondary structure with many loops at the open ends of the cone structure, and can be engineered to bind different target antigens. Anticalin is between 160-180 amino acids in size and is derived from lipocalin. About further See Biochim Biophys Acta 1482:337-350(2000), US7250297B1 and US20070224633 for details. Affibodies are scaffolds of protein a derived from Staphylococcus aureus (Staphylococcus aureus), which can be engineered to bind to an antigen. This domain consists of a triple helix bundle of about 58 amino acids. Libraries have been formed by randomization of surface residues. For further details, see Protein Eng.Des.Sel.2004,17,455-462 and EP1641818A 1. Avimer is a multidomain protein derived from the a domain scaffold family. The native domain of about 35 amino acids adopts a defined disulfide bonding structure. Diversity is created by natural variation exhibited by the recombinant a domain family. For further details, see Nature Biotechnology 23(12), 1556-. Transferrin is a monomeric serum transport glycoprotein. Transferrin can be engineered by inserting peptide sequences in permissive surface loops to bind different target antigens. Examples of engineered transferrin scaffolds include the trans body. For further details, see J.biol.chem 274,24066-24073 (1999). The designed ankyrin repeat protein (DARPin) is derived from ankyrin, a family of proteins that mediate the attachment of integral membrane proteins to cell scaffolds. The single ankyrin repeat is a 33 residue motif consisting of two alpha helices and one beta turn. They can be engineered to bind different target antigens by randomizing residues in the first alpha-helix and beta-turn in each repeat sequence. Their binding interface can be increased by increasing the number of modules (affinity maturation method). For further details, see J.mol.biol.332,489-503(2003), PNAS 100(4),1700-1705(2003) and J.mol.biol.369,1015-1028(2007) and US20040132028A 1. Single domain antibodies are antibody fragments consisting of a single monomeric variable antibody domain. The first single domain is derived from the variable domain of the heavy chain of an antibody of the camelid family (nanobody or V) _HH fragment). Furthermore, the term single domain antibody comprises an autologous human heavy chain variable domain (aVH) or shark derived V_NARAnd (3) fragment. Fibronectin may be engineered to bindA scaffold containing a synthetic antigen. Adnectin consists of a backbone of the native amino acid sequence of domain 10 of the 15 repeat unit of human fibronectin type III (FN 3). The three loops at one end of the β -sandwich can be engineered to enable the Adnectin to specifically recognize the target therapeutic target of interest. For further details, see Protein eng.des.sel.18,435-444(2005), US20080139791, WO2005056764, and US6818418B 1. Peptide aptamers are combinatorial recognition molecules consisting of a constant scaffold protein, usually thioredoxin (TrxA), containing a constrained variable peptide loop inserted at the active site. For further details, see Expert opin. biol. ther.5,783-797 (2005). The minibodies are derived from naturally occurring miniproteins of 25-50 amino acids in length containing 3-4 cysteine bridges, examples of which include KalataBI and conotoxins, and knottin. The micro-proteins have loops that can be engineered to include up to 25 amino acids without affecting the overall folding of the micro-protein. For further details on engineered knottin domains see WO 2008098796.

Lipocalins are a family of extracellular proteins that transport small hydrophobic molecules, such as steroids, cholesterol, retinoids, and lipids. Lipocalins are monomeric proteins with a weight of about 18-20kDa, which exhibit binding sites with high structural plasticity, comprising four peptide loops mounted on a stable b-cartridge scaffold (Skerra, FEBS Journal 2008,275, 2677-2683). Thus, they have a rigid β -sheet secondary structure with a number of loops at the open ends of the cone structure, which can be engineered to bind to different target antigens. Thereby generating lipocalin muteins specific for a certain target antigen. A "lipocalin mutein" is a mutated protein in which one or more amino acids are exchanged, deleted or inserted compared to the naturally occurring (wild-type) lipocalin. The term lipocalin mutein also includes fragments or variants of the wild-type lipocalin. The size of the lipocalin muteins as described herein is between 160-180 amino acids. In a particular aspect, a lipocalin mutein is a polypeptide defined by its supersecondary structure, i.e. a cylindrical β -sheet-like supersecondary structure region, comprising 8 β -strands connected in pairs at one end by four loops thereby defining a binding pocket (pocket), wherein at least one amino acid in each of at least three of the four loops has been mutated and wherein the lipocalin protein is effective to bind 4-1BB with detectable affinity.

In one aspect, the lipocalin muteins disclosed herein are muteins derived from human tear lipocalin (TLPC or Tlc), also known as pre-lacrimal albumin or von-Ebner (von Ebner) gland protein. The term "human tear lipocalin" or "Tlc", as used herein, refers to mature human tear lipocalin with the SWISS-PROT/UniProt database accession number P31025 (isoform 1). This type of lipocalin mutein is therefore derived from SEQ ID NO: 90. In particular, the lipocalin muteins disclosed herein are muteins derived from mature human neutrophil gelatinase-associated lipocalin (huNGAL) with SWISS-PROT/UniProt database accession number P80188. This type of lipocalin mutein may be designated as "huNGAL mutein" and be derived from SEQ ID NO: 1. In some aspects, a lipocalin mutein capable of specifically binding to 4-1BB with detectable affinity may comprise at least one amino acid substitution, wherein the native cysteine residue is substituted with another amino acid (e.g., a serine residue). In some other aspects, a lipocalin mutein capable of specifically binding to 4-1BB with detectable affinity may comprise one or more non-native cysteine residues substituted for one or more amino acids of the wild-type lipocalin. In another particular aspect, a lipocalin mutein capable of specifically binding to 4-1BB comprises at least two amino acid substitutions, wherein the native amino acid is substituted with a cysteine residue, thereby forming one or more cysteine bridges. In some embodiments, the cysteine bridge may link at least two loop regions. In a related aspect, the present disclosure teaches one or more lipocalin mutein(s) capable of activating the downstream signaling pathway of 4-1BB by binding to 4-1 BB.

"antigen-binding molecule that binds to the same epitope" as a reference molecule refers to an antigen-binding molecule that blocks binding of the reference molecule to its antigen by 50% or more in a competition assay, and conversely, blocks binding of the antigen-binding molecule to its antigen by 50% or more in a competition assay.

As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope" and refers to a site (e.g., a contiguous stretch of amino acids or a conformational configuration composed of different regions of non-contiguous amino acids) on a polypeptide macromolecule to which an antigen-binding portion binds, thereby forming an antigen-binding portion-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, in serum free and/or in extracellular matrix (ECM). Unless otherwise indicated, a protein used herein as an antigen can be any native form of the protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In a particular embodiment, the antigen is a human protein. When referring to a particular protein herein, the term encompasses "full-length," unprocessed protein, as well as any form of protein that results from intracellular processing. The term also encompasses naturally occurring protein variants, such as splice variants or allelic variants.

By "specific binding" is meant that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antigen-binding molecule to bind to a particular antigen can be measured by enzyme-linked immunosorbent assays (ELISAs) or other techniques familiar to those skilled in the art, such as Surface Plasmon Resonance (SPR) techniques (analysis on BIAcore instruments) (Liljeblad et al, Glyco J17, 323-. In one embodiment, the degree of binding of the antigen binding molecule to an unrelated protein is less than about 10% of the degree of binding of the antigen binding molecule to an antigen, e.g., as measured by SPR. In certain embodiments, the dissociation constant (Kd) of the molecule that binds to the antigen is less than or equal to 1 μ M, less than or equal to 100nM, less than or equal to 10nM, less than or equal to 1nM, less than or equal to 0.1nM, less than or equal to 0.01nM or less than or equal to 0.001nM (e.g., 10 nM)^-8M or less, e.g. 10^-8M to 10^-13M, e.g. 10^-9M to 10^-13M)。

"affinity" or "binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). As used herein, unless otherwise specified, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be determined by the dissociation constant (K) _D) Expressed, the dissociation constant is the ratio of the dissociation rate constant to the association rate constant (koff and kon, respectively). Affinity can be measured by conventional methods known in the art, including those described herein. A particular method of measuring affinity is Surface Plasmon Resonance (SPR).

An "affinity matured" antibody is one that has one or more alterations in one or more Complementarity Determining Regions (CDRs) that result in an improvement in the affinity of the antibody for an antigen as compared to a parent antibody that does not have such alterations.

As used herein, "target cell antigen" refers to an antigenic determinant present on the surface of a target cell, e.g., a cell in a tumor (such as a cell of a cancer cell or tumor stroma). In certain embodiments, the target cell antigen is an antigen on the surface of a tumor cell. In one embodiment, the target cell antigen is selected from the group consisting of: fibroblast Activation Protein (FAP), HER2, carcinoembryonic antigen (CEA), melanoma-associated chondroitin sulfate proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), CD19, CD20, and CD 33. Specifically, the target cell antigen is Fibroblast Activation Protein (FAP) or HER 2.

The term "Fibroblast Activation Protein (FAP)" also referred to as prolyl endopeptidase FAP or Seprase (EC 3.4.21), unless otherwise specified, refers to any native FAP from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term includes "full-length" unprocessed FAP, as well as any form of FAP produced by processing in a cell. The term also encompasses naturally occurring variants of FAP, such as splice variants or allelic variants. In one embodiment, the antigen binding molecules of the invention are capable of specifically binding to human, mouse and/or cynomolgus FAP. The amino acid sequence of human FAP is shown in UniProt (www.uniprot.org) accession number Q12884(149 th edition, SEQ ID NO:91) or NCBI (www.ncbi.nlm.nih.gov /) RefSeq NP-004451.2. The extracellular domain (ECD) of human FAP extends from amino acid position 26 to amino acid position 760. The amino acid sequence of the His-tagged human FAP ECD is shown in SEQ ID NO 92. The amino acid sequence of mouse FAP is shown in UniProt accession number P97321(126 th edition, SEQ ID NO:93) or NCBI RefSeq NP-032012.1. The extracellular domain (ECD) of mouse FAP extends from amino acid position 26 to amino acid position 761. SEQ ID No.94 shows the amino acid sequence of the His-tagged mouse FAP ECD. SEQ ID NO 95 shows the amino acid sequence of the His-tagged cynomolgus FAP ECD. Preferably, the anti-FAP binding molecules of the invention bind to the extracellular domain of FAP. Exemplary anti-FAP binding molecules are described in international patent application No. WO 2012/020006 a 2.

The term "capable of specifically binding to FAP" refers to an antigen-binding molecule that is capable of binding to FAP with sufficient affinity such that the antigen-binding molecule can be used as a diagnostic and/or therapeutic agent that targets FAP. Antigen binding molecules include, but are not limited to, antibodies, Fab molecules, exchange Fab molecules, single chain Fab molecules, Fv molecules, scFv molecules, single domain antibodies, and VH and scaffold antigen binding proteins. In one aspect, the extent of binding of the anti-FAP antigen binding molecule to an unrelated, non-FAP protein is less than about 10% of the binding of the antigen binding molecule to FAP, as measured, for example, by Surface Plasmon Resonance (SPR). In particular, antibodies capable of specifically binding to FAPThe primary binding molecule has the following dissociation constant (K)_d): less than or equal to 1 μ M, less than or equal to 100nM, less than or equal to 10nM, less than or equal to 1nM, less than or equal to 0.1nM, less than or equal to 0.01nM or less than or equal to 0.001nM (e.g., 10 nM)^-8M or less, e.g. 10^-8M to 10^-13M, e.g. 10^-9M to 10^-13M). In certain aspects, an anti-FAP antigen-binding molecule binds to FAP from a different species. In particular, the anti-FAP antigen binding molecule binds to human and cynomolgus FAP or human, cynomolgus monkey and mouse FAP.

The term "carcinoembryonic antigen (CEA)" also referred to as carcinoembryonic antigen-associated cell adhesion molecule 5(CEACAM5) refers to any native CEA from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise indicated. The amino acid sequence of human CEA is shown in UniProt accession number P06731 (version 151, SEQ ID NO: 96). CEA has long been identified as a tumor associated antigen (Gold and Freedman, J Exp Med., 121: 439-. CEA was originally classified as a protein expressed only in fetal tissues and has now been identified in a variety of normal adult tissues. These tissues are mainly of epithelial origin, including cells of the gastrointestinal, respiratory and genitourinary tracts as well as cells of the colon, cervix, sweat glands and prostate (Nap et al, Tumour biol., 9(2-3):145-53, 1988; Nap et al, Cancer Res., 52(8):2329-23339, 1992). Both epithelial-derived tumors and their metastases comprise CEA as a tumor-associated antigen. The presence of CEA itself does not indicate that it has been transformed into cancer cells, but the distribution of CEA is indicative. In normal tissues, CEA is normally expressed on the apical surface of cells (S) ((R)) S. Semin Cancer biol.9(2):67-81(1999)), rendering it unabsorbable by antibodies in the bloodstream. CEA tends to be expressed on the entire surface of cancer cells compared to normal tissues: (S.,Semin Cancer biol.9(2):67-81 (1999)). This change in expression pattern allows CEA to readily bind to antibodies in cancer cells. Furthermore, expression of CEA in cancer cells is increased. Furthermore, an increase in CEA expression promotes an increase in intercellular adhesion, which may lead to metastasis (Marshall J., Semin Oncol.,30(a suppl.8):30-6,2003). Expression of CEA in various tumor entities is generally very high. Based on published data, the high incidence of CEA has been demonstrated in its own analyses in tissue samples, with an incidence of about 95% in large bowel cancer (CRC), 90% in pancreatic cancer, 80% in gastric cancer, 60% in non-small cell lung cancer (NSCLC, co-expressed with HER 3) and 40% in breast cancer; and found to be low in expression levels in small cell lung cancer and glioblastoma.

CEA is readily cleaved from the cell surface and flows from the tumor into the bloodstream, either directly or through lymphatic vessels. Because of this property, serum CEA levels have been used as a clinical index for diagnosing Cancer and screening for recurrence of Cancer, particularly colorectal Cancer (Goldenberg D M., The International Journal of Biological Markers, 7:183-188, 1992; Chau I et al, J Clin Oncol., 22:1420-1429, 2004; Flarni et al, Clin Cancer Res; 12(23): 6985-6986, 2006).

The term "melanoma-associated chondroitin sulfate proteoglycan (MCSP)" is also referred to as chondroitin sulfate proteoglycan 4(CSPG4) and, unless otherwise specified, refers to any native MCSP from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats). The amino acid sequence of human MCSP is shown in UniProt accession No. Q6UVK1(103 th edition, SEQ ID NO: 97). The term "Epidermal Growth Factor Receptor (EGFR)" also known as the protooncogene c-ErbB-1 or the receptor tyrosine protein kinase ErbB-1, unless otherwise specified, refers to any native EGFR from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats). The amino acid sequence of human EGFR is shown in UniProt accession number P00533(211 th edition, SEQ ID NO: 98).

The term "CD 19" refers to the B lymphocyte antigen CD19, also known as the B lymphocyte surface antigen B4 or the T cell surface antigen Leu-12, and unless otherwise specified, the term includes any native CD19 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The amino acid sequence of human CD19 is shown in UniProt accession number P15391 (version 160, SEQ ID NO: 99). The term encompasses "full-length" unprocessed human CD19 as well as any form of human CD19 produced by processing in a cell, so long as the antibody as reported herein binds thereto. CD19 is a structurally distinct cell surface receptor expressed on the surface of human B cells, including but not limited to pre-B cells, early developing B cells (i.e., immature B cells), mature B cells by terminal differentiation into plasma cells, and malignant B cells. CD19 is expressed by most pre-B Acute Lymphoblastic Leukemias (ALL), non-hodgkin's lymphomas, B-cell Chronic Lymphocytic Leukemia (CLL), pre-lymphocytic leukemia, hairy cell leukemia, common acute lymphocytic leukemia, and some Null-acute lymphocytic leukemias. Expression of CD19 on plasma cells further suggests that it may be expressed on differentiated B cell tumors such as multiple myeloma. Thus, the CD19 antigen is a target for immunotherapy for the treatment of non-hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphocytic leukemia.

"CD 20" refers to the B lymphocyte antigen CD20, also known as transmembrane 4 domain subfamily a member 1(MS4a1), B lymphocyte surface antigen B1, or leukocyte surface antigen Leu-16, and unless otherwise specified, the term includes any native CD20 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The amino acid sequence of human CD20 is shown in UniProt accession number P11836(149 th edition, SEQ ID NO: 100). "CD 33" refers to the myeloid cell surface antigen CD33, also known as SIGLEC3 or gp67, and unless otherwise specified, the term includes any native CD33 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The amino acid sequence of human CD33 is shown in UniProt accession number P20138(157 th edition, SEQ ID NO: 101).

The term "HER 2," also known as "ErbB 2", "ErbB 2 receptor," or "c-Erb-B2," refers to any native, mature HER2 that results from processing of the HER2 precursor protein in a cell. Unless otherwise indicated, the term includes HER2 from any vertebrate source, including mammals such as primates (such as humans and cynomolgus monkeys) and rodents (such as mice and rats). The term also includes naturally occurring variants of HER2, for example, splice variants or allelic variants. The amino acid sequence of an exemplary human HER2 protein is shown in SEQ ID NO 102.

The term "capable of specifically binding to HER 2" refers to an antigen binding molecule capable of binding to HER2 with sufficient affinity such that the antigen binding molecule is useful as a diagnostic and/or therapeutic agent targeting HER 2. Antigen binding molecules include, but are not limited to, antibodies, Fab molecules, exchange Fab molecules, single chain Fab molecules, Fv molecules, scFv molecules, single domain antibodies, and VH and scaffold antigen binding proteins. In one aspect, the extent of binding of the anti-HER 2 antigen binding molecule to an unrelated, non-HER 2 protein is less than about 10% of the binding of the antigen binding molecule to HER2 as measured, for example, by Surface Plasmon Resonance (SPR). Specifically, antigen binding molecules capable of specifically binding to HER2 have the following dissociation constants (K)_d): less than or equal to 1 μ M, less than or equal to 100nM, less than or equal to 10nM, less than or equal to 1nM, less than or equal to 0.1nM, less than or equal to 0.01nM or less than or equal to 0.001nM (e.g., 10 nM)^-8M or less, e.g. 10^-8M to 10^-13M, e.g. 10^-9M to 10^-13M). In certain aspects, the anti-HER 2 antigen binding molecule binds to HER2 from a different species. In particular, the anti-HER 2 antigen binding molecule binds to human and cynomolgus monkey HER 2.

The term "epitope" refers to a site on a protein or non-protein antigen that binds to an anti [ [ PRO ] ] antibody. Epitopes can be formed from contiguous stretches of amino acids (linear epitopes) or comprise non-contiguous amino acids (conformational epitopes), for example due to spatial proximity by antigen folding, i.e. by tertiary folding of the protein antigen. Linear epitopes are typically still bound by antibodies after exposure of the protein antigen to a denaturant, whereas conformational epitopes are typically destroyed after treatment with the denaturant. An epitope comprises at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique conformation.

"epitope 4D 5" or "epitope 4D 5" or "4D 5" is the region in the extracellular domain of HER2 that binds to antibody 4D5(ATCC CRL 10463) and trastuzumab. This epitope is close to the transmembrane domain of HER2 and within domain IV of HER 2. To screen for Antibodies that bind to the 4D5 epitope, conventional cross-blocking assays such as those described by Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988) are required. Alternatively, epitope mapping (mapping) can be performed to assess whether the antibody binds to the 4D5 epitope of HER2 (such as any one or more residues in the region of about residue 550 to about residue 610 (inclusive) of human HER2(SEQ ID NO: 102)).

An "epitope 2C 4" or "epitope 2C 4" is a region in the extracellular domain of HER2 that binds to antibody 2C 4. To screen for Antibodies that bind to the epitope of 2C4, a conventional cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988) can be performed. Alternatively, epitope mapping can be performed to assess whether an antibody binds to the 2C4 epitope of HER 2. Epitope 2C4 comprises residues from domain II in the ectodomain of HER 2. The 2C4 antibody and pertuzumab bind to the extracellular domain of HER2 at the junction of domains I, II and III (Franklin et al, Cancer Cell 5:317-328 (2004)).

The term "variable region" or "variable domain" refers to a domain of an antibody heavy or light chain that is involved in the binding of an antigen binding molecule to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, with each domain comprising four conserved Framework Regions (FR) and three hypervariable regions (HVRs). See, e.g., Kindt et al, Kuby Immunology, 6 th edition, w.h.freeman and co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen binding specificity.

As used herein, the term "hypervariable region" or "HVR" refers to the various regions of an antibody variable domain which are hypervariable in sequence and determine antigen-binding specificity, e.g., "complementarity determining regions" ("CDRs").

Typically, an antibody comprises six CDRs; three in VH (CDR-H1, CDR-H2, CDR-H3) and three in VL (CDR-L1, CDR-L2, CDR-L3). Exemplary CDRs herein include:

(a) the hypervariable loops which occur at amino acid residues 26-32(L1), 50-52(L2), 91-96(L3), 26-32(H1), 53-55(H2) and 96-101(H3) (Chothia and Lesk, J.mol.biol.196:901-917 (1987));

(b) CDRs present at amino acid residues 24-34(L1), 50-56(L2), 89-97(L3), 31-35b (H1), 50-65(H2) and 95-102(H3) (Kabat et al, Sequences of Proteins of Immunological Interest, 5 th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and

(c) Antigen contacts present at amino acid residues 27c-36(L1), 46-55(L2), 89-96(L3), 30-35b (H1), 47-58(H2) and 93-101(H3) (MacCallum et al, J.mol.biol.262:732-745 (1996)).

Unless otherwise indicated, the CDRs are determined according to the methods described by Kabat et al (supra). One skilled in the art will appreciate that the CDR names can also be determined according to the methods described by Chothia (supra), McCallum (supra), or any other scientifically accepted nomenclature system.

"framework" or "FR" refers to variable domain residues other than the Complementarity Determining Regions (CDRs). The FRs of a variable domain typically consist of the following four FR domains: FR1, FR2, FR3 and FR 4. Thus, CDR and FR sequences typically occur in VH (or VL) as follows: FR1-CDR-H1(CDR-L1) -FR2-CDR-H2(CDR-L2) -FR3-CDR-H3(CDR-L3) -FR 4.

The terms "full-length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or having a heavy chain containing an Fc region as defined herein.

A "human consensus framework" is a framework that represents the amino acid residues that are most commonly present in the selection of human immunoglobulin VL or VH framework sequences. In general, the selection of human immunoglobulin VL or VH sequences is from a subset of variable domain sequences. In general, a subset of Sequences is a subset as described in Kabat et al, Sequences of Proteins of Immunological Interest, 5 th edition, NIH Publication 91-3242, Bethesda MD (1991), volumes 1-3. In one aspect, for VL, this subgroup is subgroup κ I as in Kabat et al, supra. In one aspect, for the VH, this subgroup is subgroup III as in Kabat et al, supra.

The term "chimeric" antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

The "class" of antibodies refers to the type of constant domain or constant region that the heavy chain of an antibody has. There are five major classes of antibodies: IgA, IgD, IgE, IgG and IgM, and some of them may be further divided into subclasses (isotypes), e.g. IgG₁、IgG₂、IgG₃、IgG₄、IgA₁And IgA₂. In certain aspects, the antibody is an IgG₁Isoforms. In certain aspects, the antibody is an IgG with P329G, L234A, and L235A mutations to reduce Fc region effector function₁Isoforms. In other aspects, the antibody is an IgG₂Isoforms. In certain aspects, the antibody is an IgG having an S228P mutation in the hinge region₄Isotyping to improve IgG₄Stability of the antibody. The heavy chain constant domains corresponding to different classes of immunoglobulins are referred to as α, δ, ε, γ, and μ, respectively. The light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

The term "constant region derived from human origin" or "human constant region" as used in this application denotes the constant heavy chain region and/or constant light chain kappa or lambda region of a human antibody of subclass IgG1, IgG2, IgG3 or IgG 4. Such constant regions are well known in the art and are described, for example, by: kabat, E.A., et al, Sequences of Proteins of Immunological Interest, 5 th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see also, e.g., Johnson, G., and Wu, T.T., Nucleic Acids Res.28(2000) 214-. Unless otherwise specified herein, the numbering of amino acid residues in the constant region is according to the EU numbering system, also known as the EU index of Kabat, as described in Kabat, E.A. et al, Sequences of Proteins of Immunological Interest, 5 th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.

A "humanized" antibody is a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. The humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. An antibody, e.g., a non-human antibody, in "humanized form" refers to an antibody that has been subjected to humanization. Other forms of "humanized antibodies" encompassed by the present invention are antibodies in which the constant regions have been otherwise modified or altered relative to the original antibody to produce the properties according to the present invention, particularly with respect to C1q binding and/or Fc receptor (FcR) binding.

A "human" antibody is an antibody having an amino acid sequence corresponding to that of an antibody produced by a human or human cell or derived from a non-human source using a human antibody repertoire or other human antibody coding sequences. This definition of human antibody specifically excludes humanized antibodies comprising non-human antigen binding residues.

The term "Fc domain" or "Fc region" is used herein to define the C-terminal region of an antibody heavy chain that contains at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxy terminus of the heavy chain. However, the antibody produced by the host cell may undergo post-translational cleavage of one or more, in particular one or two, amino acids from the C-terminus of the heavy chain. Thus, an antibody produced by a host cell by expression of a particular nucleic acid molecule encoding a full-length heavy chain may comprise the full-length heavy chain, or the antibody may comprise a cleaved variant of the full-length heavy chain. This may be the case where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, according to the Kabat EU index). Thus, the C-terminal lysine (Lys447) or the C-terminal glycine (Gly446) and lysine (Lys447) of the Fc region may or may not be present. The amino acid sequence of the heavy chain comprising the Fc region is represented herein as without the C-terminal glycine-lysine dipeptide if not otherwise indicated. In one embodiment, a heavy chain comprising an Fc region as specified herein comprising an additional C-terminal glycine-lysine dipeptide (G446 and K447, numbered according to EU index of Kabat) is comprised in an antibody according to the invention. In one embodiment, a heavy chain comprising an Fc region as specified herein is comprised in an antibody according to the invention, the heavy chain comprising an additional C-terminal glycine residue (G446, numbering according to EU index of Kabat). Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also known as the EU index, as described in Kabat et al, Sequences of Proteins of Immunological Interest, 5 th edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991. The IgG Fc region comprises an IgG CH2 domain and an IgG CH3 domain. The "CH 2 domain" of the human IgG Fc region typically extends from amino acid residue at approximately position 231 to amino acid residue at approximately position 340. In one embodiment, the carbohydrate chain is attached to a CH2 domain. The CH2 domain herein may be the native sequence CH2 domain or a variant CH2 domain. The "CH 3 domain" comprises a stretch of residues from the C-terminus to the CH2 domain in the Fc region (i.e., from the amino acid residue at about position 341 to the amino acid residue at about position 447 of an IgG). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g., a CH3 domain having an introduced "bulge" ("protuberance") in one chain and a corresponding introduced "cavity" ("pore") in the other chain; see U.S. Pat. No. 5,821,333, expressly incorporated herein by reference). Such variant CH3 domains may be used to promote heterodimerization of two non-identical antibody heavy chains as described herein.

The term "wild-type Fc domain" denotes an amino acid sequence identical to the amino acid sequence of an Fc domain found in nature. Wild-type human Fc domains include native human IgG1 Fc region (non-a and a allotypes), native human IgG2 Fc region, native human IgG3 Fc region, and native human IgG4 Fc region, as well as naturally occurring variants thereof. The wild-type Fc region is shown in SEQ ID NO 122(IgG1, Caucasian allotype), SEQ ID NO 123(IgG1, African American allotype), SEQ ID NO 124(IgG2), SEQ ID NO 125(IgG3), and SEQ ID NO 126(IgG 4).

The term "variant (human) Fc domain" denotes an amino acid sequence that differs from the amino acid sequence of a "wild-type" (human) Fc domain by at least one "amino acid mutation". In one aspect, the variant Fc region has at least one amino acid mutation as compared to the native Fc region, such as from about 1 to about 10 amino acid mutations in the native Fc region, and in one aspect, from about 1 to about 5 amino acid mutations. In one aspect, the (variant) Fc region has at least about 95% homology to a wild-type Fc region.

The "knob-and-hole" technique is described, for example, in US 5,731,168; US 7,695,936; ridgway et al, Prot Eng 9,617- & 621(1996) and Carter, J Immunol Meth 248,7-15 (2001). In general, the method involves introducing a bulge ("protuberance") at the interface of a first polypeptide and a corresponding cavity ("hole") in the interface of a second polypeptide, such that the bulge can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. The bulge is constructed by substituting a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). Compensatory cavities having the same or similar size as the bulge are created in the interface of the second polypeptide by substituting a larger amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). The projections and cavities can be made by altering the nucleic acid encoding the polypeptide, for example by site-specific mutagenesis or by peptide synthesis. In a particular embodiment, the protuberance modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain, while the pore modification comprises the amino acid substitutions T366S, L368A and Y407V in the other of the two subunits of the Fc domain. In another specific embodiment, the subunit comprising a protuberance-modified Fc domain further comprises amino acid substitution S354C, and the subunit comprising a pore-modified Fc domain further comprises amino acid substitution Y349C. The introduction of these two cysteine residues results in the formation of disulfide bridges between the two subunits of the Fc region, thereby further stabilizing the dimer (Carter, J immunological Methods 248,7-15 (2001)). Numbering is the EU index according to Kabat et al, Sequences of Proteins of Immunological Interest, 5 th edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

"region equivalent to the Fc region of an immunoglobulin" is intended to include naturally occurring allelic variants of the Fc region of an immunoglobulin, as well as modified variants having the ability to make substitutions, additions or deletions without substantially reducing the ability of the immunoglobulin to mediate effector functions, such as antibody-dependent cellular cytotoxicity. For example, one or more amino acids may be deleted from the N-terminus or C-terminus of an Fc region of an immunoglobulin without substantial loss of biological function. Such variants may be selected according to general rules known in the art so as to have minimal effect on activity (see, e.g., Bowie, J.U. et al, Science 247:1306-10 (1990)).

The term "effector function" refers to those biological activities that can be attributed to the Fc region of an antibody that vary with the isotype of the antibody. Examples of antibody effector functions include: c1q binding and Complement Dependent Cytotoxicity (CDC), Fc receptor binding, antibody dependent cell mediated cytotoxicity (ADCC), Antibody Dependent Cellular Phagocytosis (ADCP), cytokine secretion, immune complex mediated antigen uptake by antigen presenting cells, down regulation of cell surface receptors (e.g., B cell receptors), and B cell activation.

An "activating Fc receptor" is an Fc receptor that, upon engagement of the Fc region of an antibody, causes a signaling event that stimulates receptor-bearing cells to perform effector functions. Activating Fc receptors include Fc γ riia (CD16a), Fc γ rii (CD64), Fc γ riia (CD32), and Fc α rii (CD 89). A particular activating Fc receptor is human Fc γ riiiia (see UniProt accession No. P08637, version 141).

The "tumor necrosis factor receptor superfamily" or "TNF receptor superfamily" currently consists of 27 receptors. It is a group of cytokine receptors characterized by the ability to bind Tumor Necrosis Factor (TNF) through the extracellular cysteine-rich domain (CRD). These pseudo-repeats are defined by intrachain disulfides arising from highly conserved cysteine residues within the receptor chain. All TNF was homologous to the prototype TNF- α except for Nerve Growth Factor (NGF). Most TNF receptors form trimeric complexes in plasma membranes in their active form. Thus, most TNF receptors contain a transmembrane domain (TMD). Many of these receptors also contain intracellular Death Domains (DD) that recruit proteins that interact with caspases upon ligand binding, thereby initiating the exogenous pathway of caspase activation. Other TNF superfamily receptors lacking a death domain bind to TNF receptor associated factors and activate intracellular signaling pathways, leading to proliferation or differentiation. These receptors may also initiate apoptosis, but they act via an indirect mechanism. In addition to modulating apoptosis, a variety of TNF superfamily receptors are involved in modulating immune cell functions such as B cell homeostasis and activation, natural killer cell activation, and T cell co-stimulation. A variety of other agents modulate specific cell type responses such as hair follicle development and osteoclast development. Members of the TNF receptor superfamily include: tumor necrosis factor receptor 1(1A) (TNFRSF1, CD 120), tumor necrosis factor receptor 2(1B) (TNFRSF1, CD 120), lymphotoxin beta receptor (LTBR, CD), OX (TNFRSF, CD134), CD (Bp), Fas receptor (Apo-1, CD, FAS), decoy receptor 3(TR, M, TNFRSF 6), CD (S152, Tp), CD (Ki-1, TNFRSF), 4-1BB (CD137, TNFRSF), DR (TRAILR, Apo-2, CD261, TNFRSF 10), DR (TRAILR, CD262, TNFRSF 10), decoy receptor 1(TRAILR, CD263, TNFRSF 10), decoy receptor 2(TRAILR, CD264, TNFRSF 10), RANK (CD, TNFRSF 11), osteoprotegerin (OCIF, TR, TNFRSF 11), TNFRSF11, TNFRSF 271, CD266, HVRSF 12, TNFRSF13, TNFRSF17), glucocorticoid-induced TNFR-related (GITR, AITR, CD357, TNFRSF18), TROY (TNFRSF19), DR6(CD358, TNFRSF21), DR3(Apo-3, TRAMP, WS-1, TNFRSF25), and the epiblastic aplasia a2 receptor (xedr, EDA 2R).

Multiple members of the Tumor Necrosis Factor Receptor (TNFR) family maintain T cell responses after initial T cell activation. The term "co-stimulatory TNF receptor family members" or "co-stimulatory TNF family receptors" refers to a subset of TNF receptor family members that are capable of synergistically stimulating T cell proliferation and cytokine production. Unless otherwise indicated, the term refers to any native TNF family receptor from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). In a specific embodiment of the invention, the co-stimulatory TNF receptor family member is selected from the group consisting of: OX40(CD134), 4-1BB (CD137), CD27, HVEM (CD270), CD30 and GITR, all of which have a co-stimulatory effect on T cells. More specifically, the co-stimulatory TNF receptor family member is 4-1 BB.

The term "4-1 BB" as used herein, unless otherwise indicated, refers to any native 4-1BB from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed 4-1BB, as well as any form of 4-1BB produced by processing in a cell. The term also encompasses naturally occurring variants of 4-1BB, such as splice variants or allelic variants. The amino acid sequence of exemplary human 4-1BB is shown in SEQ ID NO:103(Uniprot accession No. Q07011), the amino acid sequence of exemplary murine 4-1BB is shown in SEQ ID NO:104(Uniprot accession No. P20334), and the amino acid sequence of exemplary cynomolgus monkey 4-1BB (from macaque) is shown in SEQ ID NO:105(Uniprot accession No. F6W5G 6).

The term "peptide linker" refers to a peptide comprising one or more amino acids, typically about 2 to 20 amino acids. Peptide linkers are known in the art or described herein. Suitable non-immunogenic linker peptides are, for example, (G)₄S)_n、(SG₄)_nOr G₄(SG₄)_nA peptide linker, wherein "n" is typically a number between 1 and 10, typically between 1 and 4, in particular 2, i.e. a peptide selected from the group consisting of: GGGGS (SEQ ID NO:75), GGGGSGGGGS (SEQ ID NO:76), SGGGGSGGGG (SEQ ID NO:77), (G)₄S)₃Or GGGGSGGGGSGGGGS (SEQ ID NO:78), GGGGSGGGGSGGGG or G4(SG4)₂(SEQ ID NO:79), and (G)₄S)₄Or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:80), but further comprises the sequence GSPGSSSSGS (SEQ ID NO:81), GSGSGSGSGS (SEQ ID NO:82), GSGSGNGS (SEQ ID NO:83), GGSGSGSG (SEQ ID NO:84), GGSGSG (SEQ ID NO:85), GGSG (SEQ ID NO:86), GGSGNGSG (SEQ ID NO:87), GGNGSGSG (SEQ ID NO:88) and GGNGSG (SEQ ID NO: 89). A peptide linker of particular interest is (G)₄S)₂Or GGGGSGGGGS (SEQ ID NO:76), (G)₄S)₃(SEQ ID NO:78) and (G)₄S)₄(SEQ ID NO:80), more specifically (G)₄S)₃(SEQ ID NO: 78). Other peptide linkers are selected from the group consisting of: 113, 114, 115, 116, or SEQ ID NO: 117. SEQ ID NO: 118. SEQ ID NO: 119. SEQ ID NO: 120 and SEQ ID NO: 121.

The term "amino acid" as used in this application denotes the group of naturally occurring carboxy alpha-amino acids comprising: alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).

As used herein, "fusion polypeptide" or "fusion protein" refers to a single chain polypeptide that includes antibody fragments and peptides not derived from antibodies. In one aspect, the fusion polypeptide comprises a lipocalin mutein linked via a peptide bond to the Fc region of the antibody, optionally via a peptide linker. Fusion can occur by linking the N or C terminal amino acid of the lipocalin mutein directly to the C or N terminal amino acid of the heavy chain via a peptide linker.

By "fused" or "linked to" is meant that the components (such as the polypeptides and the extracellular domains of the TNF ligand family members) are linked by peptide bonds, either directly or via one or more peptide linkers.

"percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with amino acid residues in a reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and without regard for any conservative substitutions as part of the sequence identity for purposes of alignment. Alignments to determine percent amino acid sequence identity can be performed in a variety of ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software, or the FASTA package. One skilled in the art can determine appropriate parameters for aligning the sequences, including any algorithms required to achieve maximum alignment over the full length of the sequences being compared. Alternatively, a percent identity value may be generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, inc and the source code has been submitted with the user document to u.s.copy Office, Washington d.c.,20559, where it was registered with us copyright registration number TXU510087 and as described in WO 2001/007611.

Unless otherwise indicated, for purposes herein, BLOSUM50 comparison matrices were used to generate percent amino acid sequence identity values using the ggsearch program of FASTA package 36.3.8c edition or higher. The FASTA package is comprised of W.R.Pearson and D.J.Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85: 2444-2448; W.R.Pearson (1996) "Effective protein sequence composition" meth.enzymol.266: 227-; and Pearson et al, (1997) Genomics 46:24-36, and is publicly available from www.fasta.bioch.virginia.edu/fasta _ www2/fasta _ down. shtml or www.ebi.ac.uk/Tools/sss/fasta. Alternatively, sequences can be compared using a common server accessible at fasta. bioch. virginia. edu/fasta _ www2/index. cgi, using the ggsearch (global protein: protein) program and default options (BLOSUM 50; open: -10; ext: -2; Ktup ═ 2) to ensure that global, rather than local, alignments are performed. The percent amino acid identity is given in the alignment header (alignment header) of the output.

The term "amino acid sequence variant" includes substantial variants in which there is an amino acid substitution in one or more hypervariable region residues of a parent antigen-binding molecule (e.g., a humanized or human antibody). Typically, one or more of the resulting variants selected for further study will be altered (e.g., improved) in certain biological properties (e.g., increased affinity, decreased immunogenicity) and/or will substantially retain certain biological properties of the parent antigen-binding molecule relative to the parent antigen-binding molecule. Exemplary substitution variants are affinity matured antibodies, which can be conveniently generated, for example, using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more CDR residues are mutated and variant antigen binding molecules are displayed on phage and screened for a particular biological activity (e.g., binding affinity). In certain embodiments, substitutions, insertions, or deletions may occur within one or more CDRs so long as such changes do not substantially reduce the antigen-binding molecule's ability to bind antigen. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity can be made in the CDRs. A method that can be used to identify antibody residues or regions that can be targeted for mutagenesis is referred to as "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) Science,244: 1081-1085. In this method, a residue or set of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced with a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether antibody interaction with an antigen is affected. Additional substitutions may be introduced at amino acid positions that exhibit functional sensitivity to the initial substitution. Alternatively or additionally, the crystal structure of the antigen-antigen binding molecule complex is used to identify the contact points between the antibody and the antigen. Such contact residues and adjacent residues that are candidates for substitution may be targeted or eliminated. Variants can be screened to determine if they possess the desired properties. Amino acid sequence insertions include amino and/or carboxyl terminal fusions ranging in length from one residue to polypeptides containing one hundred or more residues, as well as intrasequence insertions of one or more amino acid residues. Examples of terminal insertions include bispecific antigen binding molecules with an N-terminal methionyl residue.

In certain aspects, the bispecific antigen binding molecules provided herein are altered to increase or decrease the degree of antibody glycosylation. Glycosylated variants of the molecule may conveniently be obtained by altering the amino acid sequence such that one or more glycosylation sites are created or removed. When the bispecific antigen binding molecule comprises an Fc region, the carbohydrate attached thereto may be altered. Natural antibodies produced by mammalian cells typically comprise branched biantennary oligosaccharides, typically Asn297 attached to the CH2 domain of the Fc region by an N-linkage. See, for example, Wright et al TIBTECH 15:26-32 (1997). Oligosaccharides may include various carbohydrates, for example, mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, the oligosaccharides in the bispecific antigen binding molecule can be modified to produce variants with certain improved properties. In one aspect, variants of bispecific antigen binding molecules are provided that have a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. Such fucosylated variants may have improved ADCC function, see, e.g., U.S. patent publication No. US 2003/0157108(Presta, L.) or US 2004/0093621(Kyowa Hakko Kogyo co., Ltd.). Other variants of the bispecific antigen binding molecules of the invention include variants with bisected oligosaccharides, for example where the biantennary oligosaccharides attached to the Fc region are bisected by GlcNAc. Such variants may have reduced fucosylation and/or improved ADCC function, see for example WO 2003/011878(Jean-Mairet et al); U.S. Pat. No. 6,602,684(Umana et al); and US 2005/0123546(Umana et al). Also provided are variants having at least one galactose residue in an oligosaccharide attached to an Fc region. Such antibody variants may have improved CDC function and are described, for example, in WO 1997/30087(Patel et al); WO 1998/58964(Raju, S.); and WO 1999/22764(Raju, S.).

In certain aspects, it may be desirable to produce cysteine engineered variants of the bispecific antigen binding molecules of the invention, e.g., "thiomabs," in which one or more residues of the molecule are substituted with a cysteine residue. In particular embodiments, the substituted residue is present at an accessible site on the molecule. By replacing those residues with cysteine, the reactive thiol group is thereby localized to an accessible site of the antibody and can be used to conjugate the antibody to other moieties, such as a drug moiety or linker-drug moiety, to produce an immunoconjugate. In certain embodiments, any one or more of the following residues may be substituted with cysteine: v205 of the light chain (Kabat numbering); a118 of the heavy chain (EU numbering); and S400 of the heavy chain Fc region (EU numbering). Cysteine engineered antigen binding molecules can be formed as described, for example, in U.S. patent No. 7,521,541.

In certain aspects, the bispecific antigen binding molecules provided herein can be further modified to contain additional non-protein moieties known in the art and readily available. Moieties suitable for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1, 3-dioxolane, poly-1, 3, 6-trioxane, ethylene/maleic anhydride copolymers, polyaminoacids (homopolymers or random copolymers) and dextran or poly (n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may have any molecular weight and may or may not have branches. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or function of the antibody to be improved, whether the bispecific antibody derivative will be used in therapy under defined conditions, and the like. In another aspect, conjugates of an antibody and a non-proteinaceous moiety that can be selectively heated by exposure to radiation are provided. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, N.W. et al, Proc. Natl. Acad. Sci. USA 102(2005) 11600-. The radiation can be of any wavelength and includes, but is not limited to, wavelengths that are not harmful to normal cells, but heat the non-proteinaceous part to a temperature at which cells in the vicinity of the antibody-non-proteinaceous part are killed.

In another aspect, immunoconjugates of the bispecific antigen binding molecules provided herein can be obtained. An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including but not limited to cytotoxic agents.

The term "nucleic acid" or "polynucleotide" includes any compound and/or substance that comprises a polymer of nucleotides. Each nucleotide consists of a base, in particular a purine or pyrimidine base (i.e. cytosine (C), guanine (G), adenine (a), thymine (T) or uracil (U)), a sugar (i.e. deoxyribose or ribose) and a phosphate group. Generally, nucleic acid molecules are described by the sequence of bases, whereby the bases represent the primary structure (linear structure) of the nucleic acid molecule. The base sequence is usually expressed from 5 'to 3'. In this context, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA) (including, for example, complementary DNA (cdna) and genomic DNA), ribonucleic acid (RNA) (particularly messenger RNA (mrna)), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. The nucleic acid molecule may be linear or circular. In addition, the term nucleic acid molecule includes both sense and antisense strands, as well as single-and double-stranded forms. In addition, the nucleic acid molecules described herein can contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases having derivatized sugar or phosphate backbone linkages or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as vectors for direct expression of the antibodies of the invention in vitro and/or in vivo (e.g., in a host or patient). Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and/or expression of the encoding molecule such that mRNA can be injected into a subject to produce in vivo antibodies (see, e.g., Stadler et al, Nature Medicine 2017, published on 12.6.2017, doi:10.1038/nm.4356 or EP 2101823B 1).

An "isolated" nucleic acid is a nucleic acid molecule that has been separated from components of its natural environment. An isolated nucleic acid includes a nucleic acid molecule that is contained in a cell that normally contains the nucleic acid molecule, but which is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

By "isolated nucleic acid encoding a bispecific antigen binding molecule" is meant one or more nucleic acid molecules encoding the heavy and light chains (or fragments thereof) of the bispecific antigen binding molecule, including such nucleic acid molecules in a single vector or separate vectors, as well as such nucleic acid molecules present at one or more locations in a host cell.

The term "expression cassette" refers to a polynucleotide, generated recombinantly or synthetically, with a series of specific nucleic acid elements that permit transcription of a particular nucleic acid in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plasmid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes, among other sequences, the nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassettes of the invention comprise a polynucleotide sequence encoding a bispecific antigen binding molecule of the invention or a fragment thereof.

The term "vector" or "expression vector" is synonymous with "expression construct" and refers to a DNA molecule for introducing a particular gene into a target cell with which it is operably associated and directing the expression of the gene. The term includes vectors which are self-replicating nucleic acid structures, as well as vectors which integrate into the genome of a host cell into which they have been introduced. The expression vector of the present invention comprises an expression cassette. Expression vectors allow for the transcription of a large number of stable mrnas. Once the expression vector is inside the target cell, the ribonucleic acid molecule or protein encoded by the gene is produced by cellular transcription and/or translation machinery. In one embodiment, the expression vector of the invention comprises an expression cassette comprising a polynucleotide sequence encoding the bispecific antigen binding molecule of the invention or a fragment thereof.

The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to a cell into which an exogenous nucleic acid has been introduced, including the progeny of such a cell. Host cells include "transformants" and "transformed cells," which include a primary transformed cell and progeny derived from the primary transformed cell, regardless of the number of passages. Progeny may not be completely identical to the nucleic acid content of the parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. The host cell is any type of cellular system that can be used to produce the bispecific antigen binding molecules of the invention. Host cells include cultured cells, for example, cultured mammalian cells such as CHO cells, BHK cells, NS0 cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, per.c6 cells or hybridoma cells, yeast cells, insect cells and plant cells, as well as cells included in transgenic animals, transgenic plants or cultured plant or animal tissues, to name a few.

An "effective amount" of an agent is that amount necessary to produce a physiological change in the cell or tissue to which it is administered.

A "therapeutically effective amount" of an agent (e.g., a pharmaceutical composition) is an amount effective to achieve the desired therapeutic or prophylactic result at the necessary dosage and for the period of time. A therapeutically effective amount of an agent, for example, eliminates, reduces, delays, minimizes, or prevents the adverse effects of a disease.

An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., human and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual or subject is a human.

The term "pharmaceutical composition" refers to a formulation that is in a form that allows the biological activity of the active ingredient contained therein to be effective, and that is free of additional components that have unacceptable toxicity to the subject to which the formulation is to be administered.

"pharmaceutically acceptable excipient" refers to an ingredient of a pharmaceutical composition other than an active ingredient that is not toxic to a subject. Pharmaceutically acceptable excipients include, but are not limited to, buffers, stabilizers, or preservatives.

The term "package insert" is used to refer to instructions typically included in commercial packaging for therapeutic products that contain information regarding the indications, usage, dosage, administration, combination therapy, contraindications, and/or warnings concerning the use of such therapeutic products.

As used herein, "treatment" (and grammatical variations thereof, such as "treatment" or "treating") refers to a clinical intervention that attempts to alter the natural course of the treated individual, and may be for the purpose of prevention or in the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or palliating the disease state, and alleviating or improving prognosis. In some embodiments, the molecules of the invention are used to delay the progression of a disease or to slow the progression of a disease.

The term "cancer" as used herein refers to a proliferative disease, such as various lymphomas, carcinomas, lymphomas, blastomas, sarcomas, leukemias, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchoalveolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer (stomach cancer), stomach cancer (gastrotic cancer), colorectal cancer (CRC), pancreatic cancer, breast cancer, negative breast cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, hodgkin's disease, esophageal cancer, small bowel cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, sarcoma soft tissue, urethral cancer, penile cancer, prostate cancer, bladder cancer, kidney cancer or renal cell cancer, renal cell carcinoma, cervical cancer, bladder, Renal pelvis cancer, mesothelioma, hepatocellular carcinoma, cholangiocarcinoma, a Central Nervous System (CNS) tumor, a vertebral axis tumor, a brain stem glioma, glioblastoma multiforme, an astrocytoma, a schwannoma, an ependymoma, a medulloblastoma, a meningioma, a squamous cell carcinoma, a pituitary adenoma, and ewing's sarcoma, melanoma, multiple myeloma, a B-cell cancer (lymphoma), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), hairy cell leukemia, chronic myelogenous leukemia, refractory forms including any of the above cancers, or a combination of one or more of the above cancers.

A "HER 2 positive" cancer includes cancer cells with higher than normal levels of HER 2. Examples of HER2 positive cancers include HER2 positive breast cancer and HER2 positive gastric cancer. Optionally, the HER2 positive cancer has an Immunohistochemical (IHC) score of 2+ or 3+ and/or an In Situ Hybridization (ISH) amplification ratio > 2.0.

The term "Early Breast Cancer (EBC)" or "early breast cancer" is used herein to refer to breast cancer that has not spread beyond the breast or axillary lymph nodes. This includes ductal carcinoma in situ and stage I, IIA, IIB, and IIIA breast cancers.

Tumors or cancers are referred to as "Stage 0", "Stage I", "Stage II", "Stage III" or "Stage IV", and individual sub-stages within this classification, representing the classification of the tumor or cancer using the Overall Stage Grouping or Roman numerical Staging (Roman numerical Staging) methods known in the art. Although the actual stage of cancer depends on the type of cancer, in general, stage 0 cancer is an in situ lesion, stage I cancer is a small local tumor, stage II and III cancers are locally advanced tumors that exhibit regional lymph node involvement, and stage IV cancer represents a metastatic cancer. The specific stage of each type of tumor is known to the skilled clinician.

The term "metastatic breast cancer" refers to a state in which cancer cells are transmitted from an original site to one or more sites elsewhere in the body through blood or lymph vessels, thereby forming one or more secondary tumors in one or more organs other than the breast.

"advanced" cancer refers to cancer that spreads beyond the primary site or organ due to local invasion or metastasis. Thus, the term "advanced" cancer includes locally advanced and metastatic disease.

"recurrent" cancer refers to cancer that recurs at an initial site or beyond in response to an initial therapy (e.g., surgery). "locally recurrent" cancer refers to cancer that recurs at the same location after treatment as previously treated cancer. A "operable" or "resectable" cancer is a cancer that is confined to a major organ and is amenable to surgery (resection). A "non-resectable" or "unresectable" cancer cannot be removed (resected) by surgery.

Bispecific antigen binding molecules of the invention

The present invention provides novel bispecific antigen binding molecules capable of binding bivalent to 4-1BB and monovalent to a target cell antigen, comprising two lipocalin muteins capable of binding specifically to 4-1BB, with particularly advantageous properties, such as producibility, stability, binding affinity, biological activity, targeting efficiency, reduced toxicity and reduced immunity.

The bispecific antigen binding molecules of the invention comprise two lipocalin muteins capable of specifically binding to 4-1BB, each fused to the C-terminus of one of the subunits of the Fc domain. The geometry of the bispecific antigen binding molecule, and in particular the distance between the two different binding sites of 4-1BB and the target cell antigen, is very important for optimal tumor local activation of the co-stimulatory TNF receptor (i.e. 4-1BB) (M.Rothe and A.Skerrra, Biodrugs 2018,32, 233-. It has now also been found that an impressively better activation can be obtained when only one antigen-binding domain for a target cell antigen is present in the molecule. A lower ratio of 1:2 of tumor target binding to effector cell target binding, such as the ratio of antigen binding domain capable of specifically binding to target cell antigen to 1:2 of lipocalin mutein capable of specifically binding to 4-1BB, results in a higher occupancy density on tumor cells, thus resulting in dense cross-linking of 4-1BB agonist on effector cells and ultimately in stronger 4-1BB receptor downstream signaling.

In a first aspect, there is provided a bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising

(a) An antigen binding domain capable of specifically binding to a target cell antigen, in particular a Fab fragment capable of specifically binding to a target cell antigen,

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of said lipocalin muteins is fused to the C-terminus of said first subunit of an Fc domain and the other is fused to the C-terminus of said second subunit of said Fc domain.

In a further aspect, there is provided a bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising

(a) An antigen binding domain, in particular a Fab fragment capable of specifically binding to a target cell antigen,

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of the lipocalin muteins is fused to the C-terminus of a first subunit of the Fc domain and the other is fused to the C-terminus of a second subunit of the Fc domain, and wherein each of the lipocalin muteins capable of specifically binding to 4-1BB is derived from the amino acid sequence of SEQ ID NO: 1 mature human neutrophil gelatinase-associated lipocalin (huNGAL).

In one aspect, there is provided a bispecific antigen binding molecule as defined above, wherein each of the lipocalin muteins capable of specifically binding to 4-1BB comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 wherein one or more of the following amino acids are mutated as follows:

(a) q at position 20 is replaced by R, or

(b) N at position 25 is replaced by Y or D, or

(c) H at position 28 is replaced by Q, or

(d) Q at position 36 is replaced by M, or

(e) I at position 40 is replaced by N, or

(f) R at position 41 is replaced by L or K, or

(g) E at position 44 is replaced by V or D, or

(h) K at position 46 is replaced by S and the amino acids at positions 47 to 49 are deleted, or

(i) I at position 49 is replaced by H, N, V or S, or

(j) M at position 52 is replaced by S or G, or

(k) K at position 59 is replaced by N, or

(l) D at position 65 is replaced by N, or

(M) M at position 68 is replaced by D, G or A, or

(n) K at position 70 is replaced by M, T, A or S, or

(o) F at position 71 is replaced by L, or

(p) D at position 72 is replaced by L, or

(q) M at position 77 is replaced by Q, H, T, R or N, or

(s) D at position 79 is replaced by I or A, or

(t) I at position 80 is replaced by N, or

(u) W at position 81 is replaced by Q, S or M, or

(v) T at position 82 is replaced by P, or

(w) F at position 83 is replaced by L, or

(y) F at position 92 is replaced by L or S, or

L at (z) position 94 is replaced by F, or

K at (za) position 96 is replaced by F, or

(zb) F at position 100 is replaced by D, or

(zc) replacement of P by L at position 101, or

(zd) replacement of H at position 103 by P, or

S at (ze) position 106 is replaced by Y, or

(zf) F at position 122 is replaced by Y, or

(zg) F at position 125 is replaced by S, or

(zh) F at position 127 is replaced by I, or

E at (zi) position 132 is replaced by W, or

(zj) Y at position 134 is replaced by G.

In one aspect, a lipocalin mutein capable of specifically binding to 4-1BB comprises the amino acid sequence of SEQ ID NO 2, wherein 4 to 10 amino acids have been mutated as defined above. In some aspects, a lipocalin mutein capable of specifically binding to 4-1BB comprises one or more of the following amino acid mutations:

(d) q at position 36 is replaced by M, or

(e) I at position 40 is replaced by N, or

(f) R at position 41 is replaced by L or K, or

(i) I at position 49 is replaced by H, N, V or S, or

(j) M at position 52 is replaced by S or G, or

(M) M at position 68 is replaced by D, G or A, or

(n) K at position 70 is replaced by M, T, A or S, or

(p) D at position 72 is replaced by L, or

(q) M at position 77 is replaced by Q, H, T, R or N, or

(s) D at position 79 is replaced by I or A, or

(u) W at position 81 is replaced by Q, S or M, or

K at (za) position 96 is replaced by F, or

(zb) F at position 100 is replaced by D, or

(zd) replacement of H at position 103 by P, or

(zg) F at position 125 is replaced by S, or

(zh) F at position 127 is replaced by I, or

E at (zi) position 132 is replaced by W, or

(zj) Y at position 134 is replaced by G.

In another aspect, a lipocalin mutein capable of specifically binding to 4-1BB comprises one or more of the following amino acid mutations:

(a) q at position 20 is replaced by R, or

(b) N at position 25 is replaced by Y or D, or

(g) E at position 44 is replaced by V or D, or

(k) K at position 59 is replaced by N, or

(o) F at position 71 is replaced by L, or

(t) I at position 80 is replaced by N, or

(v) T at position 82 is replaced by P, or

(y) F at position 92 is replaced by L or S, or

(zc) replacement of P by L at position 101, or

(zf) F at position 122 is replaced by Y.

In one aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises an amino acid sequence selected from the group consisting of: SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18, SEQ ID NO 19 and SEQ ID NO 20. In one aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises an amino acid sequence selected from the group consisting of: 2, 3, 4, 5, 6, 7, 8, 9 and 10. In a further aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises an amino acid sequence selected from the group consisting of: 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20. In one aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises the amino acid sequence of SEQ ID NO. 2. In one aspect, the lipocalin muteins all comprise the same amino acid sequence.

In a further aspect, there is provided a bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising

(a) A Fab fragment capable of specifically binding to a target cell antigen;

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of the lipocalin muteins is fused to the C-terminus of a first subunit of the Fc domain and the other is fused to the C-terminus of a second subunit of the Fc domain, and wherein each of the lipocalin muteins capable of specifically binding to 4-1BB is derived from the amino acid sequence of SEQ ID NO: 90 (Tlc).

In one aspect, each of the lipocalin muteins capable of specifically binding to 4-1BB comprises an amino acid sequence selected from the group consisting of: 106, 107, 108, 109, 110, 111 and 112.

In one aspect, the invention provides a bispecific antigen binding molecule comprising two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of the lipocalin muteins is fused via a peptide linker to the C-terminus of a first subunit of the Fc domain and the other is fused via a peptide linker to the C-terminus of a second subunit of the Fc domain. In one aspect, the peptide linker has an amino acid sequence selected from the group consisting of: SEQ ID NO 75, SEQ ID NO 76, SEQ ID NO 77, SEQ ID NO 78, SEQ ID NO 79, SEQ ID NO 80, SEQ ID NO 81, SEQ ID NO 82, SEQ ID NO 83, SEQ ID NO 84, SEQ ID NO 85, SEQ ID NO 86, SEQ ID NO 87, SEQ ID NO 88, SEQ ID NO 89, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 115, SEQ ID NO 116, SEQ ID NO 117, SEQ ID NO 118, SEQ ID NO 119, SEQ ID NO 120 and SEQ ID NO 121. In one aspect, the peptide linker has an amino acid sequence selected from the group consisting of: SEQ ID NO 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88 and 89. In another aspect, the peptide linker has an amino acid sequence selected from the group consisting of: 113, 114, 115, 116, 117, 118, 119, 120 and 121. Specifically, the peptide linker has the amino acid sequence of SEQ ID NO:78, i.e., (G) ₄S)₃。

In a further aspect, the Fc domain is an IgG, in particular an IgG1 Fc domain or an IgG4 Fc domain. More specifically, the Fc domain is an IgG1 Fc domain. In a particular aspect, the Fc domain comprises a modification that facilitates association of the first subunit and the second subunit of the Fc domain.

Fc domain modification to promote heterodimerization

In one aspect, the bispecific antigen binding molecules of the invention comprise: an Fc domain comprising a first subunit and a second subunit capable of stable association; a Fab fragment capable of specifically binding to a target cell antigen, said Fab fragment fused to the N-terminus of the first subunit of the Fc domain; and two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of the lipocalin muteins is fused to the C-terminus of a first subunit of the Fc domain and the other is fused to the C-terminus of a second subunit of the Fc domain. Accordingly, the bispecific antigen binding molecules of the present invention comprise: two different polypeptide chains ("heavy chains") comprising a first and a second subunit of an Fc domain, respectively, and one light chain. Recombinant co-expression and subsequent dimerization of these polypeptides results in several possible combinations of two different heavy chains. In order to increase the yield and purity of the bispecific antigen binding molecule in recombinant production, it would therefore be advantageous to introduce modifications in the Fc domain of the bispecific antigen binding molecule that promote the association of the desired polypeptide.

Thus, the Fc domain of the bispecific antigen binding molecules of the invention comprises modifications that facilitate association of the first and second subunits of the Fc domain. The most extensive site of protein-protein interaction between the two subunits of the human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, the modification is particularly in the CH3 domain of the Fc domain.

In a particular aspect, the modification is a so-called "knob" modification, which includes a "knob" modification in one of the two subunits of the Fc domain and a "hole" modification in the other of the two subunits of the Fc domain. Thus, in one particular aspect, the invention relates to a bispecific antigen binding molecule as described herein above, comprising an IgG molecule, wherein the Fc part of the first heavy chain comprises a first dimerization module and the Fc part of the second heavy chain comprises a second dimerization module allowing heterodimerization of the two heavy chains of the IgG molecule, and the first dimerization module comprises a protuberance, and the second dimerization module comprises a pore according to the knob and hole structure technique.

Mortar and pestle construction techniques are described, for example, in US 5,731,168; US 7,695,936; ridgway et al, Prot Eng 9, 617. sup. 621(1996) and Carter, J Immunol Meth 248, 7-15 (2001). In general, the method involves introducing a bulge ("protuberance") at the interface of a first polypeptide and a corresponding cavity ("hole") in the interface of a second polypeptide, such that the bulge can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. The bulge is constructed by substituting a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). Compensatory cavities having the same or similar size as the bulge are created in the interface of the second polypeptide by substituting a larger amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine).

Thus, in one particular aspect, in the CH3 domain of the first subunit of the Fc domain of the bispecific antigen binding molecules disclosed herein, an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby creating a protuberance within the CH3 domain of the first subunit that is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain, an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby creating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.

The projections and cavities can be made by altering the nucleic acid encoding the polypeptide, for example by site-specific mutagenesis or by peptide synthesis.

In a particular aspect, in the CH3 domain of the first subunit of the Fc domain, the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain, the tyrosine residue at position 407 is replaced with a valine residue (Y407V). More specifically, in the second subunit of the Fc domain, the threonine residue at position 366 is additionally replaced with a serine residue (T366S), and the leucine residue at position 368 is replaced with an alanine residue (L368A). More specifically, in the first subunit of the Fc domain, the serine residue at position 354 was additionally replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain, the tyrosine residue at position 349 was additionally replaced with a cysteine residue (Y349C). The introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc domain. Disulfide bridges further stabilize the dimer (Carter, J Immunol Methods 248,7-15 (2001)).

In another aspect, the modifications that facilitate association of the first and second subunits of the Fc domain include modifications that mediate electrostatic steering effects, for example as described in PCT publication WO 2009/089004. Typically, the method involves substituting one or more amino acid residues at the interface of two Fc domain subunits with charged amino acid residues such that homodimer formation becomes electrostatically unfavorable, but heterodimerization is electrostatically favorable.

Fc domain modifications that reduce Fc receptor binding and/or effector function

The Fc domain of the bispecific antigen binding molecules of the present invention consists of a pair of polypeptide chains comprising the heavy chain domain of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin g (IgG) molecule is a dimer, each subunit of which comprises a CH2 and CH3 IgG heavy chain constant domain. The two subunits of the Fc domain are capable of stably associating with each other.

The Fc domain confers advantageous pharmacokinetic properties to the antigen binding molecules of the invention, including a long serum half-life and a favorable tissue-to-blood partition ratio that contribute to good accumulation in the target tissue. At the same time, however, it may result in the bispecific antibodies of the invention undesirably targeting Fc receptor expressing cells rather than the preferred antigen carrying cells. Thus, in another particular aspect, the Fc domain of the bispecific antigen binding molecules of the invention exhibits reduced binding affinity to Fc receptors and/or reduced effector function compared to a native IgG1 Fc domain. In one aspect, the Fc does not substantially bind to Fc receptors and/or does not induce effector function. In a particular aspect, the Fc receptor is an fey receptor. In one aspect, the Fc receptor is a human Fc receptor. In a particular aspect, the Fc receptor is an activated human Fc γ receptor, more particularly human Fc γ RIIIa, Fc γ RI or Fc γ RIIa, most particularly human Fc γ RIIIa. In one aspect, the Fc domain does not induce effector function. Reduced effector function may include, but is not limited to, one or more of the following: reduced Complement Dependent Cytotoxicity (CDC), reduced antibody dependent cell mediated cytotoxicity (ADCC), reduced Antibody Dependent Cellular Phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex mediated antigen uptake by antigen presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling induced apoptosis, reduced dendritic cell maturation, or reduced T cell priming.

In certain aspects, one or more amino acid modifications can be introduced into the Fc region of the bispecific antigen binding molecules provided herein, thereby generating Fc region variants. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) comprising amino acid modifications (e.g., substitutions) at one or more amino acid positions.

In one particular aspect, the invention provides a polypeptide capable of divalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising

(a) A Fab fragment capable of specifically binding to a target cell antigen;

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of the lipocalin muteins is fused to the C-terminus of a first subunit of the Fc domain and the other is fused to the C-terminus of a second subunit of the Fc domain, wherein said Fc domain comprises one or more amino acid substitutions that reduce the binding to an Fc receptor, in particular to an fey receptor.

In one aspect, the Fc domain of the bispecific antigen binding molecules of the invention comprises one or more amino acid mutations that reduce the binding affinity of the Fc domain to an Fc receptor and/or effector function. Typically, the same amino acid mutation or mutations are present in each of the two subunits of the Fc domain. Specifically, the Fc domain comprises amino acid substitutions at positions (EU numbering) E233, L234, L235, N297, P331 and P329. In particular, the Fc domain comprises amino acid substitutions at positions 234 and 235(EU numbering) and/or 329(EU numbering) of the IgG heavy chain. More specifically, antigen binding molecules comprising a trimeric TNF family ligand according to the invention are provided, comprising an Fc domain having the amino acid substitutions L234A, L235A and P329G ("P329G LALA", EU numbering) in the IgG heavy chain. The amino acid substitutions L234A and L235A refer to the so-called LALA mutations. The combination of amino acid substitutions "P329G LALA" almost completely abolishes Fc γ receptor binding of the human IgG1 Fc domain and is described in international patent application publication No. WO 2012/130831a1, which also describes methods of making such mutant Fc domains and methods for determining properties thereof, such as Fc receptor binding or effector function. "EU numbering" refers to numbering according to the EU index of Kabat et al, Sequences of Proteins of Immunological Interest, 5 th edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

In a particular aspect, an Fc domain comprising a first subunit and a second subunit capable of stable association comprises: a first subunit comprising the amino acid sequence of SEQ ID NO 128, and a second subunit comprising the amino acid sequence of SEQ ID NO 129.

Fc domains with reduced Fc receptor binding and/or effector function also include those with substitution of one or more of Fc domain residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants having substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including so-called "DANA" Fc mutants in which residues 265 and 297 are substituted with alanine (U.S. Pat. No. 7,332,581).

In another aspect, the Fc domain is an IgG4 Fc domain. Compared to the IgG1 antibody, the IgG4 antibody exhibits reduced binding affinity to Fc receptors and reduced effector function. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position S228 (Kabat numbering), in particular the amino acid substitution S228P. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising the amino acid substitutions L235E and S228P and P329G (EU numbering). The binding properties of such IgG4 Fc domain mutants and their Fc γ receptors are also described in WO 2012/130831.

The mutant Fc domain may be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods may include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, and the like. The correct nucleotide change can be verified, for example, by sequencing.

Binding to Fc receptors can be readily determined, for example, by ELISA or by Surface Plasmon Resonance (SPR) using standard instruments such as BIAcore instruments (GE Healthcare), and Fc receptors can be obtained, for example, by recombinant expression. Suitable such binding assays are described herein. Alternatively, cell lines known to express specific Fc receptors (such as human NK cells expressing Fc γ IIIa receptors) can be used to assess the binding affinity of Fc domains or Fc domain containing cell activating bispecific antigen binding molecules to Fc receptors.

The effector function of an Fc domain, or a bispecific antibody comprising an Fc domain of the invention, can be measured by methods known in the art. Suitable assays for measuring ADCC are described herein. Other examples of in vitro assays for assessing ADCC activity of a target molecule are described in: U.S. Pat. nos. 5,500,362; hellstrom et al, Proc Natl Acad Sci USA 83, 7059-; U.S. Pat. nos. 5,821,337; bruggemann et al, J Exp Med 166,1351- 1361(1987). Alternatively, non-radioactive assay methods can be used (see, e.g., ACTI for flow cytometry)^TMNon-radioactive cytotoxicity assay (CellTechnology, inc. mountain View, CA); and CytotoxNon-radioactive cytotoxicity assays (Promega, Madison, WI), Madison, maduraw, WIs). Useful effector cells for such assays include Peripheral Blood Mononuclear Cells (PBMC) and Natural Killer (NK) cells. Alternatively or additionally, the ADCC activity of the target molecule may be assessed in vivo, for example in an animal model such as disclosed in Clynes et al, Proc Natl Acad Sci USA 95, 652-.

In some embodiments, Fc domain binding to complement components, particularly C1q, is reduced. Thus, in some embodiments, wherein the Fc domain is engineered to have reduced effector function, said reduced effector function comprises reduced CDC. A C1q binding assay may be performed to determine whether a bispecific antibody of the invention is capable of binding C1q and thus has CDC activity. See, e.g., WO 2006/029879 and WO 2005/100402 for C1q and C3C binding ELISA. To assess complement activation, CDC assays may be performed (see, e.g., Gazzano-Santoro et al, J Immunol Methods 202,163 (1996); Cragg et al, Blood 101, 1045-.

Specific bispecific antigen binding molecules

In one aspect, the invention provides a bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising

(a) Fab fragments capable of binding specifically to Fibroblast Activation Protein (FAP),

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of said lipocalin muteins is fused to the C-terminus of said first subunit of an Fc domain and the other is fused to the C-terminus of said second subunit of said Fc domain.

In one aspect, a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP) comprises:

(a) heavy chain variable region (V)_HFAP) comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 23; and light chain variable region (V)_LFAP) comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 26; or

(b) Heavy chain variable region (V)_HFAP) comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:29, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:30, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 31; and light chain variable region (V)_LFAP) comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:32, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:33, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 34.

In one aspect, a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP) comprises: heavy chain variable region (V)_HFAP) comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:21, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:22, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 23; and light chain variable region (V)_LFAP) comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:24, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:25, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 26.

In one aspect, there is provided a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP), comprising:

(a) Heavy chain variable region (V)_HFAP) comprising at least about 95%, 96% of the amino acid sequence of SEQ ID NO 2797%, 98%, 99% or 100% identical amino acid sequence; and light chain variable region (V)_LFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 28; or

(b) Heavy chain variable region (V)_HFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 35; and light chain variable region (V)_LFAP) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 36.

In one aspect, there is provided a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP), comprising: heavy chain variable region (V)_HFAP) comprising the amino acid sequence of SEQ ID NO:27, and a light chain variable region (V)_LFAP) comprising the amino acid sequence of SEQ ID NO 28; or heavy chain variable region (V)_HFAP) comprising the amino acid sequence of SEQ ID NO 35, and a light chain variable region (V)_LFAP) comprising the amino acid sequence of SEQ ID NO: 36. In one aspect, a Fab fragment capable of specifically binding to Fibroblast Activation Protein (FAP) comprises: heavy chain variable region (V) _HFAP) comprising the amino acid sequence of SEQ ID NO 27; and light chain variable region (V)_LFAP) comprising the amino acid sequence of SEQ ID NO 28.

In one aspect, the bispecific antigen binding molecules provided herein comprise SEQ ID NOs: 37, SEQ ID NO: 38 and the second heavy chain of SEQ ID NO: 39.

In another aspect, the invention provides a bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen, comprising

(a) A Fab fragment capable of specifically binding to HER 2;

(b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and

(c) two lipocalin muteins capable of specifically binding to 4-1BB, wherein one of said lipocalin muteins is fused to the C-terminus of said first subunit of an Fc domain and the other is fused to the C-terminus of said second subunit of said Fc domain.

In one aspect, a Fab fragment capable of specifically binding to HER2 comprises:

(a) a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:40, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:41, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 42; and a VL domain comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:43, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:44, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 45; or

(b) A VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:48, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:49, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 50; and a VL domain comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:51, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:52, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 53; or

(c) A VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:56, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:57, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 58; and a VL domain comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:59, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:60, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 61.

In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: (a) a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:40, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:41, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 42; and a VL domain comprising: (iv) (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:43, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:44, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 45. In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: a VH domain comprising: (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:48, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:49, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 50; and a VL domain comprising: (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:51, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:52, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 53.

In one aspect, there is provided a Fab fragment capable of specifically binding to HER2 comprising:

(a) heavy chain variable region (V)_HHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 46; and light chain variable region (V)_LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 47; or

(b) Heavy chain variable region (V)_HHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 54; and light chain variable region (V)_LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 55; or

(c) Heavy chain variable region (V)_HHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 62; and light chain variable region (V)_LHER2) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID No. 63.

In one aspect, there is provided a Fab fragment capable of specifically binding to HER2 comprising: heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:46, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO: 47; or heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:54, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO: 55; or heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:62, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO: 63. In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:46, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO: 47. In one aspect, a Fab fragment capable of specifically binding to HER2 comprises: heavy chain variable region (V)_HHER2) comprising the amino acid sequence of SEQ ID NO:54, and a light chain variable region (V)_LHER2) comprising the amino acid sequence of SEQ ID NO: 55.

In one aspect, the bispecific antigen binding molecules provided herein comprise SEQ ID NOs: 64, SEQ ID NO: 65 and the second heavy chain of SEQ ID NO: 66, or a light chain of (b).

Polynucleotide

The invention further provides an isolated nucleic acid encoding a bispecific antigen binding molecule or fragment thereof as described herein.

An isolated polynucleotide encoding a bispecific antigen binding molecule of the invention may be expressed as a single polynucleotide encoding the entire antigen binding molecule, or as multiple (e.g., two or more) polynucleotides that are co-expressed. Polypeptides encoded by the co-expressed polynucleotides may associate via, for example, disulfide bonds or other means to form a functional antigen binding molecule. For example, the light chain portion of an immunoglobulin may be encoded by a separate polynucleotide from the heavy chain portion of an immunoglobulin. When co-expressed, the heavy chain polypeptide will associate with the light chain polypeptide to form an immunoglobulin.

In some aspects, the isolated nucleic acid encodes a complete bispecific antigen binding molecule according to the invention as described herein. In particular, the isolated polynucleotide encodes a polypeptide comprised in a bispecific antigen binding molecule according to the invention as described herein.

In one aspect, the invention relates to an isolated nucleic acid encoding a bispecific antigen binding molecule, wherein the nucleic acid molecule comprises: (a) a sequence encoding an antigen binding domain capable of specifically binding to a target cell antigen, (b) a sequence encoding an Fc domain comprising a first subunit and a second subunit capable of stable association, and (c) a sequence encoding a lipocalin mutein capable of specifically binding to 4-1 BB.

In another aspect, an isolated polynucleotide encoding a bispecific antigen binding molecule is provided, wherein the polynucleotide comprises a sequence encoding: (a) a Fab fragment capable of specifically binding to a target cell antigen; (b) an Fc domain comprising a first subunit and a second subunit capable of stable association, and (C) two lipocalin muteins capable of specific binding to 4-1BB, wherein one of said lipocalin muteins is fused to the C-terminus of said first subunit of the Fc domain and the other is fused to the C-terminus of said second subunit of said Fc domain.

In certain aspects, the polynucleotide or nucleic acid is DNA. In other embodiments, the polynucleotide of the invention is RNA, for example in the form of messenger RNA (mrna). The RNA of the present invention may be single-stranded or double-stranded.

Recombination method

The bispecific antigen binding molecules of the invention may be obtained, for example, by solid state peptide synthesis (e.g., Merrifield solid phase synthesis) or recombinant production. For recombinant production, one or more polynucleotides encoding bispecific antigen binding molecules or polypeptide fragments thereof, e.g., as described above, are isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such polynucleotides can be readily isolated and sequenced using conventional methods. In one aspect of the invention, there is provided a vector, preferably an expression vector, comprising one or more of the polynucleotides of the invention. Methods well known to those skilled in the art can be used to construct expression vectors containing the coding sequence of the bispecific antigen binding molecule (fragment) and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo recombination/genetic recombination. See, for example, the techniques described in: maniatis et al, Molecula clone, A Laboratory Manual, Cold Spring Harbor LABORATORY, N.Y. (1989); and Ausubel et al, Current PROTOCOLS IN MOLECULAR bond BIOLOGY, Greene Publishing Associates and Wiley Interscience, N.Y. (1989), labeling an antibody with a ligand reagent that binds, chelates, or otherwise complexes a radioisotope metal, wherein the reagent reacts with the engineered cysteine thiol of the antibody. The expression vector may be part of a plasmid, virus, or may be a nucleic acid fragment. The expression vector includes an expression cassette into which a polynucleotide encoding the bispecific antigen binding molecule or polypeptide fragment thereof (i.e., the coding region) is cloned in operable association with a promoter and/or other transcriptional or translational control elements. As used herein, a "coding region" is a portion of a nucleic acid that consists of codons that are translated into amino acids. Although the "stop codon" (TAG, TGA or TAA) is not translated into an amino acid, it (if present) can be considered part of the coding region, whereas any flanking sequences, such as promoters, ribosome binding sites, transcription terminators, introns, 5 'and 3' untranslated regions, etc., are not part of the coding region. The two or more coding regions may be present in a single polynucleotide construct (e.g., on a single vector), or in separate polynucleotide constructs (e.g., on separate (different) vectors). In addition, any vector may contain a single coding region, or may contain two or more coding regions, e.g., a vector of the invention may encode one or more polypeptides that are separated into the final protein by proteolytic cleavage post-or post-translationally. In addition, the vectors, polynucleotides or nucleic acids of the invention may encode a heterologous coding region, fused or not fused to a polynucleotide encoding a bispecific antigen binding molecule of the invention or polypeptide fragment thereof, or variant or derivative thereof. Heterologous coding regions include, but are not limited to, specialized elements or motifs, such as secretion signal peptides or heterologous functional domains. Operable association is when the coding region of a gene product (e.g., a polypeptide) is associated with one or more regulatory sequences in a manner such that expression of the gene product is under the influence or control of the regulatory sequences. Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are "operably associated" if induction of promoter function results in transcription of mRNA encoding the desired gene product, and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression control sequences to direct expression of the gene product or with the ability of the gene template to be transcribed. Thus, if a promoter is capable of affecting transcription of the nucleic acid, the promoter region will be operably associated with the nucleic acid encoding the polypeptide. The promoter may be a cell-specific promoter that directs substantial transcription of DNA only in predetermined cells. In addition to promoters, other transcriptional control elements, such as enhancers, operators, repressors, and transcriptional termination signals, may be operably associated with a polynucleotide to direct cell-specific transcription.

Suitable promoters and other transcriptional control regions are disclosed herein. Various transcriptional control regions are known to those skilled in the art. These transcriptional control regions include, but are not limited to, transcriptional control regions that function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegalovirus (e.g., immediate early promoter-binding intron-a), simian virus 40 (e.g., early promoter), and retroviruses (such as, for example, rous sarcoma virus). Other transcriptional control regions include those derived from vertebrate genes (such as actin, heat shock proteins, bovine growth hormone and rabbitGlobin), and other sequences capable of controlling gene expression in eukaryotic cells. Other suitable transcriptional control regions include tissue-specific promoters and enhancers and inducible promoters (e.g., tetracycline-inducible promoters). Similarly, various translational control elements are known to those of ordinary skill in the art. These translation control elements include, but are not limited to, ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly internal ones)Ribosome entry site, or IRES, also known as CITE sequence). The expression cassette may also include other features, such as an origin of replication, and/or chromosomal integration elements, such as retroviral Long Terminal Repeats (LTRs), or adeno-associated virus (AAV) Inverted Terminal Repeats (ITRs).

The polynucleotide and nucleic acid coding regions of the present invention may be associated with additional coding regions encoding a secretion peptide or signal peptide which direct secretion of the polypeptide encoded by the polynucleotide of the present invention. For example, if secretion of the bispecific antigen binding molecule or polypeptide fragment thereof is desired, a DNA encoding a signal sequence can be placed upstream of the nucleic acid encoding the bispecific antigen binding molecule or polypeptide fragment thereof of the present invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence that is cleaved from the mature protein once the protein chain has been initiated to grow across the rough endoplasmic reticulum export. One of ordinary skill in the art will recognize that polypeptides secreted by vertebrate cells typically have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to yield a secreted or "mature" form of the polypeptide. In certain embodiments, a native signal peptide (e.g., an immunoglobulin heavy or light chain signal peptide) is used, or a functional derivative of that sequence that retains the ability to direct secretion of a polypeptide with which it is operably associated. Alternatively, a heterologous mammalian signal peptide or functional derivative thereof may be used. For example, the wild-type leader sequence may be substituted with the leader sequence of human Tissue Plasminogen Activator (TPA) or mouse β -glucuronidase.

DNA encoding short protein sequences (e.g., histidine tags) that can be used to facilitate subsequent purification or DNA that helps label the fusion protein can be included within or at the end of the polynucleotide encoding the bispecific antigen binding molecule of the invention or polypeptide fragment thereof.

In another aspect of the invention, host cells comprising one or more polynucleotides of the invention are provided. In certain embodiments, host cells comprising one or more vectors of the invention are provided. The polynucleotide and vector may be introgressed, individually or in combination, with any of the features described herein with respect to the polynucleotide and vector, respectively. In one aspect, the host cell comprises (e.g., has been transformed or transfected with) a vector comprising a polynucleotide encoding (part of) the bispecific antigen binding molecule of the invention. As used herein, the term "host cell" refers to any kind of cellular system that can be engineered to produce a fusion protein of the invention or a fragment thereof. Host cells suitable for replicating and supporting the expression of antigen binding molecules are well known in the art. Such cells can be appropriately transfected or transduced with a particular expression vector, and large numbers of vector-containing cells can be grown for seeding large-scale fermentors to obtain sufficient quantities of antigen binding molecules for clinical use. Suitable host cells include prokaryotic microorganisms such as E.coli, or various eukaryotic cells such as Chinese hamster ovary Cells (CHO), insect cells, and the like. For example, the polypeptide may be produced in bacteria, particularly when glycosylation is not required. The polypeptide can be isolated from the bacterial cell paste after expression in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for vectors encoding polypeptides, including fungi and yeast strains whose glycosylation pathways have been "humanized" resulting in the production of polypeptides having a partially or fully human glycosylation pattern. See Gerngross, Nat Biotech 22, 1409-.

Suitable host cells for the expression (glycosylation) of polypeptides also originate from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. A number of baculovirus strains have been identified which can be used in conjunction with insect cells, particularly for transfecting Spodoptera frugiperda (Spodoptera frugiperda) cells. Plant cell cultures may also be used as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIIES for antibody production in transgenic plants^TMA technique). Vertebrate cells can also be usedAs a host. For example, mammalian cell lines suitable for growth in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney lines (293 or 293T cells, as described for example in Graham et al, J Gen Virol 36,59 (1977)), baby hamster kidney cells (BHK), mouse Sertoli cells (TM4 cells, as described for example in Mather, Biol Reprod 23, 243-. Other useful mammalian host cell lines include Chinese Hamster Ovary (CHO) cells, including dhfr-CHO cells (Urlaub et al, Proc Natl Acad Sci USA 77,4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63, and Sp 2/0. For a review of certain mammalian host cell lines suitable for protein production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol.248 (B.K.C.Lo eds., Humana Press, Totowa, NJ), pp.255-268 (2003). Host cells include cultured cells such as mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, to name a few, and also include cells contained in transgenic animals, transgenic plants or cultured plant or animal tissues. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell, a Human Embryonic Kidney (HEK) cell, or a lymphocyte (e.g., Y0, NS0, Sp20 cell). Standard techniques for expressing foreign genes in these systems are known in the art. Cells expressing a polypeptide comprising the heavy or light chain of an immunoglobulin can be engineered to also express another immunoglobulin chain, such that the expressed product is an immunoglobulin with a heavy and light chain.

In one aspect, a method of producing a bispecific antigen binding molecule or polypeptide fragment thereof of the invention is provided, wherein the method comprises culturing a host cell comprising a polynucleotide encoding the bispecific antigen binding molecule or polypeptide fragment thereof of the invention as provided herein under conditions suitable for expression of the bispecific antigen binding molecule or polypeptide fragment thereof of the invention, and recovering the bispecific antigen binding molecule or polypeptide fragment thereof of the invention from the host cell (or host cell culture medium).

In the bispecific antigen binding molecules of the invention, the components (at least one part capable of specifically binding to a target cell antigen, a subunit comprising an Fc domain and a polypeptide of a lipocalin mutein) are not genetically fused to each other. The polypeptides are designed such that their components are fused to each other directly or through linker sequences. The composition and length of the linker can be determined according to methods well known in the art, and the efficacy of the linker can be tested. Examples of linker sequences between the different components of the antigen binding molecules of the invention are found in the sequences provided herein. Additional sequences (e.g., endopeptidase recognition sequences) may also be included to incorporate cleavage sites to separate the individual components of the fusion protein, if desired.

In certain embodiments, an antigen binding domain capable of specific binding to a target cell antigen (such as a Fab fragment), which forms part of an antigen binding molecule, comprises at least one immunoglobulin variable region capable of binding to an antigen. The variable regions may form part of and be derived from naturally or non-naturally occurring antibodies and fragments thereof. Methods for producing polyclonal and monoclonal Antibodies are well known in the art (see, e.g., Harlow and Lane, "Antibodies, a Laboratory", Cold Spring Harbor Laboratory, 1988). Non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be recombinantly produced (e.g., as described in U.S. patent No. 4,186,567), or can be obtained, for example, by screening combinatorial libraries comprising variable heavy and variable light chains (see, e.g., U.S. patent No. 5,969,108 to McCafferty).

Immunoglobulins of any animal species may be used in the present invention. Non-limiting immunoglobulins useful in the present invention may be of murine, primate, or human origin. If the fusion protein is intended for human use, a chimeric form of an immunoglobulin may be used, wherein the constant region of the immunoglobulin is from a human. Immunoglobulins may also be prepared in humanized or fully human form according to methods well known in the art (see, e.g., U.S. Pat. No. 5,565,332 to Winter). Humanization can be achieved by a variety of methods including, but not limited to, (a) grafting non-human (e.g., donor antibody) CDRs onto human (e.g., acceptor antibody) frameworks and constant regions with or without retaining critical framework residues (e.g., critical framework residues important for maintaining good antigen binding affinity or antibody function), (b) grafting only non-human specificity determining regions (SDRs or a-CDRs; residues critical for antibody-antigen interaction) onto human frameworks and constant regions, or (c) grafting entire non-human variable domains but "hiding" them with human-like regions by replacing surface residues. Humanized antibodies and methods for their preparation are reviewed, for example, in Almagro and Fransson, Front Biosci 13, 1619-: riechmann et al, Nature 332, 323-E329 (1988); queen et al, Proc Natl Acad Sci USA 86, 10029-; U.S. Pat. nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; jones et al, Nature 321, 522-525 (1986); morrison et al, Proc Natl Acad Sci 81, 6851-6855 (1984); morrison and Oi, Adv Immunol 44, 65-92 (1988); verhoeyen et al, Science 239, 1534-; padlan, Molec Immun 31(3), 169-217 (1994); kashmiri et al, Methods 36, 25-34(2005) (SDR (a-CDR) grafting is described); padlan, Mol Immunol 28, 489-498(1991) (described as "surface remodeling"); dall' Acqua et al, Methods 36, 43-60(2005) (describes "FR shuffling"); and Osbourn et al, Methods 36, 61-68(2005) and Klimka et al, Br J Cancer 83, 252-. A particular immunoglobulin according to the invention is a human immunoglobulin. Various techniques known in the art can be used to generate human antibodies and human variable regions. Human antibodies are generally described in van Dijk and van de Winkel, Curr Opin Pharmacol 5,368-74(2001) and Lonberg, Curr Opin Immunol 20, 450-. The human variable region may form part of, and be derived from, human Monoclonal antibodies produced by the hybridoma method (see, e.g., Monoclonal Antibody Production Techniques and Applications, pp 51-63 (Marcel Dekker, Inc., New York, 1987)). Human antibodies and human variable regions can also be made by: immunogens are administered to transgenic animals that have been modified to produce fully human antibodies or fully antibodies with human variable regions in response to antigen challenge (see, e.g., Lonberg, Nat Biotech 23,1117-1125 (2005)). Human antibodies and Human variable regions can also be generated by isolating Fv clone variable region sequences selected from a Human phage display library (see, e.g., Hoogenboom et al in Methods in Molecular Biology 178,1-37(O' Brien et al, eds., Human Press, Totowa, NJ, 2001); and McCafferty et al, Nature 348, 552-554; Clackson et al, Nature 352,624-628 (1991)). Phage typically display antibody fragments as single chain fv (scfv) fragments or Fab fragments.

In certain aspects, the antigen binding domains (such as Fab fragments) comprised in the antigen binding molecules of the invention that are capable of specifically binding to a target cell antigen are engineered to have enhanced binding affinity, for example according to the methods disclosed in PCT publication WO 2012/020006 (see examples relating to affinity maturation) or U.S. patent application publication No. 2004/0132066. The ability of the antigen binding molecules of the invention to bind to a particular Epitope can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance (Liljeblad et al, Glyco J17, 323-329(2000)) and conventional binding assays (Heeley, Endocr Res 28,217-229(2002)) competitive assays can be used to identify antigen binding molecules that compete with a reference antibody for binding to a particular antigen. The immobilized antigen is incubated in a solution comprising a first labeled antigen binding molecule that binds to the antigen and a second unlabeled antigen binding molecule that is being tested for its ability to compete with the first antigen binding molecule for binding to the antigen. The second antigen binding molecule may be present in a hybridoma supernatant. As a control, the immobilized antigen is incubated in a solution comprising the first labeled antigen binding molecule but not the second unlabeled antigen binding molecule. After incubation under conditions that allow the first antibody to bind to the antigen, excess unbound antibody is removed and the amount of label associated with the immobilized antigen is measured. If the amount of label associated with the immobilized antigen is substantially reduced in the test sample relative to the control sample, it is indicative that the second antigen binding molecule competes with the first antigen binding molecule for binding to the antigen. See Harlow and Lane (1988) Antibodies, Chapter 14 of A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

Bispecific antigen binding molecules of the invention prepared as described herein can be purified by techniques known in the art, such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will depend in part on factors such as net charge, hydrophobicity, hydrophilicity, and the like, and will be apparent to those skilled in the art. For affinity chromatography purification, antibodies, ligands, receptors or antigens to which the bispecific antigen binding molecule binds may be used. For example, for affinity chromatography purification of the fusion protein of the invention, a matrix with protein a or protein G may be used. The antigen binding molecules can be separated using sequential protein a or G affinity chromatography and size exclusion chromatography, essentially as described in the examples. The purity of the bispecific antigen binding molecule or fragment thereof can be determined by any of a variety of well-known analytical methods, including gel electrophoresis, high pressure liquid chromatography, and the like. For example, the expressed bispecific antigen binding molecules described in the examples were shown to be intact and properly assembled as shown by reducing and non-reducing SDS-PAGE.

Measurement of

The physical/chemical properties and/or biological activities of the antigen binding molecules provided herein can be identified, screened, or characterized by various assays known in the art. Biological activity may include, for example, the ability to enhance the activation and/or proliferation of various immune cells, particularly T cells. For example, they enhance the secretion of immunomodulatory cytokines. Other immunomodulatory cytokines that are or can be enhanced are e.g. IL2, granzyme B, etc. Biological activity may also include cynomolgus binding cross-reactivity and binding to different cell types. Antigen binding molecules having such biological activity in vivo and/or in vitro are also provided.

1. Affinity assay

The affinity of the bispecific antigen binding molecules provided herein for 4-1BB (CD137) can be determined by Surface Plasmon Resonance (SPR) according to the methods set forth in the examples using standard instruments such as BIAcore instruments (GE Healthcare) and receptors or target proteins such as can be obtained by recombinant expression. Specific conditions for determining affinity for 4-1BB are also described in WO 2018/087108. The affinity of bispecific antigen binding molecules for target cell antigens such as FAP or HER2 can also be determined by Surface Plasmon Resonance (SPR) using standard instruments such as BIAcore instruments (GE Healthcare) and receptors or target proteins such as may be obtained by recombinant expression. Specific illustrative and exemplary embodiments for measuring binding affinity are described in examples 1.2 and 2.2. According to one aspect, at 25 deg.C The T100 instrument (GE Healthcare) measures K by surface plasmon resonance_D。

2. Binding assays and other assays

Binding of bispecific antigen binding molecules provided herein to cells expressing the corresponding receptor can be assessed using cell lines expressing the particular receptor or target antigen, for example, by flow cytometry (FACS). In one aspect, fresh Peripheral Blood Mononuclear Cells (PBMCs) expressing 4-1BB can be used in a binding assay. These cells can be used directly after isolation (naive PMBC) or after stimulation (activated PMBC). In another aspect, activated mouse splenocytes (expressing 4-1BB) can be used to demonstrate binding of the bispecific antigen binding molecules of the invention to cells expressing 4-1 BB.

In a further aspect, the binding of the antigen binding molecule to this target cell antigen is demonstrated using a cell line expressing FAP or HER 2.

In another aspect, a competition assay can be used to identify antigen binding molecules that compete with a particular antibody or antigen binding molecule for binding to FAP, HER2, or 4-1BB, respectively. In certain aspects, such competing antigen binding molecules bind to the same epitope (e.g., a linear or conformational epitope) bound by a particular anti-FAP antibody, an anti-HER 2 antibody, or a particular anti-4-1 BB antibody. Detailed exemplary methods for locating an epitope to which an antibody binds are provided in: morris (1996), "Epitope Mapping Protocols", from Methods in Molecular Biology Vol.66 (Humana Press, Totowa, NJ).

3. Activity assay

In one aspect, an assay method is provided for identifying bispecific antigen binding molecules that bind to FAP or HER2 and a biologically active 4-1 BB. Biological activity can include, for example, agonistic signaling by 4-1BB on FAP or HER 2-expressing cancer cells. Bispecific antigen binding molecules identified by assays having such in vitro biological activities are also provided.

In certain aspects, the bispecific antigen binding molecules of the invention are tested for such biological activity. Assays for detecting the biological activity of the molecules of the invention are those described in examples 3.3 and 4.3. In addition, methods for detecting cell lysis (e.g., by measuring LDH release), induced apoptosis kinetics (e.g., by measuring caspase 3/7 activity), or apoptosis (e.g., using TUNEL assays) are well known in the art. In addition, the biological activity of such complexes can be assessed by assessing the effect of such complexes on the survival, proliferation and lymphokine secretion of various lymphocyte subpopulations such as NK cells, NKT cells or γ δ T cells, or their ability to modulate the phenotype and function of antigen presenting cells such as dendritic cells, monocytes/macrophages or B cells.

Pharmaceutical compositions, formulations and routes of administration

In a further aspect, the invention provides a pharmaceutical composition comprising any of the bispecific antigen binding molecules provided herein, for example for use in any of the following methods of treatment. In one embodiment, the pharmaceutical composition comprises any one of the bispecific antigen binding molecules provided herein and at least one pharmaceutically acceptable excipient. In another embodiment, the pharmaceutical composition comprises any of the bispecific antigen binding molecules provided herein and at least one additional therapeutic agent as described below.

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of one or more bispecific antigen binding molecules dissolved or dispersed in a pharmaceutically acceptable excipient. The term "pharmaceutically or pharmacologically acceptable" means that the molecular entities and compositions are generally non-toxic to recipients at the dosages and concentrations employed, i.e., do not produce adverse, allergic, or other untoward reactions when administered to an animal (e.g., a human) as appropriate. The preparation of Pharmaceutical compositions containing at least one bispecific antigen binding molecule and optionally additional active ingredients will be known to those skilled in the art in view of this disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18 th edition, Mack Printing Company,1990, which is incorporated herein by reference. Specifically, the composition is a lyophilized formulation or an aqueous solution. As used herein, "pharmaceutically acceptable excipient" includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, salts, stabilizers, and combinations thereof, as known to one of ordinary skill in the art.

Parenteral compositions include those designed for injection (e.g., subcutaneous, intradermal, intralesional, intravenous, intraarterial, intramuscular, intrathecal, or intraperitoneal injection). For injection, the bispecific antigen binding molecules of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks 'solution, ringer's solution or physiological saline. The solution may contain formulating agents (formulations), such as suspending, stabilizing and/or dispersing agents. Alternatively, the fusion protein may be in powder form for constitution with a suitable vehicle (e.g., sterile pyrogen-free water) before use. Sterile injectable solutions are prepared by incorporating the fusion protein of the invention in the required amount in the appropriate solvent with various other ingredients enumerated below, as required. For example, sterility can be readily achieved by filtration through sterile filtration membranes. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains a basic dispersion medium and/or other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsions, the preferred methods of preparation are vacuum drying or lyophilization techniques that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium. The liquid medium should be suitably buffered if necessary, and sufficient saline or glucose should first be used to render the liquid diluent isotonic prior to injection. The composition must be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept to a minimum at a safe level, for example below 0.5ng/mg protein. Suitable pharmaceutically acceptable excipients include, but are not limited to: buffers such as phosphates, citrates and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyl dimethyl benzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butanol or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents, such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., zinc protein complexes); and/or a non-ionic surfactant, such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, and the like. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil; or synthetic fatty acid esters such as ethyl oleate or triglycerides; or liposomes.

The active ingredient may be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly (methylmethacylate) microcapsules, respectively); in colloidal drug delivery systems (e.g., liposomes, albumin, microspheres, microemulsions, nanoparticles, and nanocapsules); or in a coarse emulsion. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18 th edition, Mack Printing Company, 1990). Sustained release preparations can be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g., films, or microcapsules. In certain embodiments, prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate, gelatin or combinations thereof.

Exemplary pharmaceutically acceptable excipients herein also include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoprotein (sHASEGP), e.g., human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 (r: (r) ())Baxter International, Inc.). Certain exemplary shasegps and methods of use, including rHuPH20, are described in U.S. patent nos. 2005/0260186 and 2006/0104968. At one end In an aspect, the sHASEGP is combined with one or more additional glycosaminoglycanases (such as chondroitinase). Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958. Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO2006/044908, the latter formulations comprising histidine-acetate buffer. In addition to the compositions previously described, the bispecific antigen binding molecules may also be formulated as long acting preparations. Such long acting formulations may be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the fusion protein may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt).

Pharmaceutical compositions comprising the bispecific antigen binding molecules of the invention may be produced by conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes. The pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations which can be used pharmaceutically. The appropriate formulation depends on the route of administration chosen.

The bispecific antigen binding molecules can be formulated into compositions in free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or free base. Such pharmaceutically acceptable salts include acid addition salts, for example formed with the free amino groups of the proteinaceous composition, or with inorganic acids such as hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric or mandelic acid. Salts formed with free carboxyl groups may also be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or iron hydroxide; or an organic base such as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutically acceptable salts tend to be more soluble in aqueous and other protic solvents than the corresponding free base forms.

The compositions described herein may also contain more than one active ingredient necessary for the particular indication being treated, preferably active ingredients having complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in an amount effective for the intended purpose.

The formulations to be used for in vivo administration are generally sterile. For example, sterility can be readily achieved by filtration through sterile filtration membranes.

Therapeutic methods and compositions

Any of the bispecific antigen binding molecules provided herein that are capable of divalent binding to 4-1BB and monovalent binding to a target cell antigen can be used in a method of treatment.

For use in a method of treatment, the bispecific antigen binding molecules of the invention may be formulated, dosed and administered in a manner consistent with good medical practice. Factors to be considered in this context include the particular condition being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the condition, the site of delivery of the agent, the method of administration, the timing of administration, and other factors known to the practitioner.

In one aspect, bispecific antigen binding molecules capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen for use as a medicament are provided. In a further aspect, bispecific antigen binding molecules of the invention are provided for use in the treatment of diseases, in particular for use in the treatment of cancer or infectious diseases. In certain aspects, bispecific antigen binding molecules of the invention are provided for use in a method of treatment. In one aspect, the invention provides a bispecific antigen binding molecule as described herein for use in the treatment of a disease in an individual in need thereof. In certain aspects, the invention provides a bispecific antigen binding molecule for use in a method of treating an individual having a disease, the method comprising administering to the individual a therapeutically effective amount of the bispecific antigen binding molecule.

In certain aspects, the disease to be treated is cancer. The term "cancer" according to the present invention also includes cancer metastasis. "metastasis" means the spread of cancer cells from their original site to another part of the body. Tumor metastasis often occurs even after removal of the primary tumor, as tumor cells or components may retain and develop metastatic potential. In one aspect, bispecific antigen binding molecules capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen are used to treat solid tumors. Representative examples of solid tumors include colon cancer, prostate cancer, breast cancer, lung cancer, skin cancer, liver cancer, bone cancer, ovarian cancer, pancreatic cancer, brain cancer, head and neck cancer, and lymphoma. Accordingly, there is provided a bispecific antigen-binding molecule capable of bivalent binding to 4-1BB and monovalent binding to FAP as described herein for use in the treatment of a solid tumor.

In certain aspects, the disease to be treated is HER2 positive cancer. Examples of HER2 positive cancers include breast cancer, ovarian cancer, gastric cancer, bladder cancer, salivary gland cancer, endometrial cancer, pancreatic cancer and non-small cell lung cancer (NSCLC). Accordingly, bispecific antigen binding molecules capable of bivalent binding to 4-1BB and monovalent binding to HER2 as described herein are provided for use in the treatment of these cancers. The subject, patient or "individual" in need of treatment is typically a mammal, more particularly a human.

In another aspect, there is provided a bispecific antigen binding molecule as described herein for use in the treatment of an infectious disease, in particular for use in the treatment of a viral infection. The term "infectious disease" refers to any disease that can be transmitted from individual to individual or from organism to organism and is caused by a microbial pathogen. In a further aspect, there is provided a bispecific antigen binding molecule as described herein for use in the treatment of an autoimmune disease, such as lupus disease. In certain aspects, the infectious disease to be treated is a chronic viral infection, such as HIV (human immunodeficiency virus), HBV (hepatitis b virus), HCV (hepatitis c), HSV1 (herpes simplex virus type 1), CMV (cytomegalovirus), LCMV (lymphocytic meningitis virus), or EBV (Epstein-Barr virus)).

In a further aspect, the invention relates to the use of a bispecific antigen binding molecule capable of binding bivalent to 4-1BB and binding monovalent to a target cell antigen for the manufacture or preparation of a medicament for the treatment of a disease in an individual in need thereof. In one aspect, the medicament is for use in a method of treating a disease, the method comprising administering to an individual having the disease a therapeutically effective amount of the medicament. In certain aspects, the disease to be treated is a proliferative disorder, particularly cancer. Thus, in one aspect, the invention relates to the use of a bispecific binding molecule of the invention in the manufacture or preparation of a medicament for the treatment of cancer. In one aspect, there is provided the use of a bispecific binding molecule of the invention in the manufacture or manufacture of a medicament for the treatment of a solid tumor. In one aspect, there is provided the use of a bispecific binding molecule of the invention in the manufacture or preparation of a medicament for the treatment of HER2 positive cancer. Examples of HER2 positive cancers include breast cancer, ovarian cancer, gastric cancer, bladder cancer, salivary gland cancer, endometrial cancer, pancreatic cancer and non-small cell lung cancer (NSCLC). In certain aspects, the cancer to be treated is HER2 positive breast cancer, particularly HER2 positive metastatic breast cancer. One skilled in the art will recognize that in some cases, bispecific antigen binding molecules may not provide a cure, but may only provide partial benefit. In some aspects, physiological changes with certain benefits are also considered to have therapeutic benefits. Thus, in some aspects, the amount of bispecific antigen binding molecule that provides a physiological change is considered an "effective amount" or a "therapeutically effective amount".

In certain aspects, there is provided the use of a bispecific binding molecule of the invention in the manufacture or preparation of a medicament for the treatment of an infectious disease. In one aspect, the infectious disease is a chronic viral infection, such as HIV (human immunodeficiency virus), HBV (hepatitis b virus), HCV (hepatitis c), HSV1 (herpes simplex virus type 1), CMV (cytomegalovirus), LCMV (lymphocytic meningitis virus), or EBV (Epstein-Barr virus)).

In a further aspect, the invention provides a method of treating a disease in an individual comprising administering to the individual a therapeutically effective amount of a bispecific antigen binding molecule of the invention capable of binding bivalent to 4-1BB and binding monovalent to a target cell antigen. In one aspect, a composition comprising a bispecific antigen binding molecule of the invention in a pharmaceutically acceptable form is administered to the individual. In certain aspects, the disease to be treated is a proliferative disorder. In a particular aspect, the disease is cancer. In one aspect, the disease to be treated is an infectious disease. In certain aspects, if the disease to be treated is cancer, the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g., an anti-cancer agent. In certain aspects, the method comprises further administering to the individual a therapeutically effective amount of a cytotoxic agent or another immunotherapy. An "individual" according to any of the above embodiments may be a mammal, preferably a human.

For the prevention or treatment of disease, the appropriate dosage of the bispecific antigen binding molecules of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the route of administration, the patient's weight, the type of antigen binding molecule, the severity and course of the disease, whether the bispecific antigen binding molecule is administered for prophylactic or therapeutic purposes, previous or concurrent therapeutic intervention, the patient's clinical history and response to the fusion protein, and the discretion of the attending physician. In any case, the practitioner responsible for administration will determine the concentration and appropriate dosage of the active ingredient in the composition for the individual subject. Various dosing schedules are contemplated herein, including but not limited to single or multiple administrations at various time points, bolus administrations, and pulsed infusions. The bispecific antigen binding molecule is suitably administered to the patient at one time or in a series of treatments. Depending on the type and severity of the disease, about 1 μ g/kg to 15mg/kg (e.g., 0.1mg/kg-10mg/kg) of the bispecific antigen binding molecule may be an initial candidate dose administered to the patient, e.g., by one or more separate administrations, or by continuous infusion. Depending on the factors mentioned above, a typical daily dose may range from about 1. mu.g/kg to 100mg/kg or more. For repeated administrations over several days or longer, depending on the condition, the treatment will generally continue until the desired suppression of disease symptoms occurs. An exemplary dose of bispecific antigen binding molecule ranges from about 0.005mg/kg to about 10 mg/kg. In other examples, the dose may further include about 1 μ g/kg body weight, about 5 μ g/kg body weight, about 10 μ g/kg body weight, about 50 μ g/kg body weight, about 100 μ g/kg body weight, about 200 μ g/kg body weight, about 350 μ g/kg body weight, about 500 μ g/kg body weight, about 1mg/kg body weight, about 5mg/kg body weight, about 10mg/kg body weight, about 50mg/kg body weight, about 100mg/kg body weight, about 200mg/kg body weight, about 350mg/kg body weight, about 500mg/kg body weight to about 1000mg/kg body weight or more per administration, and any range derivable therein. In examples of ranges derivable from the numbers listed herein, ranges of about 5mg/kg body weight to about 100mg/kg body weight, about 5 μ g/kg body weight to about 500mg/kg body weight, etc., can be administered based on the numbers above. Thus, one or more doses of about 0.5mg/kg, 2.0mg/kg, 5.0mg/kg, or 10mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, such as weekly or every three weeks (e.g., such that the patient receives about 2 to about 20 or, e.g., about 6 doses of the bispecific antigen binding molecule). An initial higher loading dose may be administered followed by one or more lower doses. However, other dosage regimens may be useful. The progress of the therapy can be readily monitored by conventional techniques and assays.

The bispecific antigen binding molecules of the invention will generally be used in an amount effective to achieve the intended purpose. For use in treating or preventing a disorder, the bispecific antigen binding molecules of the invention or pharmaceutical compositions thereof are administered or applied in a therapeutically effective amount. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, particularly in light of the detailed disclosure provided herein. For systemic administration, the therapeutically effective dose can be estimated initially from in vitro assays, such as cell culture assays. Doses can then be formulated in animal models to achieve IC including as determined in cell culture₅₀Circulating concentration range. Such information can be used to more accurately determine useful doses for humans. Initial dosages can also be estimated from in vivo data (e.g., animal models) using techniques well known in the art. Administration to humans can be readily optimized by one of ordinary skill in the art based on animal data. Dosage and interval can be adjusted individually to provide blood with bispecific antigen binding molecules sufficient to maintain therapeutic efficacyThe slurry level. The usual patient dose for administration by injection is in the range of about 0.1 to 50 mg/kg/day, usually about 0.5 to 1 mg/kg/day. Therapeutically effective plasma levels can be achieved by administering multiple doses per day. Levels in plasma can be measured, for example, by HPLC. In the case of topical administration or selective ingestion, the effective local concentration of the bispecific antigen binding molecule may not be related to the plasma concentration. One skilled in the art will be able to optimize therapeutically effective local dosages without undue experimentation.

A therapeutically effective dose of the bispecific antigen binding molecules described herein will generally provide therapeutic benefit without causing significant toxicity. Toxicity and therapeutic efficacy of bispecific antigen binding molecules can be determined by standard pharmaceutical procedures in cell culture or experimental animals. Cell culture assays and animal studies can be used to determine LD₅₀(dose of 50% of lethal population) and ED₅₀(a therapeutically effective dose in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD₅₀/ED₅₀. Bispecific antigen binding molecules that exhibit large therapeutic indices are preferred. In one aspect, the bispecific antigen binding molecules according to the invention exhibit a high therapeutic index. Data obtained from cell culture assays and animal studies can be used to formulate a range of dosages suitable for use in humans. The dosage is preferably selected to include ED with little or no toxicity₅₀In the circulating concentration range of (c). The dosage may vary within this range depending upon a variety of factors, such as the dosage form employed, the route of administration utilized, the condition of the subject, and the like. The exact formulation, route of administration and dosage may be selected by The individual physician according to The condition of The patient (see, e.g., Fingl et al, 1975, in: The pharmaceutical Basis of Therapeutics, Chapter 1, page 1, The entire contents of which are incorporated herein by reference). The attending physician of a patient treated with a fusion protein of the invention will know how and when to terminate, discontinue or regulate administration due to toxicity, organ dysfunction, etc. Conversely, if the clinical response is inadequate (toxicity excluded), the attending physician It will also be known to adjust the treatment to higher levels. The size of the dose administered in the management of the target disorder will vary with the severity of the condition to be treated, the route of administration, and the like. For example, the severity of a condition can be assessed, in part, by standard prognostic assessment methods. In addition, the dose and possibly the frequency of dosing will also vary according to the age, weight and response of the individual patient.

Other Agents and treatments

The bispecific antigen binding molecules of the invention, which are capable of binding divalent to 4-1BB and monovalent to target cell antigens, can be administered in combination with one or more other agents in therapy. For example, a bispecific antigen binding molecule of the invention can be co-administered with at least one additional therapeutic agent. The term "therapeutic agent" includes any agent that can be administered for the treatment of a symptom or disease in an individual in need of such treatment. Such additional therapeutic agents may comprise any active ingredient suitable for the particular indication being treated, preferably active ingredients having complementary activities that do not adversely affect each other. In certain aspects, the additional therapeutic agent is another anti-cancer agent, such as a cytotoxic agent, a chemotherapeutic agent, or an anti-angiogenic agent.

In one aspect, a bispecific antigen-binding molecule of the invention capable of binding bivalently to 4-1BB and binding monovalently to a target cell antigen can be administered in combination with an agent that blocks the PD-L1/PD-1 interaction. In particular, the agent that blocks the PD-L1/PD-1 interaction is an anti-PD-L1 antibody or an anti-PD 1 antibody. More particularly, the agent that blocks the PD-L1/PD-1 interaction is selected from the group consisting of: alemtuzumab, de wagulumab, pembrolizumab, and nivolumab. In a particular aspect, the agent that blocks the PD-L1/PD-1 interaction is atelizumab.

Such other agents are suitably present in combination in an amount effective for the intended purpose. The effective amount of such other agents will depend on the amount of fusion protein used, the type of disorder or treatment, and other factors discussed above. Bispecific antigen binding molecules are typically used at the same dosage and route of administration as described herein, or about 1% to 99% of the dosage described herein, or at any dosage and by an empirically/clinically determined appropriate route.

Such combination therapies described above encompass combined administration (where two or more therapeutic agents are contained in the same composition or separate compositions), as well as separate administration, where administration of the bispecific antigen binding molecules of the invention can occur prior to, concurrently with, and/or after administration of additional therapeutic agents and/or adjuvants.

Article of manufacture

In another aspect of the invention, an article of manufacture is provided that contains materials useful for the treatment, prevention and/or diagnosis of the above-mentioned conditions. The article of manufacture comprises a container and a label or package insert (package insert) on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, Intravenous (IV) solution bags, and the like. The container may be formed from a variety of materials such as glass or plastic. The container contains the composition, alone or in combination with another composition effective for treating, preventing and/or diagnosing the condition, and may have a sterile access port (e.g., the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is a bispecific antigen binding molecule of the invention.

The label or package insert indicates that the composition is for use in treating the selected condition. Further, the article may comprise: (a) a first container having a composition contained therein, wherein the composition comprises an antigen binding molecule of the invention comprising a 4-1BBL trimer; and (b) a second container having the composition contained therein, wherein the composition comprises an additional cytotoxic or other therapeutic agent. The article of manufacture of this embodiment of the invention may further comprise a package insert indicating that the composition is useful for treating a particular condition.

Alternatively or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate buffered saline, ringer's solution, and dextrose solution. The article of manufacture may also include other materials as desired from a commercial and user standpoint, including other buffers, diluents, filters, needles and syringes.

Table B (sequence):

general information on the nucleotide sequences of human immunoglobulin light and heavy chains is given in: kabat, E.A. et al, Sequences of Proteins of Immunological Interest, 5 th edition, Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Amino acids of the antibody chain are numbered and referenced according to the EU numbering system according to Kabat (Kabat, e.a. et al, Sequences of Proteins of Immunological Interest, 5 th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991)) as defined above.

***

Examples of the invention

The following are examples of the methods and compositions of the present invention. It is to be understood that various other embodiments may be practiced given the general description provided above.

Recombinant DNA technology

DNA is manipulated using standard methods, such as those described in Sambrook et al, Molecular cloning: A laboratory Manual; cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biological reagents were used according to the manufacturer's instructions. General information on the nucleotide sequences of human immunoglobulin light and heavy chains is given in the following references: kabat, E.A. et al, (1991) Sequences of Proteins of Immunological Interest, fifth edition, NIH Publication No 91-3242.

DNA sequencing

The DNA sequence was determined by double-strand sequencing.

Gene synthesis

The desired gene segments were generated by PCR using appropriate templates, or were synthesized from synthetic oligonucleotides and PCR products by automated gene synthesis from Geneart AG (Regensburg, Germany). In the case where the exact gene sequence is not available, oligonucleotide primers are designed based on the sequence of the closest homolog and the gene is isolated by RT-PCR from RNA derived from the appropriate tissue. Gene segments flanked by single restriction enzyme cleavage sites were cloned into standard cloning/sequencing vectors. Plasmid DNA was purified from the transformed bacteria and the concentration was determined by UV spectroscopy. The DNA sequence of the subcloned gene fragments was confirmed by DNA sequencing. Gene segments with appropriate restriction sites were designed to allow subcloning into the corresponding expression vectors. All constructs were designed with a 5' DNA sequence encoding a leader peptide that targets a protein secreted by eukaryotic cells.

Cell culture technique

Standard Cell culture techniques are used as described in Current Protocols in Cell Biology (2000), Bonifacino, J.S., Dasso, M., Harford, J.B., Lippincott-Schwartz, J.and Yamada, K.M (eds.), John Wiley & Sons, Inc.

Protein purification

The protein was purified from the filtered cell culture supernatant according to standard protocols. Briefly, antibodies were applied to a protein a sepharose column (GE healthcare) and washed with PBS. Elution of the antibody was achieved at pH 2.8, immediately followed by neutralization of the sample. Aggregated proteins were separated from monomeric antibodies by size exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20mM histidine, 150mM NaCl pH 6.0. The monomeric antibody fractions are combined, concentrated (if necessary) using, for example, a MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrator, frozen and stored at-20 ℃ or-80 ℃. Portions of the sample are provided for subsequent protein analysis and analytical characterization, for example by SDS-PAGE, Size Exclusion Chromatography (SEC), or mass spectrometry.

SDS-PAGE

Use according to manufacturer's instructionsPre-gel systems (Invitrogen). Specifically, 10% or 4-12% is usedBis-TRIS precast gel (pH 6.4) andMES (reducing gel, having Antioxidant electrophoresis buffer additive) or MOPS (non-reducing gel) electrophoresis buffer.

Analytical size exclusion chromatography

Size Exclusion Chromatography (SEC) for determination of the aggregation and oligomerization status of the antibodies was performed by HPLC chromatography. Briefly, protein A purified antibody was applied to 300mM NaCl, 50mM KH on an Agilent HPLC 1100 system₂PO₄/K₂HPO₄Tosoh TSKgel G3000SW column at pH 7.5, or Superdex 200 column in 2 XPBS (GE Healthcare) applied to a Dionex HPLC system. Eluted protein was quantified by UV absorbance and peak area integration. BioRad gel filtration standards 151-1901 were used as standards.

Example 1

Preparation, purification and characterization of bispecific antibodies with bivalent binding to 4-1BB and monovalent/bivalent binding to FAP

1.1 has bivalent binding to 4-1BB and to FAGeneration of monovalent or bivalent binding bispecific antibodies to P

The preparation of bispecific agonistic 4-1BB antibodies with bivalent binding to 4-1BB and monovalent or bivalent binding to FAP is shown in FIGS. 1A and 1B. FAP binders (clone 4B9, generated and prepared as described in WO 2012/020006 a2, which is incorporated herein by reference) and 4-1BB binders (anticalins, generated and prepared as described in WO 2016/177802) were used to prepare the molecules described in fig. 1A and 1B, where TA1 is FAP. Pro329Gly, Leu234Ala and Leu235Ala mutations were introduced into the Fc constant region of the heavy chain to eliminate binding to Fc γ receptors according to the method described in international patent application publication No. WO2012/130831a 1.

The variable regions of the heavy and light chain DNA sequences encoding FAP (4B9) binders were subcloned in frame with the constant heavy chain of the well or the constant light chain of human IgG 1.

Constructs with bivalent binding to FAP were cloned as follows: each comprising two heavy chains of vh (fap) -Fc (hu IgG1) - (G4S)3 linker-4-1 BB binding lipocalin and two light chains comprising vl (fap) -ck. The amino acid sequences of the bispecific bivalent 2+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA are shown in Table 1.

Constructs with monovalent binding to FAP were cloned as follows: comprising a VH (FAP) Fc protrusion (hu IgG1) - (G4S)3 linker 4-1BB binding to one heavy chain of lipocalin, a heavy chain Fc pore (hu IgG1) - (G4S)3 linker 4-1BB binding to lipocalin, and a light chain comprising VL (FAP) -Ck. The combination of an Fc-bulge heavy chain containing the S354C/T366W mutation and an Fc-well heavy chain containing the Y349C/T366S/L368A/Y407V mutation and an anti-FAP light chain allowed the production of heterodimers comprising two 4-1 BB-binding lipocalins. The amino acid sequences of bispecific monovalent 2+1 anti-FAP, anti-4-1 BB huIgG1 PGLALA are shown in Table 2.

TABLE 1 amino acid sequence of mature bispecific bivalent 2+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA antigen-binding molecules

Table 2: amino acid sequence of mature bispecific monovalent 1+2 anti-FAP, anti-4-1 BB lipocalin huIgG1PGLALA antigen-binding molecules

Bispecific antibodies were generated by transient transfection of HEK293 EBNA cells. Cells were centrifuged and medium replaced with pre-warmed CD CHO medium. The expression vectors were mixed in CD CHO media, PEI was added, the solution was vortexed, and incubated at room temperature for 10 minutes. The cells were then mixed with the DNA/PEI solution, transferred to shake flasks and placed in an incubator at 5% CO₂Was incubated at 37 ℃ for 3 hours under the atmosphere of (2). After incubation, Excell medium with supplements was added. One day after transfection 12% Feed was added. Cell supernatants were harvested 7 days later and purified by standard methods. For the a) and b) constructs, cells were transfected with the corresponding expression vectors at a ratio of 1:1 or 1:1:1, respectively.

The protein was purified from the filtered cell culture supernatant according to standard protocols. Briefly, Fc-containing proteins were purified from cell culture supernatants by affinity chromatography using protein a. Elution was achieved at pH 3.0, and then the sample was immediately neutralized. The proteins were concentrated and aggregated proteins were separated from monomeric proteins by size exclusion chromatography in 20mM histidine, 140mM sodium chloride (pH 6.0).

The Protein concentration of the purified construct was determined by measuring the Optical Density (OD) at 280nm using the molar extinction coefficient calculated on the basis of the amino acid sequence according to Pace et al, Protein Science,1995,4, 2411-1423. The purity and molecular weight of the protein were analyzed by CE-SDS using LabChipGXII in the presence and absence of reducing agent. The determination of the aggregate content was carried out as follows: HPLC chromatography using an analytical size exclusion column (TSKgel G3000 SW XL) and running buffer (25mM K)₂HPO₄125mM NaCl,200mM L-arginine monohydrochloride (pH 6.7)) at 25 ℃.

Table 3 summarizes the yield and final monomer content of the bispecific FAP (4B9) targeted 4-1 BB-binding antigen-binding molecule.

TABLE 3 Biochemical analysis of bispecific 4-1 BB-binding antigen-binding molecules

For comparison, a 2+2FAP (4B9) x 4-1BB lipocalin huIgG4 SP molecule comprising the amino acid sequences of SEQ ID NO:69 and SEQ ID NO:70 was also generated, and a polypeptide comprising the amino acid sequence of SEQ ID NO: 71 and SEQ ID NO: 72 non-targeting 2+2DP47 x 4-1BB lipocalin huIgG4 SP control molecule.

1.2 monovalent or divalent binding with 4-1BB and with FAP by surface plasmon resonance Functional characterization of bound bispecific and trispecific antibodies

The ability to bind both human 4-1BB Fc (kih) and human FAP was assessed by Surface Plasmon Resonance (SPR). All SPR experiments used Biacore T200 using HBS-EP as running buffer (0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.005% surfactant P20, Biacore, Freiburg/Germany) at 25 ℃. Biotinylated human 4-1BB Fc (kih) was directly coupled to the flow cell of a Streptavidin (SA) sensor chip. Immobilization levels up to 500 Resonance Units (RU) were used.

Bispecific FAP-targeted anti-4-1 BB lipocalins were passed through the flow cell at a concentration range of 200nM at a flow rate of 30 μ L/min over 90 seconds and dissociation was set to 0 seconds. Human FAP was injected as a second analyte at a concentration of 500nM through the flow cell at a flow rate of 30 μ L/min over 90 seconds (fig. 2A). Dissociation was monitored for 120 seconds. Bulk refractive index differences were corrected for by subtracting the responses obtained in the reference flow cell where the protein was not immobilized.

As can be seen in the graphs of fig. 2B and 2C, dual-specific FAP targeting anti-4-1 BB lipocalins can both bind human 4-1BB and human FAP simultaneously.

Example 2

Preparation, purification and characterization of bispecific antibodies with bivalent binding to 4-1BB and monovalent/bivalent binding to HER2

2.1 Generation of bispecific antibodies with bivalent binding to 4-1BB and monovalent or bivalent binding to HER2

The preparation of bispecific agonistic 4-1BB antibodies with bivalent binding to 4-1BB and monovalent or bivalent binding to HER2 is shown in FIGS. 1A and 1B. HER2 conjugate (corresponding to trastuzumab) and 4-1BB conjugate (lipocalin, produced and prepared as described in WO 2016/177802) were used to prepare the molecules described in fig. 1A and 1B, where TA1 is HER 2. Pro329Gly, Leu234Ala and Leu235Ala mutations were introduced into the Fc constant region of the heavy chain to eliminate binding to Fc γ receptors according to the method described in international patent application publication No. WO2012/130831a 1.

The variable regions of the heavy and light chain DNA sequences encoding FAP (4B9) binders were subcloned in frame with the constant heavy chain of the well or the constant light chain of human IgG 1.

Constructs with bivalent binding to FAP were cloned as follows: each comprising the VH (HER2) -Fc (hu IgG1) - (G4S)3 linker-4-1 BB binding to both heavy chains of lipocalin and both light chains comprising VL (HER2) -ck. The amino acid sequences of bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA are shown in Table 4.

Constructs with monovalent binding to FAP were cloned as follows: comprising a VH (HER2) Fc protrusion (hu IgG1) - (G4S)3 linker 4-1BB binding to one heavy chain of lipocalin, a heavy chain Fc pore (hu IgG1) - (G4S)3 linker 4-1BB binding to lipocalin and a light chain comprising VL (HER2) -Ck. The combination of an Fc bulge heavy chain containing the S354C/T366W mutation and an Fc pore heavy chain containing the Y349C/T366S/L368A/Y407V mutation and an anti-HER 2 light chain allowed the production of heterodimers comprising two 4-1 BB-binding lipocalins. The amino acid sequences of bispecific monovalent 2+1 anti-HER 2, anti-4-1 BB huIgG1PGLALA are shown in Table 5.

Table 4: amino acid sequences of mature bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1PGLALA antigen-binding molecules

Table 5: amino acid sequences of mature bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB lipocalin huIgG1PGLALA antigen-binding molecules

Bispecific antibodies were produced and purified as described in example 1.

Table 6 summarizes the production and final monomer content of the bispecific HER2 targeting 4-1BB binding antigen binding molecule.

Table 6: biochemical analysis of bispecific 4-1 BB-binding antigen-binding molecules

For comparison, the previously described fusion polypeptide 2+2HER2(TRAS) -anticalin-4-1BB human IgG4 SP comprising the amino acid sequences of SEQ ID NO:73 and SEQ ID NO:74 was also prepared (WO 2016/177802).

2.2 bivalent binding to 4-1BB and monovalent or bivalent binding to HER2 by surface plasmon resonance Functional characterization of valency-binding bispecific and trispecific antibodies

The ability to bind both human 4-1BB Fc (kih) and human HER2 was assessed by Surface Plasmon Resonance (SPR). All SPR experiments used Biacore T200 using HBS-EP as running buffer (0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.005% surfactant P20, Biacore, Freiburg/Germany) at 25 ℃. Biotinylated human 4-1BB Fc (kih) was directly coupled to the flow cell of a Streptavidin (SA) sensor chip. Immobilization levels up to 500 Resonance Units (RU) were used.

Bispecific HER 2-targeted anti-4-1 BB lipocalin was passed through the flow cell at a concentration of 200nM at a flow rate of 30 μ L/min over 90 seconds and dissociation was set to 0 seconds. Human FAP was injected as a second analyte at a concentration of 500nM through the flow-through cell at a flow rate of 30 μ L/min over 90 seconds (fig. 3A). Dissociation was monitored for 120 seconds. Bulk refractive index differences were corrected for by subtracting the responses obtained in the reference flow cell where the protein was not immobilized.

As can be seen in the graph of figure 3B, bispecific HER2 targeting anti-4-1 BB lipocalin can both bind to human 4-1BB and human HER2 simultaneously.

Example 3

Functional characterization of FAP-targeted 4-1BB lipocalin antigen-binding molecules

3.1 binding to cell lines expressing human FAP

For binding to human Fibroblast Activation Protein (FAP) expressed on the cell surface, NIH/3T3-huFAP clone 19 cells were used. NIH/3T3-huFAP clone 19 was formed by transfecting mouse embryonic fibroblast NIH/3T3 cells (ATCC CRL-1658) with an expression pETR4921 plasmid encoding human FAP in the presence of a CMV promoter. The cells were maintained in DMEM (GIBCO provided by Life Technologies, Cat. No. 42340-. In the binding assay, 2X 10 will be used⁵NIH/3T3-huFAP clone 19 cells of (9) were added to each well of a round bottom suspension cell 96-well plate (Greiner bio-one, cellstar, Cat. 650185). The cells were washed once with 200. mu.L of DPBS, and the pellet was then resuspended in 100. mu.L/well of cold DPBS buffer at 4 ℃ containing the immobilizeable reactive dye eFluor 450(eBioscience, Cat. No. 65086318) diluted 1: 5000. The well plate was incubated at 4 ℃ for 30 minutes, Then washed once with 200 μ L of cold DPBS buffer at 4 ℃. The cells were then resuspended in 50. mu.L/well of 4 ℃ cold FACS buffer containing bispecific bivalent 2+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA antigen binding molecule (named 2+2), or bispecific monovalent 1+2 anti-FAP, anti-4-1 BB lipocalin huIgG1 PGLALA antigen binding molecule (named 1+2), at different titers (starting concentration 300nM, diluted at 1:6, in eight dilution steps), or control molecules, and then incubated for 1 hour at 4 ℃ in the dark. After four washes with 200. mu.L of DPBS/well, the cells were stained with 50. mu.L/well of 4 ℃ cold FACS buffer containing 2.5. mu.g/mL PE-conjugated AffiniPure anti-human IgG Fc fragment-specific goat F (ab')2 fragment at 4 ℃ for 30 minutes (Jackson ImmunoResearch, Cat. 109-116-098). The cells were washed twice with 200. mu.L of 4 ℃ DPBS buffer and then resuspended in 50. mu.L/well 1% formaldehyde in DPBS for fixation. Cells from the same or the next day were resuspended in 100. mu.L of FACS buffer and harvested using MACSQurant Analyzer 10(Miltenyi Biotec) or Canto II (BD). Data were analyzed using FlowJo 10.4.2(FlowJo LLC), Microsoft Office Excel Professional 2010(Microsoft Software Inc.) and GraphPad Prism (GraphPad Software Inc.).

As shown in FIG. 4, bispecific bivalent 2+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA (termed FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 2+2) bound with similar affinity to FAP (4B9) huIgG1 PG LALA, as both molecules bound to FAP bivalent. Thus, 4-1BB binds to the C-terminal fusion of lipocalins without affecting binding to FAP. The bispecific bivalent 2+2 anti-FAP, anti-4-1 BB huIgG4 SP molecules (FAP (4B9) x 4-1BB lipocalin huIgG4 SP 2+2) showed lower gMFI than other FAP bivalent binding molecules. This can be explained by the different isoforms of the Fc fragment. Since we used a polyclonal anti-human Fc fragment specific goat IgG F (ab') 2 fragment, the epitopes in the Fc portion may be different, resulting in less binding of the second detection fragment and lower gMFI. Bispecific monovalent 1+2 anti-FAP, anti-4-1 BB huIgG1 PG LALA molecules (FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 1+2, filled black triangles and lines) showed more favorable than bispecificHeterosexual bivalent 2+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA (named FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA 2+2) higher gMFI. This can be explained by its monovalent binding to FAP, resulting in a higher occupancy on the cell surface, since one molecule occupies only one FAP monomer and not both. Since FAP (4B9) shows very high affinity, no loss of affinity could be detected in this binding assay (e.g. EC) ₅₀An increase in value). EC of a Single binding Curve₅₀The values and area under the curve (AUC) are listed in tables 7 and 8, respectively.

Table 7: EC of binding curves to FAP-expressing cell line NIH/3T3-huFAP clone 19₅₀Values are shown in FIG. 4

Table 8: the area under the curve (AUC) values of the binding curve with FAP-expressing cell line NIH/3T3-huFAP clone 19 are shown in FIG. 4

3.2 binding to the reporter cell line Jurkat-hu4-1 BB-NF-. kappa.B-luc 2 expressing human 4-1BB

For binding to human 4-1BB (CD137) expressed on the cell surface, Jurkat-hu4-1BB-NFkB-luc2 reporter cell line (Promega, Germany) was used. The cells were maintained as suspension cells in RPMI 1640 medium (GIBCO supplied by Life Technologies, Cat. No. 42401-042) supplemented with 10% (v/v) fetal bovine serum (FBS, GIBCO supplied by Life Technologies, Cat. No. 16000-044, Cat. No. 941273, gamma-irradiated, mycoplasma-free, heat-inactivated), 2mM L-alanyl-L-glutamine dipeptide (Glutqa-MAX-I, GIBCO supplied by Life Technologies, Cat. No. 35050-038), 1mM sodium pyruvate (SIGMA-Aldrich, Cat. No. S8636), and 1% (v/v) MEM-nonessential amino acid solution 100x (SIGMA-Aldrich, Cat. No. M7145), 600. mu.g/ml G-418(Roche, Cat. No. 04727894001), 400. mu.g/ml hygromycin Prime B (Roche, Cat # 10843555001) and 25mM HEPES (Sigma Life science, Cat # H0887-100 mL). In the binding assay, 2X 10 will be used⁵Jurkat-hu4-1BB-NFkB-luc2 was added to each well of a round bottom suspension cell 96-well plate (Greiner bio-one, cell star, Cat. 650185). The cells were washed once with 200. mu.L of DPBS, and the pellet was then resuspended in 100. mu.L/well of cold DPBS buffer at 4 ℃ containing the immobilizeable reactive dye eFluor 450(eBioscience, Cat. No. 65086318) diluted 1: 5000. The well plates were incubated at 4 ℃ for 30 minutes and then washed once with 200 μ L of cold DPBS buffer at 4 ℃. The cells were then resuspended in 50. mu.L/well of 4 ℃ cold FACS buffer containing either bispecific bivalent 2+2 anti-FAP, anti 4-1BB huIgG1 PGLALA (named 2+2), or bispecific monovalent 1+2 anti-FAP, anti 4-1BB huIgG1 PGLALA (named 1+2), or control molecules at different titers (starting concentration 300nM, diluted at 1:6, in eight dilution steps), and then incubated at 4 ℃ for 1 hour in the dark. After four washes with 200. mu.L of DPBS/well, the cells were stained with 50. mu.L/well of 4 ℃ cold FACS buffer containing 2.5. mu.g/mL PE-conjugated AffiniPure anti-human IgG Fc fragment-specific goat F (ab')2 fragment at 4 ℃ for 30 minutes (Jackson ImmunoResearch, Cat. 109-116-098). The cells were washed twice with 200. mu.L of FACS buffer at 4 ℃ and then resuspended in 50. mu.L/well of 1% formaldehyde in DPBS for fixation. Cells from the same or the next day were resuspended in 100. mu.L of FACS buffer and harvested using MACSQurant Analyzer 10(Miltenyi Biotec) or CantoII (BD). Data were analyzed using FlowJo 10.4.2(FlowJo LLC), Microsoft Office Excel Professional 2010(Microsoft Software Inc.) and GraphPad Prism (GraphPad Software Inc.).

As shown in FIG. 5, all anti-4-1 BB lipocalin bispecific molecules bound with similar affinity to the human 4-1BB expressing transgenic human T cell lymphoma cell line Jurkat-hu4-1BB-NFkB-luc 2. Unlike binding to FAP-expressing cells during binding to human 4-1BB (fig. 4), we did not see differences in binding (gMFI) between Fc-huIgG1 PG LALA or Fc-huIgG4 SP-containing molecules. This may involve a lower expression level of 4-1BB compared to FAP, and thus a much lower gMFI value, the valuesSuch assays are not sensitive enough to detect differences. EC of binding curve₅₀Values and AUC are listed in table 9 and table 10, respectively.

Table 9: EC of binding curves to cell-expressed human 4-1BB shown in FIG. 5₅₀Summary of values

Table 10: a summary of the area under the curve (AUC) values of the binding curve with cell-expressed human 4-1BB is shown in FIG. 5

3.3 reporter cell line Jurkat-hu4-1BB-NF kappa expressing human 4-1BB and NF kappa B-luciferase reporter genes NF- κ B activation in B-luc2

Agonistic binding of the 4-1BB (CD137) receptor to its ligand (4-1BBL) induces 4-1BB downstream signaling by activating nuclear factor kappa B (NFkB) and promotes survival and activity of CD 8T cells (Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS.4-1BB promoters the subvalval of CD8(+) T lymphocytes by encrypting expression of Bcl-x (L) and Bfl-1.J Immunol 2002; 169: 4882-. To monitor this NF-. kappa.B activation mediated by either a bispecific bivalent 2+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA molecule (referred to as 2+2), or a bispecific monovalent 1+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA molecule (referred to as 1+2), Jurkat-hu4-1 BB-NF-. kappa.B-luc 2 reporter cell line was purchased from Promega (Germany). Cell culture methods were as described above (in combination with the reporter cell line Jurkat-hu4-1BB-NFkB-luc2 expressing human 4-1 BB). In the assay, cells were harvested and resuspended in assay medium RPMI 1640 medium supplemented with 10% (v/v) FBS and 1% (v/v) GlutaMAX-I. 10. mu.l of the extract containing 2X 10 ³Jurkat-hu4-1 BB-NF-. kappa.B-luc 2 reporter cells were transferred to individual wells of a capped sterile white 384-well flat-bottomed tissue culture plate (Corning, Cat. No. 3826). Adding 10. mu.L of assay medium containingTitrated concentrations of either bispecific bivalent 2+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA (referred to as 2+2), or bispecific monovalent 1+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA (referred to as 1+2), or control molecules. Finally, 10. mu.L of assay medium alone or containing 1X 10⁴Assay media for FAP-expressing cells (human melanoma cell line WM-266-4(ATCC CRL-1676) or NIH/3T3-huFAP clone 19 (as described above), and plates were placed in a cell incubator at 37 ℃ and 5% CO₂Incubate for 6 hours. To each well was added 6 μ l of freshly thawed One-Glo luciferase assay detection solution (Promega, catalog No. E6110) and the luminescence intensity was measured immediately using a Tecan plate reader (integration time 500ms, no filter, signal acquisition at all wavelengths). Data were analyzed using Microsoft Office Excel Professional 2010(Microsoft Software Inc.) and GraphPad Prism (GraphPad Software Inc.).

As shown in FIG. 6A, in the absence of FAP-expressing cells, no molecule was able to induce strong human 4-1BB receptor activation in the urkat-hu4-1BB-NF κ B-luc2 reporter cell line, resulting in NF κ B activation and therefore luciferase expression. In the presence of FAP-expressing cells (e.g., WM-266-4) (fig. 6B, human melanoma cell line, intermediate FAP expression) or NIH/3T3-huFAP clone 19 (fig. 6C, human FAP transgenic mouse fibroblast line), bispecific bivalent 2+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (referred to as FAP (4B9) x 4-1BB lipocalin huIgG 567 PG LALA 2+2, open downward black triangles and dashed lines), or bispecific monovalent 1+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (referred to as FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA1+2, solid black triangles and lines) or bispecific control molecule, bivalent 2+2 anti-FAP, anti-pg4-1 BB hula antigen binding molecule (referred to as FAP (4B9) x 4-1BB lipocalin hula 1 PG LALA1+2, solid black triangles and lines) or bispecific control molecule, bivalent 2+2 anti-FAP, anti-FAP-4-1B hula antigen binding molecule (referred to as FAP-493 4B 3B 4-B4-hula-prf-FAP-prf-iagnor chimeric FAP-prf-iag-7-iag-28 +2, FAP-iag-binding molecule 2+2, semi-solid black hexamer and dashed line) resulted in a strong increase in NF κ B-activated luciferase activity in Jurkat-hu4-1BB-NF κ B-luc2 reporter cell line. Bispecific monovalent 1+2 anti-FAP, anti-4-1 BB huIgG1 PGLALA antigen binding molecules (termed FAP (4B9) x 4-1BB lipocalin huIgG1 PG LALA1+2, solid black by the area under the highest curve (AUC) of the activation curve Triangles and lines) perform best. Lower ratios of tumor target binding side to 1:2 of effector cell target binding, such as 1:2 ratios of FAP binding moieties to 4-1BB binding moieties, appear to result in higher occupancy densities, thus leading to dense cross-linking of 4-1BB agonists on effector cells and ultimately to stronger 4-1BB receptor downstream signaling. EC of activation Curve₅₀The values and area under the curve (AUC) are listed in tables 11 and 12, respectively.

Table 11: EC of the activation curves shown in FIGS. 6B and 6C₅₀Value of

Table 12: summary of area under the Curve (AUC) values for the activation curves as shown in FIGS. 6B and 6C

Example 4

Functional characterization of HER2 targeting 4-1BB lipocalin antigen binding molecules

4.1 binding to a cell line expressing human HER2

For binding to cell surface-expressed HER2, human gastric cancer cell line NCI-N87(ATCC CRL-5822) and human breast cancer cell line KPL4 (Kawasaki Medical School) were used. NCI-N87 cells were cultured as adherent cells in RPMI 1640 medium (Life Technologies GIBCO, Cat. No. 42401-. KPL4 cells were cultured as adherent cells in DMEM medium (GIBCO from Life Technologies, Cat. No. 42430082) provided with 10% (v/v) FBS and 2mM L-alanyl-L-glutamine. In the binding assay, 2X 10 will be used ⁵Adding NCI-N87 and KPL4 into round-bottomed suspensionCell 96 well plates (Greiner bio-one, cell star, cat. No. 650185). The cells were washed once with 200. mu.L of DPBS, and the pellet was then resuspended in 100. mu.L/well of cold DPBS buffer at 4 ℃ containing the immobilizeable reactive dye eFluor 450(eBioscience, Cat. No. 65086318) diluted 1: 5000. The well plates were incubated at 4 ℃ for 30 minutes and then washed once with 200 μ L of cold DPBS buffer at 4 ℃. The cells were then resuspended in 50. mu.L/well of 4 ℃ cold FACS buffer containing bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (designated 2+2), or bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (designated 1+2), or control molecules at different titers (starting concentration 300nM, diluted at 1:6 in eight dilution steps), and then incubated for 1 hour at 4 ℃ in the dark. After four washes with 200. mu.L of DPBS/well, the cells were stained with 50. mu.L/well of 4 ℃ cold FACS buffer containing 2.5. mu.g/mL PE-conjugated AffiniPure anti-human IgG Fc fragment-specific goat F (ab')2 fragment at 4 ℃ for 30 minutes (Jackson ImmunoResearch, Cat. 109-116-098). The cells were washed twice with 200. mu.L of 4 ℃ DPBS buffer and then resuspended in 50. mu.L/well 1% formaldehyde in DPBS for fixation. Cells from the same or the next day were resuspended in 100. mu.L of FACS buffer and harvested using MACSQurant Analyzer 10(Miltenyi Biotec) or CantoII (BD). Data were analyzed using FlowJo 10.4.2(FlowJo LLC), Microsoft Office Excel Professional 2010(Microsoft Software Inc.) and GraphPad Prism (GraphPad Software Inc.).

As shown in fig. 7A and 7B, the bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG1PGLALA antigen binding molecule (named HER2(TRAS) x 4-1BB lipocalin huIgG1PG LALA 2+2) bound with similar affinity to HER2(TRAS) huIgG1PG LALA, as both molecules bound to HER2 bivalent. Thus, 4-1BB binds to the C-terminal fusion of lipocalins without affecting the binding to HER 2. Bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG4 SP molecules (HER2(TRAS) x 4-1BB lipocalin huIgG4 SP 2+2) showed lower MFI than other HER2 bivalent binding molecules. This can be explained by the different isoforms of the Fc fragment. Since we use a multi-gramThe epitope in the Fc portion may be different, resulting in less binding of the second detection fragment and lower gMFI, for the monoclonal anti-human Fc fragment-specific goat IgG F (ab') 2 fragment. The bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB huIgG1PG LALA molecules (HER2(TRAS) x 4-1BB lipocalin huIgG1PG LALA 1+2, filled black triangles and lines) showed higher gMFI than the bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG1PGLALA antigen binding molecules (termed HER2(TRAS) x 4-1BB lipocalin huIgG1PG LALA 2+ 2). This can be explained by its monovalent binding to HER2, resulting in a higher occupancy on the cell surface, since one molecule possesses only one HER2 instead of two. EC of a Single binding Curve ₅₀The values and area under the curve (AUC) are listed in tables 13 and 14, respectively.

Table 13: EC for binding curves to cell lines NCI-N87 and KPL4 expressing HER2₅₀Values are shown in FIGS. 7A and 7B

Table 14: the area under the curve (AUC) values of the binding curves with cell lines NCI-N87 and KPL4 expressing HER2 are shown in FIGS. 7A and 7B

4.2 binding to the reporter cell line Jurkat-hu4-1BB-NF kappa B-luc2 expressing human 4-1BB

For binding to human 4-1BB (CD137) expressed on the cell surface, Jurkat-hu4-1BB-NFkB-luc2 reporter cell line (Promega, Germany) was used. The cells were maintained as suspension cells in RPMI 1640 medium (GIBCO supplied by Life Technologies, Cat. No. 42401-042) supplemented with 10% (v/v) fetal bovine serum (FBS, GIBCO supplied by Life Technologies, Cat. No. 16000-044, Lot. 941273, gamma-irradiated, mycoplasma-free, heat inactivated), 2mM L-alanyl-L-glutamine dipeptide (GlutaMAX-I, GIBCO supplied by Life Technologies, Cat. No. 35050-038)) 1mM sodium pyruvate (SIGMA-Aldrich, Cat. No. S8636) and 1% (v/v) MEM-nonessential amino acid solution 100x (SIGMA-Aldrich, Cat. No. M7145), 600. mu.g/mL G-418(Roche, Cat. No. 04727894001), 400. mu.g/mL hygromycin B (Roche, Cat. No. 10843555001) and 25mM HEPES (Sigma Life science, Cat. No. H0887-100 mL). In the binding assay, 2X 10 will be used ⁵Jurkat-hu4-1BB-NFkB-luc2 was added to each well of a round bottom suspension cell 96-well plate (Greiner bio-one, cell star, Cat. 650185). The cells were washed once with 200. mu.L of DPBS, and the pellet was then resuspended in 100. mu.L/well of cold DPBS buffer at 4 ℃ containing the immobilizeable reactive dye eFluor 450(eBioscience, Cat. No. 65086318) diluted 1: 5000. The well plates were incubated at 4 ℃ for 30 minutes and then washed once with 200 μ L of cold DPBS buffer at 4 ℃. The cells were then resuspended in 50. mu.L/well of 4 ℃ cold FACS buffer containing bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (designated 2+2), or bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (designated 1+2), or control molecules at different titers (starting concentration 300nM, diluted at 1:6 in eight dilution steps), and then incubated for 1 hour at 4 ℃ in the dark. After four washes with 200. mu.L of DPBS/well, the cells were stained with 50. mu.L/well of 4 ℃ cold FACS buffer containing 2.5. mu.g/mL PE-conjugated AffiniPure anti-human IgG Fc fragment-specific goat F (ab')2 fragment at 4 ℃ for 30 minutes (Jackson ImmunoResearch, Cat. 109-116-098). The cells were washed twice with 200. mu.L of FACS buffer at 4 ℃ and then resuspended in 50. mu.L/well of 1% formaldehyde in DPBS for fixation. Cells from the same or the next day were resuspended in 100. mu.L of FACS buffer and harvested using MACSQurant Analyzer 10(Miltenyi Biotec) or CantoII (BD). Data were analyzed using FlowJo 10.4.2(FlowJo LLC), Microsoft Office Excel Professional 2010(Microsoft Software Inc.) and GraphPad Prism (GraphPad Software Inc.).

As shown in FIG. 8, all anti-4-1 BB lipocalin bispecific molecules bound with similar affinity to the human 4-1BB expressing transgenic human T cell lymphoma cell line Jurkat-hu4-1BB-NFkB-luc 2. And during binding to human 4-1BBUnlike cells expressing HER2 (fig. 7A and 7B), we did not see a difference in binding (gMFI) between molecules containing Fc-huIgG1 PG LALA or Fc-huIgG4 SP. This may involve lower expression levels of 4-1BB compared to HER2, and therefore far lower gMFI values, such that the assay is not sensitive enough to detect differences. EC of binding curve₅₀The values and AUC are listed in table 15 and table 16, respectively.

Table 15: EC of binding curves to cell-expressed human 4-1BB shown in FIG. 8₅₀Summary of values

Table 16: the area under the curve (AUC) values of the binding curves with cell lines NCI-N87 and KPL4 expressing HER2 are shown in FIG. 8

4.3 reporter cell line Jurkat-hu4-1BB-NF kappa expressing human 4-1BB and NF kappa B-luciferase reporter genes NF- κ B activation in B-luc2

Agonistic binding of the 4-1BB (CD137) receptor to its ligand (4-1BBL) induces 4-1BB downstream signaling by activating nuclear factor kappa B (NFkB) and promotes survival and activity of CD 8T cells (Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS.4-1BB promoters the subvalval of CD8(+) T lymphocytes by encrypting expression of Bcl-x (L) and Bfl-1.J Immunol 2002; 169: 4882-. To monitor this NF-. kappa.B activation mediated by either a bispecific bivalent 2+2 anti-HER 2, an anti-4-1 BB huIgG1 PGLALA antigen molecule (referred to as 2+2), or a bispecific monovalent 1+2 anti-HER 2, an anti-4-1 BB huIgG1 PGLALA antigen binding molecule (referred to as 1+2), Jurkat-hu4-1 BB-NF-. kappa.B-luc 2 reporter cell line was purchased from Promega (Germany). Cell culture methods were as described above (in combination with the reporter cell line Jurkat-hu4-1BB-NFkB-luc2 expressing human 4-1 BB). In the assay, cells were harvested and resuspended in 10% (v/v) FBS supplemented and 1% (v/v) GlutaMAX-I assay Medium RPMI 1640 medium. 10. mu.l of the extract containing 2X 10³Jurkat-hu4-1 BB-NF-. kappa.B-luc 2 reporter cells were transferred to individual wells of a capped sterile white 384-well flat-bottomed tissue culture plate (Corning, Cat. No. 3826). mu.L of assay medium containing titrated concentrations of either bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (referred to as 2+2), or bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecule (referred to as 1+2), or control molecules was added. Finally, 10. mu.L of assay medium alone, or containing 1X 10⁴Assay medium for HER 2-expressing cells KPL4, NCI-N87 (as described above) or SK-Br3 (human breast cancer, ATCC HTB-30), and plates were placed in a cell culture incubator at 37 ℃ and 5% CO₂Incubate for 6 hours. To each well was added 6 μ l of freshly thawed One-Glo luciferase assay detection solution (Promega, catalog No. E6110) and the luminescence intensity was measured immediately using a Tecan plate reader (integration time 500ms, no filter, signal acquisition at all wavelengths).

As shown in figures 9A to 9D, in the absence of HER2 expressing cells (figure 9A), no molecule was able to induce strong human 4-1BB receptor activation in Jurkat-hu4-1BB-NFkB-luc2 reporter cell line, leading to NFkB activation and therefore luciferase expression. Cross-linking of bispecific monovalent 2+1 anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecules, termed HER2(TRAS) x 4-1BB lipocalin huIgG1 PG LALA 2+1, filled black triangles and solid lines, in the presence of HER2 expressing cells like SK-Br3 (FIG. 9B), KPL4 (FIG. 9C) and NCI-N87 (FIG. 9D), shows a good activation curve, the height and/or EC of which is ₅₀Values correlate with the strength of HER2 expression of cross-linked cells. Bispecific bivalent 2+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA antigen binding molecules (named HER2(TRAS) x 4-1BB lipocalin huIgG1PG LALA 2+2, filled black triangles and lines), and their control molecules HER2(TRAS) x 4-1BB lipocalin huIgG4 SP (semi-filled black hexamers and dashed lines) all bound to HER2 bivalent and induced similar activation curves, whereby the activation of both molecules was much lower than that of HER2(TRAS) x 4-1BB lipocalin huIgG1PG LALA 2+1 (filled black triangles and lines)) The activation curve of (2). The bispecific monovalent 1+2 anti-HER 2, anti-4-1 BB huIgG1 PGLALA (designated HER2(TRAS) x 4-1BB lipocalin huIgG1PG LALA 1+2, filled black triangles and lines) performed best by the highest area under the curve (AUC) of the activation curve. We believe that a lower ratio of 1:2 of tumor target binding side to effector cell target binding, such as a ratio of 1:2 of HER2 binding moiety to 4-1BB binding moiety, results in a higher occupancy density on tumor cells, thus resulting in dense cross-linking of 4-1BB agonists on effector cells and ultimately in stronger 4-1BB receptor downstream signaling. EC of activation Curve ₅₀The values and area under the curve (AUC) are listed in tables 17 and 18, respectively.

Table 17: EC of activation curves as shown in FIGS. 9B, 9C and 9D₅₀Summary of values

Table 18: area under the Curve (AUC) values for the activation curves shown in FIGS. 9B, 9C, and 9D

Sequence listing

<110> Haofmai Roche Ltd

<120> bispecific antigen binding molecules comprising lipocalin muteins

<130> P35474-WO

<150> EP19169022.1

<151> 2019-04-12

<160> 129

<170> PatentIn 3.5 edition

<210> 1

<211> 178

<212> PRT

<213> Intelligent people

<400> 1

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro

35 40 45

Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile

65 70 75 80

Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu Gly Asn

85 90 95

Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln

115 120 125

Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 2

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 13

<400> 2

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro

35 40 45

Ile Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asp Val Thr Met Val Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys

85 90 95

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

115 120 125

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 3

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 12

<400> 3

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Lys Leu Arg Glu Asp Lys Asp Pro

35 40 45

Asn Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Gly Val Thr Phe Asp Asp Lys Lys Cys Thr Tyr Ala Ile

65 70 75 80

Ser Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys

85 90 95

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

115 120 125

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 4

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 14

<400> 4

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro

35 40 45

Asn Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asp Val Thr Ala Val Ala Phe Asp Asp Lys Lys Cys Thr Tyr Asp Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys

85 90 95

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

115 120 125

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 5

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 15

<400> 5

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Lys Leu Arg Glu Asp Lys Asp Pro

35 40 45

Asn Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asp Val Thr Ala Val Ala Phe Asp Asp Lys Lys Cys Thr Tyr Asp Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys

85 90 95

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

115 120 125

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 6

<211> 175

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 16

<400> 6

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Lys Leu Arg Glu Asp Ser Lys Met

35 40 45

Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asp Val Thr

50 55 60

Gly Val Ser Phe Asp Asp Lys Lys Cys Thr Tyr Ala Ile Met Thr Phe

65 70 75 80

Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys Ile Lys Ser

85 90 95

Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser Thr Asn Tyr

100 105 110

Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln Asn Arg Glu

115 120 125

Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu

130 135 140

Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu

145 150 155 160

Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly

165 170 175

<210> 7

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> lipocalin mutein variant 17

<400> 7

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Lys Leu Arg Glu Asp Lys Asp Pro

35 40 45

Val Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asp Val Thr Gly Val Thr Phe Asp Asp Lys Lys Cys Arg Tyr Asp Ile

65 70 75 80

Ser Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Phe Gly Lys

85 90 95

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

115 120 125

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 8

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 18

<400> 8

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asp Val Thr Gly Val Thr Phe Asp Asp Lys Lys Cys Thr Tyr Ala Ile

65 70 75 80

Ser Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys

85 90 95

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

115 120 125

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 9

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 19

<400> 9

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Lys Leu Arg Glu Asp Lys Asp Pro

35 40 45

Asn Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asp Val Thr Gly Val Thr Phe Asp Asp Lys Lys Cys Thr Tyr Ala Ile

65 70 75 80

Ser Thr Leu Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Phe Gly Lys

85 90 95

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

115 120 125

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 10

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 20

<400> 10

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro

35 40 45

Ser Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asp Val Thr Ala Val Thr Phe Asp Asp Lys Lys Cys Asn Tyr Ala Ile

65 70 75 80

Ser Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys

85 90 95

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

115 120 125

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 11

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> lipocalin mutein variant 47

<400> 11

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Ser Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Phe Leu Asp Lys Lys Cys Gln Tyr Ile Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Pro Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 12

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 48

<400> 12

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Ser Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Phe Leu Asp Lys Lys Cys Gln Tyr Ile Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Leu Thr Leu Gly Phe

85 90 95

Ile Arg Ser Asp Leu Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 13

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> lipocalin mutein variant 49

<400> 13

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Tyr Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Gly Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Leu Leu Asp Lys Lys Cys Gln Tyr Ile Ile

65 70 75 80

Gln Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Ser Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Pro Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 14

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein 50

<400> 14

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Gly Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Phe Leu Asp Lys Lys Cys Gln His Ile Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Leu Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Pro Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 15

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> lipocalin mutein variant 51

<400> 15

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asp Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Gly Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Phe Leu Asp Lys Lys Cys Gln Tyr Ile Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Leu Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Pro Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 16

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 52

<400> 16

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Ile Val Gly Met Ala Gly Asn Asn Leu Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Gly Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Phe Leu Asp Lys Lys Cys Gln Tyr Ile Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Leu Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Pro Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 17

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 53

<400> 17

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Arg Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Val Asp Lys Asp Pro

35 40 45

His Lys Met Gly Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Phe Leu Asp Lys Lys Cys Gln Tyr Ile Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Leu Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Pro Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Tyr Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 18

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 54

<400> 18

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Ser Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Phe Leu Asp Lys Lys Cys Gln Tyr Ile Asn

65 70 75 80

Trp Pro Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Leu Gly Pro Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 19

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 55

<400> 19

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Glu Asp Lys Asp Pro

35 40 45

His Lys Met Gly Ala Thr Ile Tyr Glu Leu Asn Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Phe Leu Asp Lys Lys Cys Gln Tyr Ile Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Leu Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Pro Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 20

<211> 178

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 56

<400> 20

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

1 5 10 15

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr

20 25 30

Val Val Gly Met Ala Gly Asn Asn Leu Leu Arg Asp Asp Lys Asp Pro

35 40 45

His Lys Met Ser Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

50 55 60

Asn Val Thr Asp Val Met Leu Leu Asp Lys Lys Cys His Tyr Ile Ile

65 70 75 80

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Leu Thr Leu Gly Phe

85 90 95

Ile Lys Ser Asp Pro Gly His Thr Ser Tyr Leu Val Arg Val Val Ser

100 105 110

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Ser Val Ile Gln

115 120 125

Asn Arg Glu Trp Phe Gly Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

130 135 140

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

145 150 155 160

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

165 170 175

Asp Gly

<210> 21

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(4B9) CDR-H1

<400> 21

Ser Tyr Ala Met Ser

1 5

<210> 22

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(4B9) CDR-H2

<400> 22

Ala Ile Ile Gly Ser Gly Ala Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 23

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(4B9) CDR-H3

<400> 23

Gly Trp Phe Gly Gly Phe Asn Tyr

1 5

<210> 24

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(4B9) CDR-L1

<400> 24

Arg Ala Ser Gln Ser Val Thr Ser Ser Tyr Leu Ala

1 5 10

<210> 25

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(4B9) CDR-L2

<400> 25

Val Gly Ser Arg Arg Ala Thr

1 5

<210> 26

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(4B9) CDR-L3

<400> 26

Gln Gln Gly Ile Met Leu Pro Pro Thr

1 5

<210> 27

<211> 117

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(4B9) VH

<400> 27

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ile Gly Ser Gly Ala Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Gly Trp Phe Gly Gly Phe Asn Tyr Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser

115

<210> 28

<211> 108

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(4B9) VL

<400> 28

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Asn Val Gly Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Ile Met Leu Pro

85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 29

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> FAP (28H1) CDR-H1

<400> 29

Ser His Ala Met Ser

1 5

<210> 30

<211> 16

<212> PRT

<213> Artificial sequence

<220>

<223> FAP (28H1) CDR-H2

<400> 30

Ala Ile Trp Ala Ser Gly Glu Gln Tyr Tyr Ala Asp Ser Val Lys Gly

1 5 10 15

<210> 31

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> FAP (28H1) CDR-H3

<400> 31

Gly Trp Leu Gly Asn Phe Asp Tyr

1 5

<210> 32

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> FAP (28H1) CDR-L1

<400> 32

Arg Ala Ser Gln Ser Val Ser Arg Ser Tyr Leu Ala

1 5 10

<210> 33

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> FAP (28H1) CDR-L2

<400> 33

Gly Ala Ser Thr Arg Ala Thr

1 5

<210> 34

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> FAP (28H1) CDR-L3

<400> 34

Gln Gln Gly Gln Val Ile Pro Pro Thr

1 5

<210> 35

<211> 116

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(28H1) VH

<400> 35

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Trp Ala Ser Gly Glu Gln Tyr Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Lys Gly Trp Leu Gly Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val

100 105 110

Thr Val Ser Ser

115

<210> 36

<211> 108

<212> PRT

<213> Artificial sequence

<220>

<223> FAP(28H1) VL

<400> 36

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Ile Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Gln Val Ile Pro

85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 37

<211> 419

<212> PRT

<213> Artificial sequence

<220>

<223> Fc pore huIgG1 PGLALA-4-1BB lipocalin heavy chain

<400> 37

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

225 230 235 240

Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys

245 250 255

Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp

260 265 270

Tyr Val Val Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp

275 280 285

Pro Ile Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser

290 295 300

Tyr Asp Val Thr Met Val Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp

305 310 315 320

Ile Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly

325 330 335

Lys Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val

340 345 350

Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe

355 360 365

Gln Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu

370 375 380

Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu

385 390 395 400

Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys

405 410 415

Ile Asp Gly

<210> 38

<211> 639

<212> PRT

<213> Artificial sequence

<220>

<223> VH (FAP 4B9) Fc protuberant huIgG1 PGLALA 4-1BB lipocalin heavy chain

<400> 38

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ile Gly Ser Gly Ala Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Gly Trp Phe Gly Gly Phe Asn Tyr Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu

115 120 125

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys

130 135 140

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser

145 150 155 160

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser

165 170 175

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser

180 185 190

Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn

195 200 205

Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His

210 215 220

Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu

260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly

435 440 445

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Asp Ser

450 455 460

Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val Pro Leu Gln

465 470 475 480

Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr Val Val Gly

485 490 495

Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro Ile Lys Met

500 505 510

Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asp Val Thr

515 520 525

Met Val Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp Ile Trp Thr Phe

530 535 540

Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys Ile Lys Ser

545 550 555 560

Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser Thr Asn Tyr

565 570 575

Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln Asn Arg Glu

580 585 590

Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu

595 600 605

Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu

610 615 620

Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly

625 630 635

<210> 39

<211> 215

<212> PRT

<213> Artificial sequence

<220>

<223> VL (FAP 4B9) C kappa light chain

<400> 39

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Asn Val Gly Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Ile Met Leu Pro

85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 40

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H1, pertuzumab

<400> 40

Gly Phe Thr Phe Thr Asp Tyr Thr Met Asp

1 5 10

<210> 41

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H2, pertuzumab

<400> 41

Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe Lys

1 5 10 15

Gly

<210> 42

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H3, pertuzumab

<400> 42

Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr

1 5 10

<210> 43

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L1, pertuzumab

<400> 43

Lys Ala Ser Gln Asp Val Ser Ile Gly Val Ala

1 5 10

<210> 44

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L2, pertuzumab

<400> 44

Ser Ala Ser Tyr Arg Tyr Thr

1 5

<210> 45

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L3, pertuzumab

<400> 45

Gln Gln Tyr Tyr Ile Tyr Pro Tyr Thr

1 5

<210> 46

<211> 119

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain variable domain VH, Pertuzumab (PER)

<400> 46

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr

20 25 30

Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe

50 55 60

Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly

100 105 110

Thr Leu Val Thr Val Ser Ser

115

<210> 47

<211> 107

<212> PRT

<213> Artificial sequence

<220>

<223> light chain variable domain VL, Pertuzumab (PER)

<400> 47

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly

20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr

85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 48

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H1, trastuzumab

<400> 48

Gly Phe Asn Ile Lys Asp Thr Tyr Ile His

1 5 10

<210> 49

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H2, trastuzumab

<400> 49

Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 50

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H3, trastuzumab

<400> 50

Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr

1 5 10

<210> 51

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L1, trastuzumab

<400> 51

Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala

1 5 10

<210> 52

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L2, trastuzumab

<400> 52

Ser Ala Ser Phe Leu Tyr Ser

1 5

<210> 53

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L3, trastuzumab

<400> 53

Gln Gln His Tyr Thr Thr Pro Pro Thr

1 5

<210> 54

<211> 120

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain variable Domain VH, Trastuzumab (TRAS)

<400> 54

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr

20 25 30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 55

<211> 107

<212> PRT

<213> Artificial sequence

<220>

<223> light chain variable domain VL, Trastuzumab (TRAS)

<400> 55

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala

20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro

85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 56

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H1, aff. pertuzumab

<400> 56

Gly Phe Thr Phe Asn Asp Tyr Thr Met Asp

1 5 10

<210> 57

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H2, aff. pertuzumab

<400> 57

Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Val Asn Arg Arg Phe Lys

1 5 10 15

Gly

<210> 58

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain CDR-H3, aff. pertuzumab

<400> 58

Asn Leu Gly Pro Phe Phe Tyr Phe Asp Tyr

1 5 10

<210> 59

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L1, aff. pertuzumab

<400> 59

Lys Ala Ser Gln Asp Val Ser Thr Ala Val Ala

1 5 10

<210> 60

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L2, aff. pertuzumab

<400> 60

Ser Ala Ser Phe Arg Tyr Thr

1 5

<210> 61

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> light chain CDR-L1, aff. pertuzumab

<400> 61

Gln Gln His Tyr Thr Thr Pro Pro Thr

1 5

<210> 62

<211> 119

<212> PRT

<213> Artificial sequence

<220>

<223> heavy chain variable domain VH, aff. pertuzumab (aff-PER)

<400> 62

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Tyr

20 25 30

Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Val Asn Arg Arg Phe

50 55 60

Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asn Leu Gly Pro Phe Phe Tyr Phe Asp Tyr Trp Gly Gln Gly

100 105 110

Thr Leu Val Thr Val Ser Ser

115

<210> 63

<211> 107

<212> PRT

<213> Artificial sequence

<220>

<223> light chain variable domain VL, aff. pertuzumab (aff-PER)

<400> 63

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala

20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ser Ala Ser Phe Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro

85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 64

<211> 419

<212> PRT

<213> Artificial sequence

<220>

<223> Fc pore huIgG1 PGLALA-4-1BB lipocalin heavy chain

<400> 64

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

225 230 235 240

Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys

245 250 255

Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp

260 265 270

Tyr Val Val Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp

275 280 285

Pro Ile Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser

290 295 300

Tyr Asp Val Thr Met Val Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp

305 310 315 320

Ile Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly

325 330 335

Lys Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val

340 345 350

Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe

355 360 365

Gln Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu

370 375 380

Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu

385 390 395 400

Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys

405 410 415

Ile Asp Gly

<210> 65

<211> 642

<212> PRT

<213> Artificial sequence

<220>

<223> VH (Her2 TRAS) Fc protuberant huIgG1 PGLALA 4-1BB lipocalin heavy chain

<400> 65

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr

20 25 30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu

355 360 365

Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

450 455 460

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

465 470 475 480

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

485 490 495

Val Val Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro

500 505 510

Ile Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

515 520 525

Asp Val Thr Met Val Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp Ile

530 535 540

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys

545 550 555 560

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

565 570 575

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

580 585 590

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

595 600 605

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

610 615 620

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

625 630 635 640

Asp Gly

<210> 66

<211> 214

<212> PRT

<213> Artificial sequence

<220>

<223> VL (Her2 TRAS) C kappa light chain

<400> 66

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala

20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro

85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala

100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly

115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala

130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln

145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser

165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser

195 200 205

Phe Asn Arg Gly Glu Cys

210

<210> 67

<211> 639

<212> PRT

<213> Artificial sequence

<220>

<223> VH (FAP 4B9) -Fc huIgG1 PGLALA-4-1BB lipocalin heavy chain

<400> 67

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ile Gly Ser Gly Ala Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Gly Trp Phe Gly Gly Phe Asn Tyr Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu

115 120 125

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys

130 135 140

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser

145 150 155 160

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser

165 170 175

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser

180 185 190

Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn

195 200 205

Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His

210 215 220

Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu

260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly

435 440 445

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Asp Ser

450 455 460

Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val Pro Leu Gln

465 470 475 480

Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr Val Val Gly

485 490 495

Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro Ile Lys Met

500 505 510

Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asp Val Thr

515 520 525

Met Val Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp Ile Trp Thr Phe

530 535 540

Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys Ile Lys Ser

545 550 555 560

Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser Thr Asn Tyr

565 570 575

Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln Asn Arg Glu

580 585 590

Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu

595 600 605

Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu

610 615 620

Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly

625 630 635

<210> 68

<211> 642

<212> PRT

<213> Artificial sequence

<220>

<223> VH (Her2 TRAS) -Fc huIgG1 PGLALA-4-1BB lipocalin heavy chain

<400> 68

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr

20 25 30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp

210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly

225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu

325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr

340 345 350

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu

355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

435 440 445

Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

450 455 460

Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val

465 470 475 480

Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr

485 490 495

Val Val Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro

500 505 510

Ile Lys Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr

515 520 525

Asp Val Thr Met Val Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp Ile

530 535 540

Trp Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys

545 550 555 560

Ile Lys Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser

565 570 575

Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln

580 585 590

Asn Arg Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu

595 600 605

Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly

610 615 620

Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile

625 630 635 640

Asp Gly

<210> 69

<211> 637

<212> PRT

<213> Artificial sequence

<220>

<223> VH (FAP 4B9) -Fc huIgG4 SP-4-1BB lipocalin heavy chain

<400> 69

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ile Gly Ser Gly Ala Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Gly Trp Phe Gly Gly Phe Asn Tyr Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu

115 120 125

Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys

130 135 140

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser

145 150 155 160

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser

165 170 175

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser

180 185 190

Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn

195 200 205

Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro

210 215 220

Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe

225 230 235 240

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val

245 250 255

Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe

260 265 270

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro

275 280 285

Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr

290 295 300

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val

305 310 315 320

Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala

325 330 335

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln

340 345 350

Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly

355 360 365

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro

370 375 380

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser

385 390 395 400

Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu

405 410 415

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His

420 425 430

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Gly Gly Gly Gly

435 440 445

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Asp Ser Thr Ser

450 455 460

Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val Pro Leu Gln Gln Asn

465 470 475 480

Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr Val Val Gly Gln Ala

485 490 495

Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro Ile Lys Met Met Ala

500 505 510

Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asp Val Thr Met Val

515 520 525

Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp Ile Trp Thr Phe Val Pro

530 535 540

Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys Ile Lys Ser Phe Pro

545 550 555 560

Gly His Thr Ser Ser Leu Val Arg Val Val Ser Thr Asn Tyr Asn Gln

565 570 575

His Ala Met Val Phe Phe Lys Phe Val Phe Gln Asn Arg Glu Glu Phe

580 585 590

Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys

595 600 605

Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu Asn His

610 615 620

Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly

625 630 635

<210> 70

<211> 215

<212> PRT

<213> Artificial sequence

<220>

<223> VL (FAP 4B9) light chain

<400> 70

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Asn Val Gly Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Ile Met Leu Pro

85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 71

<211> 635

<212> PRT

<213> Artificial sequence

<220>

<223> VH (DP47) -Fc huIgG4 SP-4-1BB lipocalin heavy chain

<400> 71

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Gly Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val

130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala

145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly

180 185 190

Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys

210 215 220

Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro

225 230 235 240

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys

245 250 255

Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp

260 265 270

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu

275 280 285

Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu

290 295 300

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn

305 310 315 320

Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

325 330 335

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu

340 345 350

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

355 360 365

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

370 375 380

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

385 390 395 400

Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn

405 410 415

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr

420 425 430

Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Gly Gly Gly Gly Ser Gly

435 440 445

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Asp Ser Thr Ser Asp Leu

450 455 460

Ile Pro Ala Pro Pro Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln

465 470 475 480

Asp Asn Gln Phe His Gly Lys Trp Tyr Val Val Gly Gln Ala Gly Asn

485 490 495

Ile Arg Leu Arg Glu Asp Lys Asp Pro Ile Lys Met Met Ala Thr Ile

500 505 510

Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asp Val Thr Met Val Lys Phe

515 520 525

Asp Asp Lys Lys Cys Met Tyr Asp Ile Trp Thr Phe Val Pro Gly Ser

530 535 540

Gln Pro Gly Glu Phe Thr Leu Gly Lys Ile Lys Ser Phe Pro Gly His

545 550 555 560

Thr Ser Ser Leu Val Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala

565 570 575

Met Val Phe Phe Lys Phe Val Phe Gln Asn Arg Glu Glu Phe Tyr Ile

580 585 590

Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn

595 600 605

Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val

610 615 620

Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly

625 630 635

<210> 72

<211> 215

<212> PRT

<213> Artificial sequence

<220>

<223> VL (DP47) light chain

<400> 72

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro

85 90 95

Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala

100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser

115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu

130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser

145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu

165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val

180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys

195 200 205

Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 73

<211> 640

<212> PRT

<213> Artificial sequence

<220>

<223> VH (Her2 TRAS) -Fc huIgG4 SP-4-1BB lipocalin heavy chain

<400> 73

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr

20 25 30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val

115 120 125

Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala

130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser

145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val

165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

180 185 190

Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys

195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro

210 215 220

Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu

260 265 270

Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Gly

435 440 445

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Asp

450 455 460

Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val Pro Leu

465 470 475 480

Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr Val Val

485 490 495

Gly Gln Ala Gly Asn Ile Arg Leu Arg Glu Asp Lys Asp Pro Ile Lys

500 505 510

Met Met Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asp Val

515 520 525

Thr Met Val Lys Phe Asp Asp Lys Lys Cys Met Tyr Asp Ile Trp Thr

530 535 540

Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Lys Ile Lys

545 550 555 560

Ser Phe Pro Gly His Thr Ser Ser Leu Val Arg Val Val Ser Thr Asn

565 570 575

Tyr Asn Gln His Ala Met Val Phe Phe Lys Phe Val Phe Gln Asn Arg

580 585 590

Glu Glu Phe Tyr Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser

595 600 605

Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro

610 615 620

Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly

625 630 635 640

<210> 74

<211> 214

<212> PRT

<213> Artificial sequence

<220>

<223> VL (Her2 TRAS) light chain

<400> 74

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala

20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro

85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala

100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly

115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala

130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln

145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser

165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser

195 200 205

Phe Asn Arg Gly Glu Cys

210

<210> 75

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 75

Gly Gly Gly Gly Ser

1 5

<210> 76

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 76

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

1 5 10

<210> 77

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 77

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

1 5 10

<210> 78

<211> 15

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 78

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

1 5 10 15

<210> 79

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 79

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

1 5 10

<210> 80

<211> 20

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 80

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

1 5 10 15

Gly Gly Gly Ser

20

<210> 81

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 81

Gly Ser Pro Gly Ser Ser Ser Ser Gly Ser

1 5 10

<210> 82

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 82

Gly Ser Gly Ser Gly Ser Gly Ser

1 5

<210> 83

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 83

Gly Ser Gly Ser Gly Asn Gly Ser

1 5

<210> 84

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 84

Gly Gly Ser Gly Ser Gly Ser Gly

1 5

<210> 85

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 85

Gly Gly Ser Gly Ser Gly

1 5

<210> 86

<211> 4

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 86

Gly Gly Ser Gly

1

<210> 87

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 87

Gly Gly Ser Gly Asn Gly Ser Gly

1 5

<210> 88

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 88

Gly Gly Asn Gly Ser Gly Ser Gly

1 5

<210> 89

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 89

Gly Gly Asn Gly Ser Gly

1 5

<210> 90

<211> 152

<212> PRT

<213> Intelligent people

<400> 90

Ala Ser Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys

1 5 10 15

Ala Met Thr Val Asp Arg Glu Phe Pro Glu Met Asn Leu Glu Ser Val

20 25 30

Thr Pro Met Thr Leu Thr Thr Leu Glu Gly Gly Asn Leu Glu Ala Lys

35 40 45

Val Thr Met Leu Ile Ser Gly Arg Cys Gln Glu Val Lys Ala Val Leu

50 55 60

Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly Gly Lys His

65 70 75 80

Val Ala Tyr Ile Ile Arg Ser His Val Lys Asp His Tyr Ile Phe Tyr

85 90 95

Cys Glu Gly Glu Leu His Gly Lys Pro Val Arg Gly Val Lys Leu Val

100 105 110

Gly Arg Asp Pro Lys Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys

115 120 125

Ala Ala Gly Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Arg

130 135 140

Gln Ser Glu Thr Cys Ser Pro Gly

145 150

<210> 91

<211> 760

<212> PRT

<213> Intelligent people

<400> 91

Met Lys Thr Trp Val Lys Ile Val Phe Gly Val Ala Thr Ser Ala Val

1 5 10 15

Leu Ala Leu Leu Val Met Cys Ile Val Leu Arg Pro Ser Arg Val His

20 25 30

Asn Ser Glu Glu Asn Thr Met Arg Ala Leu Thr Leu Lys Asp Ile Leu

35 40 45

Asn Gly Thr Phe Ser Tyr Lys Thr Phe Phe Pro Asn Trp Ile Ser Gly

50 55 60

Gln Glu Tyr Leu His Gln Ser Ala Asp Asn Asn Ile Val Leu Tyr Asn

65 70 75 80

Ile Glu Thr Gly Gln Ser Tyr Thr Ile Leu Ser Asn Arg Thr Met Lys

85 90 95

Ser Val Asn Ala Ser Asn Tyr Gly Leu Ser Pro Asp Arg Gln Phe Val

100 105 110

Tyr Leu Glu Ser Asp Tyr Ser Lys Leu Trp Arg Tyr Ser Tyr Thr Ala

115 120 125

Thr Tyr Tyr Ile Tyr Asp Leu Ser Asn Gly Glu Phe Val Arg Gly Asn

130 135 140

Glu Leu Pro Arg Pro Ile Gln Tyr Leu Cys Trp Ser Pro Val Gly Ser

145 150 155 160

Lys Leu Ala Tyr Val Tyr Gln Asn Asn Ile Tyr Leu Lys Gln Arg Pro

165 170 175

Gly Asp Pro Pro Phe Gln Ile Thr Phe Asn Gly Arg Glu Asn Lys Ile

180 185 190

Phe Asn Gly Ile Pro Asp Trp Val Tyr Glu Glu Glu Met Leu Ala Thr

195 200 205

Lys Tyr Ala Leu Trp Trp Ser Pro Asn Gly Lys Phe Leu Ala Tyr Ala

210 215 220

Glu Phe Asn Asp Thr Asp Ile Pro Val Ile Ala Tyr Ser Tyr Tyr Gly

225 230 235 240

Asp Glu Gln Tyr Pro Arg Thr Ile Asn Ile Pro Tyr Pro Lys Ala Gly

245 250 255

Ala Lys Asn Pro Val Val Arg Ile Phe Ile Ile Asp Thr Thr Tyr Pro

260 265 270

Ala Tyr Val Gly Pro Gln Glu Val Pro Val Pro Ala Met Ile Ala Ser

275 280 285

Ser Asp Tyr Tyr Phe Ser Trp Leu Thr Trp Val Thr Asp Glu Arg Val

290 295 300

Cys Leu Gln Trp Leu Lys Arg Val Gln Asn Val Ser Val Leu Ser Ile

305 310 315 320

Cys Asp Phe Arg Glu Asp Trp Gln Thr Trp Asp Cys Pro Lys Thr Gln

325 330 335

Glu His Ile Glu Glu Ser Arg Thr Gly Trp Ala Gly Gly Phe Phe Val

340 345 350

Ser Thr Pro Val Phe Ser Tyr Asp Ala Ile Ser Tyr Tyr Lys Ile Phe

355 360 365

Ser Asp Lys Asp Gly Tyr Lys His Ile His Tyr Ile Lys Asp Thr Val

370 375 380

Glu Asn Ala Ile Gln Ile Thr Ser Gly Lys Trp Glu Ala Ile Asn Ile

385 390 395 400

Phe Arg Val Thr Gln Asp Ser Leu Phe Tyr Ser Ser Asn Glu Phe Glu

405 410 415

Glu Tyr Pro Gly Arg Arg Asn Ile Tyr Arg Ile Ser Ile Gly Ser Tyr

420 425 430

Pro Pro Ser Lys Lys Cys Val Thr Cys His Leu Arg Lys Glu Arg Cys

435 440 445

Gln Tyr Tyr Thr Ala Ser Phe Ser Asp Tyr Ala Lys Tyr Tyr Ala Leu

450 455 460

Val Cys Tyr Gly Pro Gly Ile Pro Ile Ser Thr Leu His Asp Gly Arg

465 470 475 480

Thr Asp Gln Glu Ile Lys Ile Leu Glu Glu Asn Lys Glu Leu Glu Asn

485 490 495

Ala Leu Lys Asn Ile Gln Leu Pro Lys Glu Glu Ile Lys Lys Leu Glu

500 505 510

Val Asp Glu Ile Thr Leu Trp Tyr Lys Met Ile Leu Pro Pro Gln Phe

515 520 525

Asp Arg Ser Lys Lys Tyr Pro Leu Leu Ile Gln Val Tyr Gly Gly Pro

530 535 540

Cys Ser Gln Ser Val Arg Ser Val Phe Ala Val Asn Trp Ile Ser Tyr

545 550 555 560

Leu Ala Ser Lys Glu Gly Met Val Ile Ala Leu Val Asp Gly Arg Gly

565 570 575

Thr Ala Phe Gln Gly Asp Lys Leu Leu Tyr Ala Val Tyr Arg Lys Leu

580 585 590

Gly Val Tyr Glu Val Glu Asp Gln Ile Thr Ala Val Arg Lys Phe Ile

595 600 605

Glu Met Gly Phe Ile Asp Glu Lys Arg Ile Ala Ile Trp Gly Trp Ser

610 615 620

Tyr Gly Gly Tyr Val Ser Ser Leu Ala Leu Ala Ser Gly Thr Gly Leu

625 630 635 640

Phe Lys Cys Gly Ile Ala Val Ala Pro Val Ser Ser Trp Glu Tyr Tyr

645 650 655

Ala Ser Val Tyr Thr Glu Arg Phe Met Gly Leu Pro Thr Lys Asp Asp

660 665 670

Asn Leu Glu His Tyr Lys Asn Ser Thr Val Met Ala Arg Ala Glu Tyr

675 680 685

Phe Arg Asn Val Asp Tyr Leu Leu Ile His Gly Thr Ala Asp Asp Asn

690 695 700

Val His Phe Gln Asn Ser Ala Gln Ile Ala Lys Ala Leu Val Asn Ala

705 710 715 720

Gln Val Asp Phe Gln Ala Met Trp Tyr Ser Asp Gln Asn His Gly Leu

725 730 735

Ser Gly Leu Ser Thr Asn His Leu Tyr Thr His Met Thr His Phe Leu

740 745 750

Lys Gln Cys Phe Ser Leu Ser Asp

755 760

<210> 92

<211> 748

<212> PRT

<213> Artificial sequence

<220>

<223> hu FAP extracellular domain + poly-lys-tag + his 6-tag

<400> 92

Arg Pro Ser Arg Val His Asn Ser Glu Glu Asn Thr Met Arg Ala Leu

1 5 10 15

Thr Leu Lys Asp Ile Leu Asn Gly Thr Phe Ser Tyr Lys Thr Phe Phe

20 25 30

Pro Asn Trp Ile Ser Gly Gln Glu Tyr Leu His Gln Ser Ala Asp Asn

35 40 45

Asn Ile Val Leu Tyr Asn Ile Glu Thr Gly Gln Ser Tyr Thr Ile Leu

50 55 60

Ser Asn Arg Thr Met Lys Ser Val Asn Ala Ser Asn Tyr Gly Leu Ser

65 70 75 80

Pro Asp Arg Gln Phe Val Tyr Leu Glu Ser Asp Tyr Ser Lys Leu Trp

85 90 95

Arg Tyr Ser Tyr Thr Ala Thr Tyr Tyr Ile Tyr Asp Leu Ser Asn Gly

100 105 110

Glu Phe Val Arg Gly Asn Glu Leu Pro Arg Pro Ile Gln Tyr Leu Cys

115 120 125

Trp Ser Pro Val Gly Ser Lys Leu Ala Tyr Val Tyr Gln Asn Asn Ile

130 135 140

Tyr Leu Lys Gln Arg Pro Gly Asp Pro Pro Phe Gln Ile Thr Phe Asn

145 150 155 160

Gly Arg Glu Asn Lys Ile Phe Asn Gly Ile Pro Asp Trp Val Tyr Glu

165 170 175

Glu Glu Met Leu Ala Thr Lys Tyr Ala Leu Trp Trp Ser Pro Asn Gly

180 185 190

Lys Phe Leu Ala Tyr Ala Glu Phe Asn Asp Thr Asp Ile Pro Val Ile

195 200 205

Ala Tyr Ser Tyr Tyr Gly Asp Glu Gln Tyr Pro Arg Thr Ile Asn Ile

210 215 220

Pro Tyr Pro Lys Ala Gly Ala Lys Asn Pro Val Val Arg Ile Phe Ile

225 230 235 240

Ile Asp Thr Thr Tyr Pro Ala Tyr Val Gly Pro Gln Glu Val Pro Val

245 250 255

Pro Ala Met Ile Ala Ser Ser Asp Tyr Tyr Phe Ser Trp Leu Thr Trp

260 265 270

Val Thr Asp Glu Arg Val Cys Leu Gln Trp Leu Lys Arg Val Gln Asn

275 280 285

Val Ser Val Leu Ser Ile Cys Asp Phe Arg Glu Asp Trp Gln Thr Trp

290 295 300

Asp Cys Pro Lys Thr Gln Glu His Ile Glu Glu Ser Arg Thr Gly Trp

305 310 315 320

Ala Gly Gly Phe Phe Val Ser Thr Pro Val Phe Ser Tyr Asp Ala Ile

325 330 335

Ser Tyr Tyr Lys Ile Phe Ser Asp Lys Asp Gly Tyr Lys His Ile His

340 345 350

Tyr Ile Lys Asp Thr Val Glu Asn Ala Ile Gln Ile Thr Ser Gly Lys

355 360 365

Trp Glu Ala Ile Asn Ile Phe Arg Val Thr Gln Asp Ser Leu Phe Tyr

370 375 380

Ser Ser Asn Glu Phe Glu Glu Tyr Pro Gly Arg Arg Asn Ile Tyr Arg

385 390 395 400

Ile Ser Ile Gly Ser Tyr Pro Pro Ser Lys Lys Cys Val Thr Cys His

405 410 415

Leu Arg Lys Glu Arg Cys Gln Tyr Tyr Thr Ala Ser Phe Ser Asp Tyr

420 425 430

Ala Lys Tyr Tyr Ala Leu Val Cys Tyr Gly Pro Gly Ile Pro Ile Ser

435 440 445

Thr Leu His Asp Gly Arg Thr Asp Gln Glu Ile Lys Ile Leu Glu Glu

450 455 460

Asn Lys Glu Leu Glu Asn Ala Leu Lys Asn Ile Gln Leu Pro Lys Glu

465 470 475 480

Glu Ile Lys Lys Leu Glu Val Asp Glu Ile Thr Leu Trp Tyr Lys Met

485 490 495

Ile Leu Pro Pro Gln Phe Asp Arg Ser Lys Lys Tyr Pro Leu Leu Ile

500 505 510

Gln Val Tyr Gly Gly Pro Cys Ser Gln Ser Val Arg Ser Val Phe Ala

515 520 525

Val Asn Trp Ile Ser Tyr Leu Ala Ser Lys Glu Gly Met Val Ile Ala

530 535 540

Leu Val Asp Gly Arg Gly Thr Ala Phe Gln Gly Asp Lys Leu Leu Tyr

545 550 555 560

Ala Val Tyr Arg Lys Leu Gly Val Tyr Glu Val Glu Asp Gln Ile Thr

565 570 575

Ala Val Arg Lys Phe Ile Glu Met Gly Phe Ile Asp Glu Lys Arg Ile

580 585 590

Ala Ile Trp Gly Trp Ser Tyr Gly Gly Tyr Val Ser Ser Leu Ala Leu

595 600 605

Ala Ser Gly Thr Gly Leu Phe Lys Cys Gly Ile Ala Val Ala Pro Val

610 615 620

Ser Ser Trp Glu Tyr Tyr Ala Ser Val Tyr Thr Glu Arg Phe Met Gly

625 630 635 640

Leu Pro Thr Lys Asp Asp Asn Leu Glu His Tyr Lys Asn Ser Thr Val

645 650 655

Met Ala Arg Ala Glu Tyr Phe Arg Asn Val Asp Tyr Leu Leu Ile His

660 665 670

Gly Thr Ala Asp Asp Asn Val His Phe Gln Asn Ser Ala Gln Ile Ala

675 680 685

Lys Ala Leu Val Asn Ala Gln Val Asp Phe Gln Ala Met Trp Tyr Ser

690 695 700

Asp Gln Asn His Gly Leu Ser Gly Leu Ser Thr Asn His Leu Tyr Thr

705 710 715 720

His Met Thr His Phe Leu Lys Gln Cys Phe Ser Leu Ser Asp Gly Lys

725 730 735

Lys Lys Lys Lys Lys Gly His His His His His His

740 745

<210> 93

<211> 762

<212> PRT

<213> mouse

<400> 93

Met Met Lys Thr Trp Leu Lys Thr Val Phe Gly Val Thr Thr Leu Ala

1 5 10 15

Ala Leu Ala Leu Val Val Ile Cys Ile Val Leu Arg Pro Ser Arg Val

20 25 30

Tyr Lys Pro Glu Gly Asn Thr Lys Arg Ala Leu Thr Leu Lys Asp Ile

35 40 45

Leu Asn Gly Thr Phe Ser Tyr Lys Thr Tyr Phe Pro Asn Trp Ile Ser

50 55 60

Glu Gln Glu Tyr Leu His Gln Ser Glu Asp Asp Asn Ile Val Phe Tyr

65 70 75 80

Asn Ile Glu Thr Arg Glu Ser Tyr Ile Ile Leu Ser Asn Ser Thr Met

85 90 95

Lys Ser Val Asn Ala Thr Asp Tyr Gly Leu Ser Pro Asp Arg Gln Phe

100 105 110

Val Tyr Leu Glu Ser Asp Tyr Ser Lys Leu Trp Arg Tyr Ser Tyr Thr

115 120 125

Ala Thr Tyr Tyr Ile Tyr Asp Leu Gln Asn Gly Glu Phe Val Arg Gly

130 135 140

Tyr Glu Leu Pro Arg Pro Ile Gln Tyr Leu Cys Trp Ser Pro Val Gly

145 150 155 160

Ser Lys Leu Ala Tyr Val Tyr Gln Asn Asn Ile Tyr Leu Lys Gln Arg

165 170 175

Pro Gly Asp Pro Pro Phe Gln Ile Thr Tyr Thr Gly Arg Glu Asn Arg

180 185 190

Ile Phe Asn Gly Ile Pro Asp Trp Val Tyr Glu Glu Glu Met Leu Ala

195 200 205

Thr Lys Tyr Ala Leu Trp Trp Ser Pro Asp Gly Lys Phe Leu Ala Tyr

210 215 220

Val Glu Phe Asn Asp Ser Asp Ile Pro Ile Ile Ala Tyr Ser Tyr Tyr

225 230 235 240

Gly Asp Gly Gln Tyr Pro Arg Thr Ile Asn Ile Pro Tyr Pro Lys Ala

245 250 255

Gly Ala Lys Asn Pro Val Val Arg Val Phe Ile Val Asp Thr Thr Tyr

260 265 270

Pro His His Val Gly Pro Met Glu Val Pro Val Pro Glu Met Ile Ala

275 280 285

Ser Ser Asp Tyr Tyr Phe Ser Trp Leu Thr Trp Val Ser Ser Glu Arg

290 295 300

Val Cys Leu Gln Trp Leu Lys Arg Val Gln Asn Val Ser Val Leu Ser

305 310 315 320

Ile Cys Asp Phe Arg Glu Asp Trp His Ala Trp Glu Cys Pro Lys Asn

325 330 335

Gln Glu His Val Glu Glu Ser Arg Thr Gly Trp Ala Gly Gly Phe Phe

340 345 350

Val Ser Thr Pro Ala Phe Ser Gln Asp Ala Thr Ser Tyr Tyr Lys Ile

355 360 365

Phe Ser Asp Lys Asp Gly Tyr Lys His Ile His Tyr Ile Lys Asp Thr

370 375 380

Val Glu Asn Ala Ile Gln Ile Thr Ser Gly Lys Trp Glu Ala Ile Tyr

385 390 395 400

Ile Phe Arg Val Thr Gln Asp Ser Leu Phe Tyr Ser Ser Asn Glu Phe

405 410 415

Glu Gly Tyr Pro Gly Arg Arg Asn Ile Tyr Arg Ile Ser Ile Gly Asn

420 425 430

Ser Pro Pro Ser Lys Lys Cys Val Thr Cys His Leu Arg Lys Glu Arg

435 440 445

Cys Gln Tyr Tyr Thr Ala Ser Phe Ser Tyr Lys Ala Lys Tyr Tyr Ala

450 455 460

Leu Val Cys Tyr Gly Pro Gly Leu Pro Ile Ser Thr Leu His Asp Gly

465 470 475 480

Arg Thr Asp Gln Glu Ile Gln Val Leu Glu Glu Asn Lys Glu Leu Glu

485 490 495

Asn Ser Leu Arg Asn Ile Gln Leu Pro Lys Val Glu Ile Lys Lys Leu

500 505 510

Lys Asp Gly Gly Leu Thr Phe Trp Tyr Lys Met Ile Leu Pro Pro Gln

515 520 525

Phe Asp Arg Ser Lys Lys Tyr Pro Leu Leu Ile Gln Val Tyr Gly Gly

530 535 540

Pro Cys Ser Gln Ser Val Lys Ser Val Phe Ala Val Asn Trp Ile Thr

545 550 555 560

Tyr Leu Ala Ser Lys Glu Gly Ile Val Ile Ala Leu Val Asp Gly Arg

565 570 575

Gly Thr Ala Phe Gln Gly Asp Lys Phe Leu His Ala Val Tyr Arg Lys

580 585 590

Leu Gly Val Tyr Glu Val Glu Asp Gln Leu Thr Ala Val Arg Lys Phe

595 600 605

Ile Glu Met Gly Phe Ile Asp Glu Glu Arg Ile Ala Ile Trp Gly Trp

610 615 620

Ser Tyr Gly Gly Tyr Val Ser Ser Leu Ala Leu Ala Ser Gly Thr Gly

625 630 635 640

Leu Phe Lys Cys Gly Ile Ala Val Ala Pro Val Ser Ser Trp Glu Tyr

645 650 655

Tyr Ala Ser Ile Tyr Ser Glu Arg Phe Met Gly Leu Pro Thr Lys Asp

660 665 670

Asp Asn Leu Glu His Tyr Lys Asn Ser Thr Val Met Ala Arg Ala Glu

675 680 685

Tyr Phe Arg Asn Val Asp Tyr Leu Leu Ile His Gly Thr Ala Asp Asp

690 695 700

Asn Val His Phe Gln Asn Ser Ala Gln Ile Ala Lys Ala Leu Val Asn

705 710 715 720

Ala Gln Val Asp Phe Gln Ala Met Trp Tyr Ser Asp Gln Asn His Gly

725 730 735

Ile Ser Ser Gly Arg Ser Gln Asn His Leu Tyr Thr His Met Thr His

740 745 750

Phe Leu Lys Gln Cys Phe Ser Leu Ser Asp

755 760

<210> 94

<211> 749

<212> PRT

<213> Artificial sequence

<220>

<223> murine FAP extracellular domain + poly-lys-tag + his 6-tag

<400> 94

Arg Pro Ser Arg Val Tyr Lys Pro Glu Gly Asn Thr Lys Arg Ala Leu

1 5 10 15

Thr Leu Lys Asp Ile Leu Asn Gly Thr Phe Ser Tyr Lys Thr Tyr Phe

20 25 30

Pro Asn Trp Ile Ser Glu Gln Glu Tyr Leu His Gln Ser Glu Asp Asp

35 40 45

Asn Ile Val Phe Tyr Asn Ile Glu Thr Arg Glu Ser Tyr Ile Ile Leu

50 55 60

Ser Asn Ser Thr Met Lys Ser Val Asn Ala Thr Asp Tyr Gly Leu Ser

65 70 75 80

Pro Asp Arg Gln Phe Val Tyr Leu Glu Ser Asp Tyr Ser Lys Leu Trp

85 90 95

Arg Tyr Ser Tyr Thr Ala Thr Tyr Tyr Ile Tyr Asp Leu Gln Asn Gly

100 105 110

Glu Phe Val Arg Gly Tyr Glu Leu Pro Arg Pro Ile Gln Tyr Leu Cys

115 120 125

Trp Ser Pro Val Gly Ser Lys Leu Ala Tyr Val Tyr Gln Asn Asn Ile

130 135 140

Tyr Leu Lys Gln Arg Pro Gly Asp Pro Pro Phe Gln Ile Thr Tyr Thr

145 150 155 160

Gly Arg Glu Asn Arg Ile Phe Asn Gly Ile Pro Asp Trp Val Tyr Glu

165 170 175

Glu Glu Met Leu Ala Thr Lys Tyr Ala Leu Trp Trp Ser Pro Asp Gly

180 185 190

Lys Phe Leu Ala Tyr Val Glu Phe Asn Asp Ser Asp Ile Pro Ile Ile

195 200 205

Ala Tyr Ser Tyr Tyr Gly Asp Gly Gln Tyr Pro Arg Thr Ile Asn Ile

210 215 220

Pro Tyr Pro Lys Ala Gly Ala Lys Asn Pro Val Val Arg Val Phe Ile

225 230 235 240

Val Asp Thr Thr Tyr Pro His His Val Gly Pro Met Glu Val Pro Val

245 250 255

Pro Glu Met Ile Ala Ser Ser Asp Tyr Tyr Phe Ser Trp Leu Thr Trp

260 265 270

Val Ser Ser Glu Arg Val Cys Leu Gln Trp Leu Lys Arg Val Gln Asn

275 280 285

Val Ser Val Leu Ser Ile Cys Asp Phe Arg Glu Asp Trp His Ala Trp

290 295 300

Glu Cys Pro Lys Asn Gln Glu His Val Glu Glu Ser Arg Thr Gly Trp

305 310 315 320

Ala Gly Gly Phe Phe Val Ser Thr Pro Ala Phe Ser Gln Asp Ala Thr

325 330 335

Ser Tyr Tyr Lys Ile Phe Ser Asp Lys Asp Gly Tyr Lys His Ile His

340 345 350

Tyr Ile Lys Asp Thr Val Glu Asn Ala Ile Gln Ile Thr Ser Gly Lys

355 360 365

Trp Glu Ala Ile Tyr Ile Phe Arg Val Thr Gln Asp Ser Leu Phe Tyr

370 375 380

Ser Ser Asn Glu Phe Glu Gly Tyr Pro Gly Arg Arg Asn Ile Tyr Arg

385 390 395 400

Ile Ser Ile Gly Asn Ser Pro Pro Ser Lys Lys Cys Val Thr Cys His

405 410 415

Leu Arg Lys Glu Arg Cys Gln Tyr Tyr Thr Ala Ser Phe Ser Tyr Lys

420 425 430

Ala Lys Tyr Tyr Ala Leu Val Cys Tyr Gly Pro Gly Leu Pro Ile Ser

435 440 445

Thr Leu His Asp Gly Arg Thr Asp Gln Glu Ile Gln Val Leu Glu Glu

450 455 460

Asn Lys Glu Leu Glu Asn Ser Leu Arg Asn Ile Gln Leu Pro Lys Val

465 470 475 480

Glu Ile Lys Lys Leu Lys Asp Gly Gly Leu Thr Phe Trp Tyr Lys Met

485 490 495

Ile Leu Pro Pro Gln Phe Asp Arg Ser Lys Lys Tyr Pro Leu Leu Ile

500 505 510

Gln Val Tyr Gly Gly Pro Cys Ser Gln Ser Val Lys Ser Val Phe Ala

515 520 525

Val Asn Trp Ile Thr Tyr Leu Ala Ser Lys Glu Gly Ile Val Ile Ala

530 535 540

Leu Val Asp Gly Arg Gly Thr Ala Phe Gln Gly Asp Lys Phe Leu His

545 550 555 560

Ala Val Tyr Arg Lys Leu Gly Val Tyr Glu Val Glu Asp Gln Leu Thr

565 570 575

Ala Val Arg Lys Phe Ile Glu Met Gly Phe Ile Asp Glu Glu Arg Ile

580 585 590

Ala Ile Trp Gly Trp Ser Tyr Gly Gly Tyr Val Ser Ser Leu Ala Leu

595 600 605

Ala Ser Gly Thr Gly Leu Phe Lys Cys Gly Ile Ala Val Ala Pro Val

610 615 620

Ser Ser Trp Glu Tyr Tyr Ala Ser Ile Tyr Ser Glu Arg Phe Met Gly

625 630 635 640

Leu Pro Thr Lys Asp Asp Asn Leu Glu His Tyr Lys Asn Ser Thr Val

645 650 655

Met Ala Arg Ala Glu Tyr Phe Arg Asn Val Asp Tyr Leu Leu Ile His

660 665 670

Gly Thr Ala Asp Asp Asn Val His Phe Gln Asn Ser Ala Gln Ile Ala

675 680 685

Lys Ala Leu Val Asn Ala Gln Val Asp Phe Gln Ala Met Trp Tyr Ser

690 695 700

Asp Gln Asn His Gly Ile Leu Ser Gly Arg Ser Gln Asn His Leu Tyr

705 710 715 720

Thr His Met Thr His Phe Leu Lys Gln Cys Phe Ser Leu Ser Asp Gly

725 730 735

Lys Lys Lys Lys Lys Lys Gly His His His His His His

740 745

<210> 95

<211> 748

<212> PRT

<213> Artificial sequence

<220>

<223> cynomolgus FAP extracellular domain + poly-lys-tag + his 6-tag

<400> 95

Arg Pro Pro Arg Val His Asn Ser Glu Glu Asn Thr Met Arg Ala Leu

1 5 10 15

Thr Leu Lys Asp Ile Leu Asn Gly Thr Phe Ser Tyr Lys Thr Phe Phe

20 25 30

Pro Asn Trp Ile Ser Gly Gln Glu Tyr Leu His Gln Ser Ala Asp Asn

35 40 45

Asn Ile Val Leu Tyr Asn Ile Glu Thr Gly Gln Ser Tyr Thr Ile Leu

50 55 60

Ser Asn Arg Thr Met Lys Ser Val Asn Ala Ser Asn Tyr Gly Leu Ser

65 70 75 80

Pro Asp Arg Gln Phe Val Tyr Leu Glu Ser Asp Tyr Ser Lys Leu Trp

85 90 95

Arg Tyr Ser Tyr Thr Ala Thr Tyr Tyr Ile Tyr Asp Leu Ser Asn Gly

100 105 110

Glu Phe Val Arg Gly Asn Glu Leu Pro Arg Pro Ile Gln Tyr Leu Cys

115 120 125

Trp Ser Pro Val Gly Ser Lys Leu Ala Tyr Val Tyr Gln Asn Asn Ile

130 135 140

Tyr Leu Lys Gln Arg Pro Gly Asp Pro Pro Phe Gln Ile Thr Phe Asn

145 150 155 160

Gly Arg Glu Asn Lys Ile Phe Asn Gly Ile Pro Asp Trp Val Tyr Glu

165 170 175

Glu Glu Met Leu Ala Thr Lys Tyr Ala Leu Trp Trp Ser Pro Asn Gly

180 185 190

Lys Phe Leu Ala Tyr Ala Glu Phe Asn Asp Thr Asp Ile Pro Val Ile

195 200 205

Ala Tyr Ser Tyr Tyr Gly Asp Glu Gln Tyr Pro Arg Thr Ile Asn Ile

210 215 220

Pro Tyr Pro Lys Ala Gly Ala Lys Asn Pro Phe Val Arg Ile Phe Ile

225 230 235 240

Ile Asp Thr Thr Tyr Pro Ala Tyr Val Gly Pro Gln Glu Val Pro Val

245 250 255

Pro Ala Met Ile Ala Ser Ser Asp Tyr Tyr Phe Ser Trp Leu Thr Trp

260 265 270

Val Thr Asp Glu Arg Val Cys Leu Gln Trp Leu Lys Arg Val Gln Asn

275 280 285

Val Ser Val Leu Ser Ile Cys Asp Phe Arg Glu Asp Trp Gln Thr Trp

290 295 300

Asp Cys Pro Lys Thr Gln Glu His Ile Glu Glu Ser Arg Thr Gly Trp

305 310 315 320

Ala Gly Gly Phe Phe Val Ser Thr Pro Val Phe Ser Tyr Asp Ala Ile

325 330 335

Ser Tyr Tyr Lys Ile Phe Ser Asp Lys Asp Gly Tyr Lys His Ile His

340 345 350

Tyr Ile Lys Asp Thr Val Glu Asn Ala Ile Gln Ile Thr Ser Gly Lys

355 360 365

Trp Glu Ala Ile Asn Ile Phe Arg Val Thr Gln Asp Ser Leu Phe Tyr

370 375 380

Ser Ser Asn Glu Phe Glu Asp Tyr Pro Gly Arg Arg Asn Ile Tyr Arg

385 390 395 400

Ile Ser Ile Gly Ser Tyr Pro Pro Ser Lys Lys Cys Val Thr Cys His

405 410 415

Leu Arg Lys Glu Arg Cys Gln Tyr Tyr Thr Ala Ser Phe Ser Asp Tyr

420 425 430

Ala Lys Tyr Tyr Ala Leu Val Cys Tyr Gly Pro Gly Ile Pro Ile Ser

435 440 445

Thr Leu His Asp Gly Arg Thr Asp Gln Glu Ile Lys Ile Leu Glu Glu

450 455 460

Asn Lys Glu Leu Glu Asn Ala Leu Lys Asn Ile Gln Leu Pro Lys Glu

465 470 475 480

Glu Ile Lys Lys Leu Glu Val Asp Glu Ile Thr Leu Trp Tyr Lys Met

485 490 495

Ile Leu Pro Pro Gln Phe Asp Arg Ser Lys Lys Tyr Pro Leu Leu Ile

500 505 510

Gln Val Tyr Gly Gly Pro Cys Ser Gln Ser Val Arg Ser Val Phe Ala

515 520 525

Val Asn Trp Ile Ser Tyr Leu Ala Ser Lys Glu Gly Met Val Ile Ala

530 535 540

Leu Val Asp Gly Arg Gly Thr Ala Phe Gln Gly Asp Lys Leu Leu Tyr

545 550 555 560

Ala Val Tyr Arg Lys Leu Gly Val Tyr Glu Val Glu Asp Gln Ile Thr

565 570 575

Ala Val Arg Lys Phe Ile Glu Met Gly Phe Ile Asp Glu Lys Arg Ile

580 585 590

Ala Ile Trp Gly Trp Ser Tyr Gly Gly Tyr Val Ser Ser Leu Ala Leu

595 600 605

Ala Ser Gly Thr Gly Leu Phe Lys Cys Gly Ile Ala Val Ala Pro Val

610 615 620

Ser Ser Trp Glu Tyr Tyr Ala Ser Val Tyr Thr Glu Arg Phe Met Gly

625 630 635 640

Leu Pro Thr Lys Asp Asp Asn Leu Glu His Tyr Lys Asn Ser Thr Val

645 650 655

Met Ala Arg Ala Glu Tyr Phe Arg Asn Val Asp Tyr Leu Leu Ile His

660 665 670

Gly Thr Ala Asp Asp Asn Val His Phe Gln Asn Ser Ala Gln Ile Ala

675 680 685

Lys Ala Leu Val Asn Ala Gln Val Asp Phe Gln Ala Met Trp Tyr Ser

690 695 700

Asp Gln Asn His Gly Leu Ser Gly Leu Ser Thr Asn His Leu Tyr Thr

705 710 715 720

His Met Thr His Phe Leu Lys Gln Cys Phe Ser Leu Ser Asp Gly Lys

725 730 735

Lys Lys Lys Lys Lys Gly His His His His His His

740 745

<210> 96

<211> 702

<212> PRT

<213> Intelligent people

<400> 96

Met Glu Ser Pro Ser Ala Pro Pro His Arg Trp Cys Ile Pro Trp Gln

1 5 10 15

Arg Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr

20 25 30

Thr Ala Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly

35 40 45

Lys Glu Val Leu Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly

50 55 60

Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Ile

65 70 75 80

Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Tyr Ser

85 90 95

Gly Arg Glu Ile Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Ile

100 105 110

Ile Gln Asn Asp Thr Gly Phe Tyr Thr Leu His Val Ile Lys Ser Asp

115 120 125

Leu Val Asn Glu Glu Ala Thr Gly Gln Phe Arg Val Tyr Pro Glu Leu

130 135 140

Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro Val Glu Asp Lys

145 150 155 160

Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Thr Gln Asp Ala Thr Tyr

165 170 175

Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Gln

180 185 190

Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn Val Thr Arg Asn

195 200 205

Asp Thr Ala Ser Tyr Lys Cys Glu Thr Gln Asn Pro Val Ser Ala Arg

210 215 220

Arg Ser Asp Ser Val Ile Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro

225 230 235 240

Thr Ile Ser Pro Leu Asn Thr Ser Tyr Arg Ser Gly Glu Asn Leu Asn

245 250 255

Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser Trp Phe

260 265 270

Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn

275 280 285

Ile Thr Val Asn Asn Ser Gly Ser Tyr Thr Cys Gln Ala His Asn Ser

290 295 300

Asp Thr Gly Leu Asn Arg Thr Thr Val Thr Thr Ile Thr Val Tyr Ala

305 310 315 320

Glu Pro Pro Lys Pro Phe Ile Thr Ser Asn Asn Ser Asn Pro Val Glu

325 330 335

Asp Glu Asp Ala Val Ala Leu Thr Cys Glu Pro Glu Ile Gln Asn Thr

340 345 350

Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg

355 360 365

Leu Gln Leu Ser Asn Asp Asn Arg Thr Leu Thr Leu Leu Ser Val Thr

370 375 380

Arg Asn Asp Val Gly Pro Tyr Glu Cys Gly Ile Gln Asn Lys Leu Ser

385 390 395 400

Val Asp His Ser Asp Pro Val Ile Leu Asn Val Leu Tyr Gly Pro Asp

405 410 415

Asp Pro Thr Ile Ser Pro Ser Tyr Thr Tyr Tyr Arg Pro Gly Val Asn

420 425 430

Leu Ser Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser

435 440 445

Trp Leu Ile Asp Gly Asn Ile Gln Gln His Thr Gln Glu Leu Phe Ile

450 455 460

Ser Asn Ile Thr Glu Lys Asn Ser Gly Leu Tyr Thr Cys Gln Ala Asn

465 470 475 480

Asn Ser Ala Ser Gly His Ser Arg Thr Thr Val Lys Thr Ile Thr Val

485 490 495

Ser Ala Glu Leu Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro

500 505 510

Val Glu Asp Lys Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Ala Gln

515 520 525

Asn Thr Thr Tyr Leu Trp Trp Val Asn Gly Gln Ser Leu Pro Val Ser

530 535 540

Pro Arg Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn

545 550 555 560

Val Thr Arg Asn Asp Ala Arg Ala Tyr Val Cys Gly Ile Gln Asn Ser

565 570 575

Val Ser Ala Asn Arg Ser Asp Pro Val Thr Leu Asp Val Leu Tyr Gly

580 585 590

Pro Asp Thr Pro Ile Ile Ser Pro Pro Asp Ser Ser Tyr Leu Ser Gly

595 600 605

Ala Asn Leu Asn Leu Ser Cys His Ser Ala Ser Asn Pro Ser Pro Gln

610 615 620

Tyr Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln His Thr Gln Val Leu

625 630 635 640

Phe Ile Ala Lys Ile Thr Pro Asn Asn Asn Gly Thr Tyr Ala Cys Phe

645 650 655

Val Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Ser Ile

660 665 670

Thr Val Ser Ala Ser Gly Thr Ser Pro Gly Leu Ser Ala Gly Ala Thr

675 680 685

Val Gly Ile Met Ile Gly Val Leu Val Gly Val Ala Leu Ile

690 695 700

<210> 97

<211> 2322

<212> PRT

<213> Intelligent people

<400> 97

Met Gln Ser Gly Pro Arg Pro Pro Leu Pro Ala Pro Gly Leu Ala Leu

1 5 10 15

Ala Leu Thr Leu Thr Met Leu Ala Arg Leu Ala Ser Ala Ala Ser Phe

20 25 30

Phe Gly Glu Asn His Leu Glu Val Pro Val Ala Thr Ala Leu Thr Asp

35 40 45

Ile Asp Leu Gln Leu Gln Phe Ser Thr Ser Gln Pro Glu Ala Leu Leu

50 55 60

Leu Leu Ala Ala Gly Pro Ala Asp His Leu Leu Leu Gln Leu Tyr Ser

65 70 75 80

Gly Arg Leu Gln Val Arg Leu Val Leu Gly Gln Glu Glu Leu Arg Leu

85 90 95

Gln Thr Pro Ala Glu Thr Leu Leu Ser Asp Ser Ile Pro His Thr Val

100 105 110

Val Leu Thr Val Val Glu Gly Trp Ala Thr Leu Ser Val Asp Gly Phe

115 120 125

Leu Asn Ala Ser Ser Ala Val Pro Gly Ala Pro Leu Glu Val Pro Tyr

130 135 140

Gly Leu Phe Val Gly Gly Thr Gly Thr Leu Gly Leu Pro Tyr Leu Arg

145 150 155 160

Gly Thr Ser Arg Pro Leu Arg Gly Cys Leu His Ala Ala Thr Leu Asn

165 170 175

Gly Arg Ser Leu Leu Arg Pro Leu Thr Pro Asp Val His Glu Gly Cys

180 185 190

Ala Glu Glu Phe Ser Ala Ser Asp Asp Val Ala Leu Gly Phe Ser Gly

195 200 205

Pro His Ser Leu Ala Ala Phe Pro Ala Trp Gly Thr Gln Asp Glu Gly

210 215 220

Thr Leu Glu Phe Thr Leu Thr Thr Gln Ser Arg Gln Ala Pro Leu Ala

225 230 235 240

Phe Gln Ala Gly Gly Arg Arg Gly Asp Phe Ile Tyr Val Asp Ile Phe

245 250 255

Glu Gly His Leu Arg Ala Val Val Glu Lys Gly Gln Gly Thr Val Leu

260 265 270

Leu His Asn Ser Val Pro Val Ala Asp Gly Gln Pro His Glu Val Ser

275 280 285

Val His Ile Asn Ala His Arg Leu Glu Ile Ser Val Asp Gln Tyr Pro

290 295 300

Thr His Thr Ser Asn Arg Gly Val Leu Ser Tyr Leu Glu Pro Arg Gly

305 310 315 320

Ser Leu Leu Leu Gly Gly Leu Asp Ala Glu Ala Ser Arg His Leu Gln

325 330 335

Glu His Arg Leu Gly Leu Thr Pro Glu Ala Thr Asn Ala Ser Leu Leu

340 345 350

Gly Cys Met Glu Asp Leu Ser Val Asn Gly Gln Arg Arg Gly Leu Arg

355 360 365

Glu Ala Leu Leu Thr Arg Asn Met Ala Ala Gly Cys Arg Leu Glu Glu

370 375 380

Glu Glu Tyr Glu Asp Asp Ala Tyr Gly His Tyr Glu Ala Phe Ser Thr

385 390 395 400

Leu Ala Pro Glu Ala Trp Pro Ala Met Glu Leu Pro Glu Pro Cys Val

405 410 415

Pro Glu Pro Gly Leu Pro Pro Val Phe Ala Asn Phe Thr Gln Leu Leu

420 425 430

Thr Ile Ser Pro Leu Val Val Ala Glu Gly Gly Thr Ala Trp Leu Glu

435 440 445

Trp Arg His Val Gln Pro Thr Leu Asp Leu Met Glu Ala Glu Leu Arg

450 455 460

Lys Ser Gln Val Leu Phe Ser Val Thr Arg Gly Ala Arg His Gly Glu

465 470 475 480

Leu Glu Leu Asp Ile Pro Gly Ala Gln Ala Arg Lys Met Phe Thr Leu

485 490 495

Leu Asp Val Val Asn Arg Lys Ala Arg Phe Ile His Asp Gly Ser Glu

500 505 510

Asp Thr Ser Asp Gln Leu Val Leu Glu Val Ser Val Thr Ala Arg Val

515 520 525

Pro Met Pro Ser Cys Leu Arg Arg Gly Gln Thr Tyr Leu Leu Pro Ile

530 535 540

Gln Val Asn Pro Val Asn Asp Pro Pro His Ile Ile Phe Pro His Gly

545 550 555 560

Ser Leu Met Val Ile Leu Glu His Thr Gln Lys Pro Leu Gly Pro Glu

565 570 575

Val Phe Gln Ala Tyr Asp Pro Asp Ser Ala Cys Glu Gly Leu Thr Phe

580 585 590

Gln Val Leu Gly Thr Ser Ser Gly Leu Pro Val Glu Arg Arg Asp Gln

595 600 605

Pro Gly Glu Pro Ala Thr Glu Phe Ser Cys Arg Glu Leu Glu Ala Gly

610 615 620

Ser Leu Val Tyr Val His Arg Gly Gly Pro Ala Gln Asp Leu Thr Phe

625 630 635 640

Arg Val Ser Asp Gly Leu Gln Ala Ser Pro Pro Ala Thr Leu Lys Val

645 650 655

Val Ala Ile Arg Pro Ala Ile Gln Ile His Arg Ser Thr Gly Leu Arg

660 665 670

Leu Ala Gln Gly Ser Ala Met Pro Ile Leu Pro Ala Asn Leu Ser Val

675 680 685

Glu Thr Asn Ala Val Gly Gln Asp Val Ser Val Leu Phe Arg Val Thr

690 695 700

Gly Ala Leu Gln Phe Gly Glu Leu Gln Lys Gln Gly Ala Gly Gly Val

705 710 715 720

Glu Gly Ala Glu Trp Trp Ala Thr Gln Ala Phe His Gln Arg Asp Val

725 730 735

Glu Gln Gly Arg Val Arg Tyr Leu Ser Thr Asp Pro Gln His His Ala

740 745 750

Tyr Asp Thr Val Glu Asn Leu Ala Leu Glu Val Gln Val Gly Gln Glu

755 760 765

Ile Leu Ser Asn Leu Ser Phe Pro Val Thr Ile Gln Arg Ala Thr Val

770 775 780

Trp Met Leu Arg Leu Glu Pro Leu His Thr Gln Asn Thr Gln Gln Glu

785 790 795 800

Thr Leu Thr Thr Ala His Leu Glu Ala Thr Leu Glu Glu Ala Gly Pro

805 810 815

Ser Pro Pro Thr Phe His Tyr Glu Val Val Gln Ala Pro Arg Lys Gly

820 825 830

Asn Leu Gln Leu Gln Gly Thr Arg Leu Ser Asp Gly Gln Gly Phe Thr

835 840 845

Gln Asp Asp Ile Gln Ala Gly Arg Val Thr Tyr Gly Ala Thr Ala Arg

850 855 860

Ala Ser Glu Ala Val Glu Asp Thr Phe Arg Phe Arg Val Thr Ala Pro

865 870 875 880

Pro Tyr Phe Ser Pro Leu Tyr Thr Phe Pro Ile His Ile Gly Gly Asp

885 890 895

Pro Asp Ala Pro Val Leu Thr Asn Val Leu Leu Val Val Pro Glu Gly

900 905 910

Gly Glu Gly Val Leu Ser Ala Asp His Leu Phe Val Lys Ser Leu Asn

915 920 925

Ser Ala Ser Tyr Leu Tyr Glu Val Met Glu Arg Pro Arg His Gly Arg

930 935 940

Leu Ala Trp Arg Gly Thr Gln Asp Lys Thr Thr Met Val Thr Ser Phe

945 950 955 960

Thr Asn Glu Asp Leu Leu Arg Gly Arg Leu Val Tyr Gln His Asp Asp

965 970 975

Ser Glu Thr Thr Glu Asp Asp Ile Pro Phe Val Ala Thr Arg Gln Gly

980 985 990

Glu Ser Ser Gly Asp Met Ala Trp Glu Glu Val Arg Gly Val Phe Arg

995 1000 1005

Val Ala Ile Gln Pro Val Asn Asp His Ala Pro Val Gln Thr Ile

1010 1015 1020

Ser Arg Ile Phe His Val Ala Arg Gly Gly Arg Arg Leu Leu Thr

1025 1030 1035

Thr Asp Asp Val Ala Phe Ser Asp Ala Asp Ser Gly Phe Ala Asp

1040 1045 1050

Ala Gln Leu Val Leu Thr Arg Lys Asp Leu Leu Phe Gly Ser Ile

1055 1060 1065

Val Ala Val Asp Glu Pro Thr Arg Pro Ile Tyr Arg Phe Thr Gln

1070 1075 1080

Glu Asp Leu Arg Lys Arg Arg Val Leu Phe Val His Ser Gly Ala

1085 1090 1095

Asp Arg Gly Trp Ile Gln Leu Gln Val Ser Asp Gly Gln His Gln

1100 1105 1110

Ala Thr Ala Leu Leu Glu Val Gln Ala Ser Glu Pro Tyr Leu Arg

1115 1120 1125

Val Ala Asn Gly Ser Ser Leu Val Val Pro Gln Gly Gly Gln Gly

1130 1135 1140

Thr Ile Asp Thr Ala Val Leu His Leu Asp Thr Asn Leu Asp Ile

1145 1150 1155

Arg Ser Gly Asp Glu Val His Tyr His Val Thr Ala Gly Pro Arg

1160 1165 1170

Trp Gly Gln Leu Val Arg Ala Gly Gln Pro Ala Thr Ala Phe Ser

1175 1180 1185

Gln Gln Asp Leu Leu Asp Gly Ala Val Leu Tyr Ser His Asn Gly

1190 1195 1200

Ser Leu Ser Pro Arg Asp Thr Met Ala Phe Ser Val Glu Ala Gly

1205 1210 1215

Pro Val His Thr Asp Ala Thr Leu Gln Val Thr Ile Ala Leu Glu

1220 1225 1230

Gly Pro Leu Ala Pro Leu Lys Leu Val Arg His Lys Lys Ile Tyr

1235 1240 1245

Val Phe Gln Gly Glu Ala Ala Glu Ile Arg Arg Asp Gln Leu Glu

1250 1255 1260

Ala Ala Gln Glu Ala Val Pro Pro Ala Asp Ile Val Phe Ser Val

1265 1270 1275

Lys Ser Pro Pro Ser Ala Gly Tyr Leu Val Met Val Ser Arg Gly

1280 1285 1290

Ala Leu Ala Asp Glu Pro Pro Ser Leu Asp Pro Val Gln Ser Phe

1295 1300 1305

Ser Gln Glu Ala Val Asp Thr Gly Arg Val Leu Tyr Leu His Ser

1310 1315 1320

Arg Pro Glu Ala Trp Ser Asp Ala Phe Ser Leu Asp Val Ala Ser

1325 1330 1335

Gly Leu Gly Ala Pro Leu Glu Gly Val Leu Val Glu Leu Glu Val

1340 1345 1350

Leu Pro Ala Ala Ile Pro Leu Glu Ala Gln Asn Phe Ser Val Pro

1355 1360 1365

Glu Gly Gly Ser Leu Thr Leu Ala Pro Pro Leu Leu Arg Val Ser

1370 1375 1380

Gly Pro Tyr Phe Pro Thr Leu Leu Gly Leu Ser Leu Gln Val Leu

1385 1390 1395

Glu Pro Pro Gln His Gly Ala Leu Gln Lys Glu Asp Gly Pro Gln

1400 1405 1410

Ala Arg Thr Leu Ser Ala Phe Ser Trp Arg Met Val Glu Glu Gln

1415 1420 1425

Leu Ile Arg Tyr Val His Asp Gly Ser Glu Thr Leu Thr Asp Ser

1430 1435 1440

Phe Val Leu Met Ala Asn Ala Ser Glu Met Asp Arg Gln Ser His

1445 1450 1455

Pro Val Ala Phe Thr Val Thr Val Leu Pro Val Asn Asp Gln Pro

1460 1465 1470

Pro Ile Leu Thr Thr Asn Thr Gly Leu Gln Met Trp Glu Gly Ala

1475 1480 1485

Thr Ala Pro Ile Pro Ala Glu Ala Leu Arg Ser Thr Asp Gly Asp

1490 1495 1500

Ser Gly Ser Glu Asp Leu Val Tyr Thr Ile Glu Gln Pro Ser Asn

1505 1510 1515

Gly Arg Val Val Leu Arg Gly Ala Pro Gly Thr Glu Val Arg Ser

1520 1525 1530

Phe Thr Gln Ala Gln Leu Asp Gly Gly Leu Val Leu Phe Ser His

1535 1540 1545

Arg Gly Thr Leu Asp Gly Gly Phe Arg Phe Arg Leu Ser Asp Gly

1550 1555 1560

Glu His Thr Ser Pro Gly His Phe Phe Arg Val Thr Ala Gln Lys

1565 1570 1575

Gln Val Leu Leu Ser Leu Lys Gly Ser Gln Thr Leu Thr Val Cys

1580 1585 1590

Pro Gly Ser Val Gln Pro Leu Ser Ser Gln Thr Leu Arg Ala Ser

1595 1600 1605

Ser Ser Ala Gly Thr Asp Pro Gln Leu Leu Leu Tyr Arg Val Val

1610 1615 1620

Arg Gly Pro Gln Leu Gly Arg Leu Phe His Ala Gln Gln Asp Ser

1625 1630 1635

Thr Gly Glu Ala Leu Val Asn Phe Thr Gln Ala Glu Val Tyr Ala

1640 1645 1650

Gly Asn Ile Leu Tyr Glu His Glu Met Pro Pro Glu Pro Phe Trp

1655 1660 1665

Glu Ala His Asp Thr Leu Glu Leu Gln Leu Ser Ser Pro Pro Ala

1670 1675 1680

Arg Asp Val Ala Ala Thr Leu Ala Val Ala Val Ser Phe Glu Ala

1685 1690 1695

Ala Cys Pro Gln Arg Pro Ser His Leu Trp Lys Asn Lys Gly Leu

1700 1705 1710

Trp Val Pro Glu Gly Gln Arg Ala Arg Ile Thr Val Ala Ala Leu

1715 1720 1725

Asp Ala Ser Asn Leu Leu Ala Ser Val Pro Ser Pro Gln Arg Ser

1730 1735 1740

Glu His Asp Val Leu Phe Gln Val Thr Gln Phe Pro Ser Arg Gly

1745 1750 1755

Gln Leu Leu Val Ser Glu Glu Pro Leu His Ala Gly Gln Pro His

1760 1765 1770

Phe Leu Gln Ser Gln Leu Ala Ala Gly Gln Leu Val Tyr Ala His

1775 1780 1785

Gly Gly Gly Gly Thr Gln Gln Asp Gly Phe His Phe Arg Ala His

1790 1795 1800

Leu Gln Gly Pro Ala Gly Ala Ser Val Ala Gly Pro Gln Thr Ser

1805 1810 1815

Glu Ala Phe Ala Ile Thr Val Arg Asp Val Asn Glu Arg Pro Pro

1820 1825 1830

Gln Pro Gln Ala Ser Val Pro Leu Arg Leu Thr Arg Gly Ser Arg

1835 1840 1845

Ala Pro Ile Ser Arg Ala Gln Leu Ser Val Val Asp Pro Asp Ser

1850 1855 1860

Ala Pro Gly Glu Ile Glu Tyr Glu Val Gln Arg Ala Pro His Asn

1865 1870 1875

Gly Phe Leu Ser Leu Val Gly Gly Gly Leu Gly Pro Val Thr Arg

1880 1885 1890

Phe Thr Gln Ala Asp Val Asp Ser Gly Arg Leu Ala Phe Val Ala

1895 1900 1905

Asn Gly Ser Ser Val Ala Gly Ile Phe Gln Leu Ser Met Ser Asp

1910 1915 1920

Gly Ala Ser Pro Pro Leu Pro Met Ser Leu Ala Val Asp Ile Leu

1925 1930 1935

Pro Ser Ala Ile Glu Val Gln Leu Arg Ala Pro Leu Glu Val Pro

1940 1945 1950

Gln Ala Leu Gly Arg Ser Ser Leu Ser Gln Gln Gln Leu Arg Val

1955 1960 1965

Val Ser Asp Arg Glu Glu Pro Glu Ala Ala Tyr Arg Leu Ile Gln

1970 1975 1980

Gly Pro Gln Tyr Gly His Leu Leu Val Gly Gly Arg Pro Thr Ser

1985 1990 1995

Ala Phe Ser Gln Phe Gln Ile Asp Gln Gly Glu Val Val Phe Ala

2000 2005 2010

Phe Thr Asn Phe Ser Ser Ser His Asp His Phe Arg Val Leu Ala

2015 2020 2025

Leu Ala Arg Gly Val Asn Ala Ser Ala Val Val Asn Val Thr Val

2030 2035 2040

Arg Ala Leu Leu His Val Trp Ala Gly Gly Pro Trp Pro Gln Gly

2045 2050 2055

Ala Thr Leu Arg Leu Asp Pro Thr Val Leu Asp Ala Gly Glu Leu

2060 2065 2070

Ala Asn Arg Thr Gly Ser Val Pro Arg Phe Arg Leu Leu Glu Gly

2075 2080 2085

Pro Arg His Gly Arg Val Val Arg Val Pro Arg Ala Arg Thr Glu

2090 2095 2100

Pro Gly Gly Ser Gln Leu Val Glu Gln Phe Thr Gln Gln Asp Leu

2105 2110 2115

Glu Asp Gly Arg Leu Gly Leu Glu Val Gly Arg Pro Glu Gly Arg

2120 2125 2130

Ala Pro Gly Pro Ala Gly Asp Ser Leu Thr Leu Glu Leu Trp Ala

2135 2140 2145

Gln Gly Val Pro Pro Ala Val Ala Ser Leu Asp Phe Ala Thr Glu

2150 2155 2160

Pro Tyr Asn Ala Ala Arg Pro Tyr Ser Val Ala Leu Leu Ser Val

2165 2170 2175

Pro Glu Ala Ala Arg Thr Glu Ala Gly Lys Pro Glu Ser Ser Thr

2180 2185 2190

Pro Thr Gly Glu Pro Gly Pro Met Ala Ser Ser Pro Glu Pro Ala

2195 2200 2205

Val Ala Lys Gly Gly Phe Leu Ser Phe Leu Glu Ala Asn Met Phe

2210 2215 2220

Ser Val Ile Ile Pro Met Cys Leu Val Leu Leu Leu Leu Ala Leu

2225 2230 2235

Ile Leu Pro Leu Leu Phe Tyr Leu Arg Lys Arg Asn Lys Thr Gly

2240 2245 2250

Lys His Asp Val Gln Val Leu Thr Ala Lys Pro Arg Asn Gly Leu

2255 2260 2265

Ala Gly Asp Thr Glu Thr Phe Arg Lys Val Glu Pro Gly Gln Ala

2270 2275 2280

Ile Pro Leu Thr Ala Val Pro Gly Gln Gly Pro Pro Pro Gly Gly

2285 2290 2295

Gln Pro Asp Pro Glu Leu Leu Gln Phe Cys Arg Thr Pro Asn Pro

2300 2305 2310

Ala Leu Lys Asn Gly Gln Tyr Trp Val

2315 2320

<210> 98

<211> 1210

<212> PRT

<213> Intelligent people

<400> 98

Met Arg Pro Ser Gly Thr Ala Gly Ala Ala Leu Leu Ala Leu Leu Ala

1 5 10 15

Ala Leu Cys Pro Ala Ser Arg Ala Leu Glu Glu Lys Lys Val Cys Gln

20 25 30

Gly Thr Ser Asn Lys Leu Thr Gln Leu Gly Thr Phe Glu Asp His Phe

35 40 45

Leu Ser Leu Gln Arg Met Phe Asn Asn Cys Glu Val Val Leu Gly Asn

50 55 60

Leu Glu Ile Thr Tyr Val Gln Arg Asn Tyr Asp Leu Ser Phe Leu Lys

65 70 75 80

Thr Ile Gln Glu Val Ala Gly Tyr Val Leu Ile Ala Leu Asn Thr Val

85 90 95

Glu Arg Ile Pro Leu Glu Asn Leu Gln Ile Ile Arg Gly Asn Met Tyr

100 105 110

Tyr Glu Asn Ser Tyr Ala Leu Ala Val Leu Ser Asn Tyr Asp Ala Asn

115 120 125

Lys Thr Gly Leu Lys Glu Leu Pro Met Arg Asn Leu Gln Glu Ile Leu

130 135 140

His Gly Ala Val Arg Phe Ser Asn Asn Pro Ala Leu Cys Asn Val Glu

145 150 155 160

Ser Ile Gln Trp Arg Asp Ile Val Ser Ser Asp Phe Leu Ser Asn Met

165 170 175

Ser Met Asp Phe Gln Asn His Leu Gly Ser Cys Gln Lys Cys Asp Pro

180 185 190

Ser Cys Pro Asn Gly Ser Cys Trp Gly Ala Gly Glu Glu Asn Cys Gln

195 200 205

Lys Leu Thr Lys Ile Ile Cys Ala Gln Gln Cys Ser Gly Arg Cys Arg

210 215 220

Gly Lys Ser Pro Ser Asp Cys Cys His Asn Gln Cys Ala Ala Gly Cys

225 230 235 240

Thr Gly Pro Arg Glu Ser Asp Cys Leu Val Cys Arg Lys Phe Arg Asp

245 250 255

Glu Ala Thr Cys Lys Asp Thr Cys Pro Pro Leu Met Leu Tyr Asn Pro

260 265 270

Thr Thr Tyr Gln Met Asp Val Asn Pro Glu Gly Lys Tyr Ser Phe Gly

275 280 285

Ala Thr Cys Val Lys Lys Cys Pro Arg Asn Tyr Val Val Thr Asp His

290 295 300

Gly Ser Cys Val Arg Ala Cys Gly Ala Asp Ser Tyr Glu Met Glu Glu

305 310 315 320

Asp Gly Val Arg Lys Cys Lys Lys Cys Glu Gly Pro Cys Arg Lys Val

325 330 335

Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp Ser Leu Ser Ile Asn

340 345 350

Ala Thr Asn Ile Lys His Phe Lys Asn Cys Thr Ser Ile Ser Gly Asp

355 360 365

Leu His Ile Leu Pro Val Ala Phe Arg Gly Asp Ser Phe Thr His Thr

370 375 380

Pro Pro Leu Asp Pro Gln Glu Leu Asp Ile Leu Lys Thr Val Lys Glu

385 390 395 400

Ile Thr Gly Phe Leu Leu Ile Gln Ala Trp Pro Glu Asn Arg Thr Asp

405 410 415

Leu His Ala Phe Glu Asn Leu Glu Ile Ile Arg Gly Arg Thr Lys Gln

420 425 430

His Gly Gln Phe Ser Leu Ala Val Val Ser Leu Asn Ile Thr Ser Leu

435 440 445

Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly Asp Val Ile Ile Ser

450 455 460

Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile Asn Trp Lys Lys Leu

465 470 475 480

Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile Ile Ser Asn Arg Gly Glu

485 490 495

Asn Ser Cys Lys Ala Thr Gly Gln Val Cys His Ala Leu Cys Ser Pro

500 505 510

Glu Gly Cys Trp Gly Pro Glu Pro Arg Asp Cys Val Ser Cys Arg Asn

515 520 525

Val Ser Arg Gly Arg Glu Cys Val Asp Lys Cys Asn Leu Leu Glu Gly

530 535 540

Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys Ile Gln Cys His Pro

545 550 555 560

Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys Thr Gly Arg Gly Pro

565 570 575

Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp Gly Pro His Cys Val

580 585 590

Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn Asn Thr Leu Val Trp

595 600 605

Lys Tyr Ala Asp Ala Gly His Val Cys His Leu Cys His Pro Asn Cys

610 615 620

Thr Tyr Gly Cys Thr Gly Pro Gly Leu Glu Gly Cys Pro Thr Asn Gly

625 630 635 640

Pro Lys Ile Pro Ser Ile Ala Thr Gly Met Val Gly Ala Leu Leu Leu

645 650 655

Leu Leu Val Val Ala Leu Gly Ile Gly Leu Phe Met Arg Arg Arg His

660 665 670

Ile Val Arg Lys Arg Thr Leu Arg Arg Leu Leu Gln Glu Arg Glu Leu

675 680 685

Val Glu Pro Leu Thr Pro Ser Gly Glu Ala Pro Asn Gln Ala Leu Leu

690 695 700

Arg Ile Leu Lys Glu Thr Glu Phe Lys Lys Ile Lys Val Leu Gly Ser

705 710 715 720

Gly Ala Phe Gly Thr Val Tyr Lys Gly Leu Trp Ile Pro Glu Gly Glu

725 730 735

Lys Val Lys Ile Pro Val Ala Ile Lys Glu Leu Arg Glu Ala Thr Ser

740 745 750

Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Ser

755 760 765

Val Asp Asn Pro His Val Cys Arg Leu Leu Gly Ile Cys Leu Thr Ser

770 775 780

Thr Val Gln Leu Ile Thr Gln Leu Met Pro Phe Gly Cys Leu Leu Asp

785 790 795 800

Tyr Val Arg Glu His Lys Asp Asn Ile Gly Ser Gln Tyr Leu Leu Asn

805 810 815

Trp Cys Val Gln Ile Ala Lys Gly Met Asn Tyr Leu Glu Asp Arg Arg

820 825 830

Leu Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Lys Thr Pro

835 840 845

Gln His Val Lys Ile Thr Asp Phe Gly Leu Ala Lys Leu Leu Gly Ala

850 855 860

Glu Glu Lys Glu Tyr His Ala Glu Gly Gly Lys Val Pro Ile Lys Trp

865 870 875 880

Met Ala Leu Glu Ser Ile Leu His Arg Ile Tyr Thr His Gln Ser Asp

885 890 895

Val Trp Ser Tyr Gly Val Thr Val Trp Glu Leu Met Thr Phe Gly Ser

900 905 910

Lys Pro Tyr Asp Gly Ile Pro Ala Ser Glu Ile Ser Ser Ile Leu Glu

915 920 925

Lys Gly Glu Arg Leu Pro Gln Pro Pro Ile Cys Thr Ile Asp Val Tyr

930 935 940

Met Ile Met Val Lys Cys Trp Met Ile Asp Ala Asp Ser Arg Pro Lys

945 950 955 960

Phe Arg Glu Leu Ile Ile Glu Phe Ser Lys Met Ala Arg Asp Pro Gln

965 970 975

Arg Tyr Leu Val Ile Gln Gly Asp Glu Arg Met His Leu Pro Ser Pro

980 985 990

Thr Asp Ser Asn Phe Tyr Arg Ala Leu Met Asp Glu Glu Asp Met Asp

995 1000 1005

Asp Val Val Asp Ala Asp Glu Tyr Leu Ile Pro Gln Gln Gly Phe

1010 1015 1020

Phe Ser Ser Pro Ser Thr Ser Arg Thr Pro Leu Leu Ser Ser Leu

1025 1030 1035

Ser Ala Thr Ser Asn Asn Ser Thr Val Ala Cys Ile Asp Arg Asn

1040 1045 1050

Gly Leu Gln Ser Cys Pro Ile Lys Glu Asp Ser Phe Leu Gln Arg

1055 1060 1065

Tyr Ser Ser Asp Pro Thr Gly Ala Leu Thr Glu Asp Ser Ile Asp

1070 1075 1080

Asp Thr Phe Leu Pro Val Pro Glu Tyr Ile Asn Gln Ser Val Pro

1085 1090 1095

Lys Arg Pro Ala Gly Ser Val Gln Asn Pro Val Tyr His Asn Gln

1100 1105 1110

Pro Leu Asn Pro Ala Pro Ser Arg Asp Pro His Tyr Gln Asp Pro

1115 1120 1125

His Ser Thr Ala Val Gly Asn Pro Glu Tyr Leu Asn Thr Val Gln

1130 1135 1140

Pro Thr Cys Val Asn Ser Thr Phe Asp Ser Pro Ala His Trp Ala

1145 1150 1155

Gln Lys Gly Ser His Gln Ile Ser Leu Asp Asn Pro Asp Tyr Gln

1160 1165 1170

Gln Asp Phe Phe Pro Lys Glu Ala Lys Pro Asn Gly Ile Phe Lys

1175 1180 1185

Gly Ser Thr Ala Glu Asn Ala Glu Tyr Leu Arg Val Ala Pro Gln

1190 1195 1200

Ser Ser Glu Phe Ile Gly Ala

1205 1210

<210> 99

<211> 556

<212> PRT

<213> Intelligent people

<400> 99

Met Pro Pro Pro Arg Leu Leu Phe Phe Leu Leu Phe Leu Thr Pro Met

1 5 10 15

Glu Val Arg Pro Glu Glu Pro Leu Val Val Lys Val Glu Glu Gly Asp

20 25 30

Asn Ala Val Leu Gln Cys Leu Lys Gly Thr Ser Asp Gly Pro Thr Gln

35 40 45

Gln Leu Thr Trp Ser Arg Glu Ser Pro Leu Lys Pro Phe Leu Lys Leu

50 55 60

Ser Leu Gly Leu Pro Gly Leu Gly Ile His Met Arg Pro Leu Ala Ile

65 70 75 80

Trp Leu Phe Ile Phe Asn Val Ser Gln Gln Met Gly Gly Phe Tyr Leu

85 90 95

Cys Gln Pro Gly Pro Pro Ser Glu Lys Ala Trp Gln Pro Gly Trp Thr

100 105 110

Val Asn Val Glu Gly Ser Gly Glu Leu Phe Arg Trp Asn Val Ser Asp

115 120 125

Leu Gly Gly Leu Gly Cys Gly Leu Lys Asn Arg Ser Ser Glu Gly Pro

130 135 140

Ser Ser Pro Ser Gly Lys Leu Met Ser Pro Lys Leu Tyr Val Trp Ala

145 150 155 160

Lys Asp Arg Pro Glu Ile Trp Glu Gly Glu Pro Pro Cys Leu Pro Pro

165 170 175

Arg Asp Ser Leu Asn Gln Ser Leu Ser Gln Asp Leu Thr Met Ala Pro

180 185 190

Gly Ser Thr Leu Trp Leu Ser Cys Gly Val Pro Pro Asp Ser Val Ser

195 200 205

Arg Gly Pro Leu Ser Trp Thr His Val His Pro Lys Gly Pro Lys Ser

210 215 220

Leu Leu Ser Leu Glu Leu Lys Asp Asp Arg Pro Ala Arg Asp Met Trp

225 230 235 240

Val Met Glu Thr Gly Leu Leu Leu Pro Arg Ala Thr Ala Gln Asp Ala

245 250 255

Gly Lys Tyr Tyr Cys His Arg Gly Asn Leu Thr Met Ser Phe His Leu

260 265 270

Glu Ile Thr Ala Arg Pro Val Leu Trp His Trp Leu Leu Arg Thr Gly

275 280 285

Gly Trp Lys Val Ser Ala Val Thr Leu Ala Tyr Leu Ile Phe Cys Leu

290 295 300

Cys Ser Leu Val Gly Ile Leu His Leu Gln Arg Ala Leu Val Leu Arg

305 310 315 320

Arg Lys Arg Lys Arg Met Thr Asp Pro Thr Arg Arg Phe Phe Lys Val

325 330 335

Thr Pro Pro Pro Gly Ser Gly Pro Gln Asn Gln Tyr Gly Asn Val Leu

340 345 350

Ser Leu Pro Thr Pro Thr Ser Gly Leu Gly Arg Ala Gln Arg Trp Ala

355 360 365

Ala Gly Leu Gly Gly Thr Ala Pro Ser Tyr Gly Asn Pro Ser Ser Asp

370 375 380

Val Gln Ala Asp Gly Ala Leu Gly Ser Arg Ser Pro Pro Gly Val Gly

385 390 395 400

Pro Glu Glu Glu Glu Gly Glu Gly Tyr Glu Glu Pro Asp Ser Glu Glu

405 410 415

Asp Ser Glu Phe Tyr Glu Asn Asp Ser Asn Leu Gly Gln Asp Gln Leu

420 425 430

Ser Gln Asp Gly Ser Gly Tyr Glu Asn Pro Glu Asp Glu Pro Leu Gly

435 440 445

Pro Glu Asp Glu Asp Ser Phe Ser Asn Ala Glu Ser Tyr Glu Asn Glu

450 455 460

Asp Glu Glu Leu Thr Gln Pro Val Ala Arg Thr Met Asp Phe Leu Ser

465 470 475 480

Pro His Gly Ser Ala Trp Asp Pro Ser Arg Glu Ala Thr Ser Leu Gly

485 490 495

Ser Gln Ser Tyr Glu Asp Met Arg Gly Ile Leu Tyr Ala Ala Pro Gln

500 505 510

Leu Arg Ser Ile Arg Gly Gln Pro Gly Pro Asn His Glu Glu Asp Ala

515 520 525

Asp Ser Tyr Glu Asn Met Asp Asn Pro Asp Gly Pro Asp Pro Ala Trp

530 535 540

Gly Gly Gly Gly Arg Met Gly Thr Trp Ser Thr Arg

545 550 555

<210> 100

<211> 297

<212> PRT

<213> Intelligent people

<400> 100

Met Thr Thr Pro Arg Asn Ser Val Asn Gly Thr Phe Pro Ala Glu Pro

1 5 10 15

Met Lys Gly Pro Ile Ala Met Gln Ser Gly Pro Lys Pro Leu Phe Arg

20 25 30

Arg Met Ser Ser Leu Val Gly Pro Thr Gln Ser Phe Phe Met Arg Glu

35 40 45

Ser Lys Thr Leu Gly Ala Val Gln Ile Met Asn Gly Leu Phe His Ile

50 55 60

Ala Leu Gly Gly Leu Leu Met Ile Pro Ala Gly Ile Tyr Ala Pro Ile

65 70 75 80

Cys Val Thr Val Trp Tyr Pro Leu Trp Gly Gly Ile Met Tyr Ile Ile

85 90 95

Ser Gly Ser Leu Leu Ala Ala Thr Glu Lys Asn Ser Arg Lys Cys Leu

100 105 110

Val Lys Gly Lys Met Ile Met Asn Ser Leu Ser Leu Phe Ala Ala Ile

115 120 125

Ser Gly Met Ile Leu Ser Ile Met Asp Ile Leu Asn Ile Lys Ile Ser

130 135 140

His Phe Leu Lys Met Glu Ser Leu Asn Phe Ile Arg Ala His Thr Pro

145 150 155 160

Tyr Ile Asn Ile Tyr Asn Cys Glu Pro Ala Asn Pro Ser Glu Lys Asn

165 170 175

Ser Pro Ser Thr Gln Tyr Cys Tyr Ser Ile Gln Ser Leu Phe Leu Gly

180 185 190

Ile Leu Ser Val Met Leu Ile Phe Ala Phe Phe Gln Glu Leu Val Ile

195 200 205

Ala Gly Ile Val Glu Asn Glu Trp Lys Arg Thr Cys Ser Arg Pro Lys

210 215 220

Ser Asn Ile Val Leu Leu Ser Ala Glu Glu Lys Lys Glu Gln Thr Ile

225 230 235 240

Glu Ile Lys Glu Glu Val Val Gly Leu Thr Glu Thr Ser Ser Gln Pro

245 250 255

Lys Asn Glu Glu Asp Ile Glu Ile Ile Pro Ile Gln Glu Glu Glu Glu

260 265 270

Glu Glu Thr Glu Thr Asn Phe Pro Glu Pro Pro Gln Asp Gln Glu Ser

275 280 285

Ser Pro Ile Glu Asn Asp Ser Ser Pro

290 295

<210> 101

<211> 364

<212> PRT

<213> Intelligent people

<400> 101

Met Pro Leu Leu Leu Leu Leu Pro Leu Leu Trp Ala Gly Ala Leu Ala

1 5 10 15

Met Asp Pro Asn Phe Trp Leu Gln Val Gln Glu Ser Val Thr Val Gln

20 25 30

Glu Gly Leu Cys Val Leu Val Pro Cys Thr Phe Phe His Pro Ile Pro

35 40 45

Tyr Tyr Asp Lys Asn Ser Pro Val His Gly Tyr Trp Phe Arg Glu Gly

50 55 60

Ala Ile Ile Ser Arg Asp Ser Pro Val Ala Thr Asn Lys Leu Asp Gln

65 70 75 80

Glu Val Gln Glu Glu Thr Gln Gly Arg Phe Arg Leu Leu Gly Asp Pro

85 90 95

Ser Arg Asn Asn Cys Ser Leu Ser Ile Val Asp Ala Arg Arg Arg Asp

100 105 110

Asn Gly Ser Tyr Phe Phe Arg Met Glu Arg Gly Ser Thr Lys Tyr Ser

115 120 125

Tyr Lys Ser Pro Gln Leu Ser Val His Val Thr Asp Leu Thr His Arg

130 135 140

Pro Lys Ile Leu Ile Pro Gly Thr Leu Glu Pro Gly His Ser Lys Asn

145 150 155 160

Leu Thr Cys Ser Val Ser Trp Ala Cys Glu Gln Gly Thr Pro Pro Ile

165 170 175

Phe Ser Trp Leu Ser Ala Ala Pro Thr Ser Leu Gly Pro Arg Thr Thr

180 185 190

His Ser Ser Val Leu Ile Ile Thr Pro Arg Pro Gln Asp His Gly Thr

195 200 205

Asn Leu Thr Cys Gln Val Lys Phe Ala Gly Ala Gly Val Thr Thr Glu

210 215 220

Arg Thr Ile Gln Leu Asn Val Thr Tyr Val Pro Gln Asn Pro Thr Thr

225 230 235 240

Gly Ile Phe Pro Gly Asp Gly Ser Gly Lys Gln Glu Thr Arg Ala Gly

245 250 255

Val Val His Gly Ala Ile Gly Gly Ala Gly Val Thr Ala Leu Leu Ala

260 265 270

Leu Cys Leu Cys Leu Ile Phe Phe Ile Val Lys Thr His Arg Arg Lys

275 280 285

Ala Ala Arg Thr Ala Val Gly Arg Asn Asp Thr His Pro Thr Thr Gly

290 295 300

Ser Ala Ser Pro Lys His Gln Lys Lys Ser Lys Leu His Gly Pro Thr

305 310 315 320

Glu Thr Ser Ser Cys Ser Gly Ala Ala Pro Thr Val Glu Met Asp Glu

325 330 335

Glu Leu His Tyr Ala Ser Leu Asn Phe His Gly Met Asn Pro Ser Lys

340 345 350

Asp Thr Ser Thr Glu Tyr Ser Glu Val Arg Thr Gln

355 360

<210> 102

<211> 1245

<212> PRT

<213> Intelligent people

<400> 102

Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu

1 5 10 15

Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys

20 25 30

Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His

35 40 45

Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr

50 55 60

Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val

65 70 75 80

Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu

85 90 95

Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr

100 105 110

Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro

115 120 125

Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser

130 135 140

Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln

145 150 155 160

Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn

165 170 175

Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys

180 185 190

His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser

195 200 205

Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys

210 215 220

Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys

225 230 235 240

Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu

245 250 255

His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val

260 265 270

Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg

275 280 285

Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu

290 295 300

Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln

305 310 315 320

Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys

325 330 335

Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu

340 345 350

Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys

355 360 365

Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp

370 375 380

Pro Ala Ser Asn Thr Ala Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu

385 390 395 400

Tyr Ile Ser Ala Trp Pro Asp Ser Leu Pro Asp Leu Ser Val Phe Gln

405 410 415

Asn Leu Gln Val Ile Arg Gly Arg Ile Leu His Asn Gly Ala Tyr Ser

420 425 430

Leu Thr Leu Gln Gly Leu Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu

435 440 445

Arg Glu Leu Gly Ser Gly Leu Ala Leu Ile His His Asn Thr His Leu

450 455 460

Cys Phe Val His Thr Val Pro Trp Asp Gln Leu Phe Arg Asn Pro His

465 470 475 480

Gln Ala Leu Leu His Thr Ala Asn Arg Pro Glu Asp Glu Cys Val Gly

485 490 495

Glu Gly Leu Ala Cys His Gln Leu Cys Ala Arg Gly His Cys Trp Gly

500 505 510

Pro Gly Pro Thr Gln Cys Val Asn Cys Ser Gln Phe Leu Arg Gly Gln

515 520 525

Glu Cys Val Glu Glu Cys Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr

530 535 540

Val Asn Ala Arg His Cys Leu Pro Cys His Pro Glu Cys Gln Pro Gln

545 550 555 560

Asn Gly Ser Val Thr Cys Phe Gly Pro Glu Ala Asp Gln Cys Val Ala

565 570 575

Cys Ala His Tyr Lys Asp Pro Pro Phe Cys Val Ala Arg Cys Pro Ser

580 585 590

Gly Val Lys Pro Asp Leu Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp

595 600 605

Glu Glu Gly Ala Cys Gln Pro Cys Pro Ile Asn Cys Thr His Ser Cys

610 615 620

Val Asp Leu Asp Asp Lys Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro

625 630 635 640

Leu Thr Ser Ile Ile Ser Ala Val Val Gly Ile Leu Leu Val Val Val

645 650 655

Leu Gly Val Val Phe Gly Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile

660 665 670

Arg Lys Tyr Thr Met Arg Arg Leu Leu Gln Glu Thr Glu Leu Val Glu

675 680 685

Pro Leu Thr Pro Ser Gly Ala Met Pro Asn Gln Ala Gln Met Arg Ile

690 695 700

Leu Lys Glu Thr Glu Leu Arg Lys Val Lys Val Leu Gly Ser Gly Ala

705 710 715 720

Phe Gly Thr Val Tyr Lys Gly Ile Trp Ile Pro Asp Gly Glu Asn Val

725 730 735

Lys Ile Pro Val Ala Ile Lys Val Leu Arg Glu Asn Thr Ser Pro Lys

740 745 750

Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Gly Val Gly

755 760 765

Ser Pro Tyr Val Ser Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val

770 775 780

Gln Leu Val Thr Gln Leu Met Pro Tyr Gly Cys Leu Leu Asp His Val

785 790 795 800

Arg Glu Asn Arg Gly Arg Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys

805 810 815

Met Gln Ile Ala Lys Gly Met Ser Tyr Leu Glu Asp Val Arg Leu Val

820 825 830

His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Lys Ser Pro Asn His

835 840 845

Val Lys Ile Thr Asp Phe Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu

850 855 860

Thr Glu Tyr His Ala Asp Gly Gly Lys Val Pro Ile Lys Trp Met Ala

865 870 875 880

Leu Glu Ser Ile Leu Arg Arg Arg Phe Thr His Gln Ser Asp Val Trp

885 890 895

Ser Tyr Gly Val Thr Val Trp Glu Leu Met Thr Phe Gly Ala Lys Pro

900 905 910

Tyr Asp Gly Ile Pro Ala Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly

915 920 925

Glu Arg Leu Pro Gln Pro Pro Ile Cys Thr Ile Asp Val Tyr Met Ile

930 935 940

Met Val Lys Cys Trp Met Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg

945 950 955 960

Glu Leu Val Ser Glu Phe Ser Arg Met Ala Arg Asp Pro Gln Arg Phe

965 970 975

Val Val Ile Gln Asn Glu Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser

980 985 990

Thr Phe Tyr Arg Ser Leu Leu Glu Asp Asp Asp Met Gly Asp Leu Val

995 1000 1005

Asp Ala Glu Glu Tyr Leu Val Pro Gln Gln Gly Phe Phe Cys Pro

1010 1015 1020

Asp Pro Ala Pro Gly Ala Gly Gly Met Val His His Arg His Arg

1025 1030 1035

Ser Ser Ser Thr Arg Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu

1040 1045 1050

Glu Pro Ser Glu Glu Glu Ala Pro Arg Ser Pro Leu Ala Pro Ser

1055 1060 1065

Glu Gly Ala Gly Ser Asp Val Phe Asp Gly Asp Leu Gly Met Gly

1070 1075 1080

Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His Asp Pro Ser Pro

1085 1090 1095

Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu Pro Ser Glu

1100 1105 1110

Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln Pro Glu

1115 1120 1125

Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro Arg

1130 1135 1140

Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu

1145 1150 1155

Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp

1160 1165 1170

Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr

1175 1180 1185

Pro Gln Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe

1190 1195 1200

Ser Pro Ala Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro

1205 1210 1215

Glu Arg Gly Ala Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala

1220 1225 1230

Glu Asn Pro Glu Tyr Leu Gly Leu Asp Val Pro Val

1235 1240 1245

<210> 103

<211> 163

<212> PRT

<213> Intelligent people

<400> 103

Leu Gln Asp Pro Cys Ser Asn Cys Pro Ala Gly Thr Phe Cys Asp Asn

1 5 10 15

Asn Arg Asn Gln Ile Cys Ser Pro Cys Pro Pro Asn Ser Phe Ser Ser

20 25 30

Ala Gly Gly Gln Arg Thr Cys Asp Ile Cys Arg Gln Cys Lys Gly Val

35 40 45

Phe Arg Thr Arg Lys Glu Cys Ser Ser Thr Ser Asn Ala Glu Cys Asp

50 55 60

Cys Thr Pro Gly Phe His Cys Leu Gly Ala Gly Cys Ser Met Cys Glu

65 70 75 80

Gln Asp Cys Lys Gln Gly Gln Glu Leu Thr Lys Lys Gly Cys Lys Asp

85 90 95

Cys Cys Phe Gly Thr Phe Asn Asp Gln Lys Arg Gly Ile Cys Arg Pro

100 105 110

Trp Thr Asn Cys Ser Leu Asp Gly Lys Ser Val Leu Val Asn Gly Thr

115 120 125

Lys Glu Arg Asp Val Val Cys Gly Pro Ser Pro Ala Asp Leu Ser Pro

130 135 140

Gly Ala Ser Ser Val Thr Pro Pro Ala Pro Ala Arg Glu Pro Gly His

145 150 155 160

Ser Pro Gln

<210> 104

<211> 163

<212> PRT

<213> cynomolgus monkey

<400> 104

Leu Gln Asp Leu Cys Ser Asn Cys Pro Ala Gly Thr Phe Cys Asp Asn

1 5 10 15

Asn Arg Ser Gln Ile Cys Ser Pro Cys Pro Pro Asn Ser Phe Ser Ser

20 25 30

Ala Gly Gly Gln Arg Thr Cys Asp Ile Cys Arg Gln Cys Lys Gly Val

35 40 45

Phe Lys Thr Arg Lys Glu Cys Ser Ser Thr Ser Asn Ala Glu Cys Asp

50 55 60

Cys Ile Ser Gly Tyr His Cys Leu Gly Ala Glu Cys Ser Met Cys Glu

65 70 75 80

Gln Asp Cys Lys Gln Gly Gln Glu Leu Thr Lys Lys Gly Cys Lys Asp

85 90 95

Cys Cys Phe Gly Thr Phe Asn Asp Gln Lys Arg Gly Ile Cys Arg Pro

100 105 110

Trp Thr Asn Cys Ser Leu Asp Gly Lys Ser Val Leu Val Asn Gly Thr

115 120 125

Lys Glu Arg Asp Val Val Cys Gly Pro Ser Pro Ala Asp Leu Ser Pro

130 135 140

Gly Ala Ser Ser Ala Thr Pro Pro Ala Pro Ala Arg Glu Pro Gly His

145 150 155 160

Ser Pro Gln

<210> 105

<211> 164

<212> PRT

<213> mouse

<400> 105

Val Gln Asn Ser Cys Asp Asn Cys Gln Pro Gly Thr Phe Cys Arg Lys

1 5 10 15

Tyr Asn Pro Val Cys Lys Ser Cys Pro Pro Ser Thr Phe Ser Ser Ile

20 25 30

Gly Gly Gln Pro Asn Cys Asn Ile Cys Arg Val Cys Ala Gly Tyr Phe

35 40 45

Arg Phe Lys Lys Phe Cys Ser Ser Thr His Asn Ala Glu Cys Glu Cys

50 55 60

Ile Glu Gly Phe His Cys Leu Gly Pro Gln Cys Thr Arg Cys Glu Lys

65 70 75 80

Asp Cys Arg Pro Gly Gln Glu Leu Thr Lys Gln Gly Cys Lys Thr Cys

85 90 95

Ser Leu Gly Thr Phe Asn Asp Gln Asn Gly Thr Gly Val Cys Arg Pro

100 105 110

Trp Thr Asn Cys Ser Leu Asp Gly Arg Ser Val Leu Lys Thr Gly Thr

115 120 125

Thr Glu Lys Asp Val Val Cys Gly Pro Pro Val Val Ser Phe Ser Pro

130 135 140

Ser Thr Thr Ile Ser Val Thr Pro Glu Gly Gly Pro Gly Gly His Ser

145 150 155 160

Leu Gln Val Leu

<210> 106

<211> 152

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 32

<400> 106

Ala Ser Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys

1 5 10 15

Ala Met Thr Val Asp Glu Gly Cys Arg Pro Trp Asn Ile Phe Ser Val

20 25 30

Thr Pro Met Thr Leu Thr Thr Leu Glu Gly Gly Asn Leu Glu Ala Lys

35 40 45

Val Thr Met Ala Ile Asp Gly Pro Ala Gln Glu Val Lys Ala Val Leu

50 55 60

Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly Gly Lys His

65 70 75 80

Val Ala Tyr Ile Ile Arg Ser His Val Lys Asp His Tyr Ile Phe Tyr

85 90 95

Ser Glu Gly Val Cys Asp Gly Ser Pro Val Pro Gly Val Trp Leu Val

100 105 110

Gly Arg Asp Pro Lys Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys

115 120 125

Ala Ala Gly Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Arg

130 135 140

Gln Ser Glu Thr Ser Ser Pro Gly

145 150

<210> 107

<211> 152

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 33

<400> 107

Thr Ser Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys

1 5 10 15

Ala Met Thr Val Asp Glu Gly Cys Arg Pro Trp Asn Ile Phe Ser Val

20 25 30

Thr Pro Met Thr Leu Thr Thr Leu Glu Gly Gly Asn Leu Glu Ala Lys

35 40 45

Val Thr Met Ala Ile Asp Gly Pro Ala Gln Glu Val Arg Ala Val Leu

50 55 60

Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly Gly Lys His

65 70 75 80

Asp Ala Tyr Ile Ile Arg Ser His Val Lys Asp His Tyr Ile Phe Tyr

85 90 95

Ser Glu Gly Val Cys Asp Gly Ser Pro Val Pro Gly Val Trp Leu Val

100 105 110

Gly Arg Asp Pro Glu Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys

115 120 125

Thr Ala Gly Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Arg

130 135 140

Gln Ser Glu Thr Ser Ser Pro Gly

145 150

<210> 108

<211> 152

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 34

<400> 108

Ala Ser Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys

1 5 10 15

Ala Met Thr Val Asp Glu Gly Cys Arg Pro Trp Asn Ile Phe Ser Val

20 25 30

Thr Pro Met Thr Leu Thr Thr Leu Glu Gly Gly Asn Leu Glu Ala Lys

35 40 45

Val Thr Met Ala Ile Asp Gly Pro Ala Gln Glu Val Asn Ala Val Leu

50 55 60

Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly Gly Lys His

65 70 75 80

Val Ala Tyr Ile Ile Arg Ser His Val Arg Asp His Tyr Ile Phe Tyr

85 90 95

Ser Glu Gly Val Cys Asp Gly Ser Pro Val Pro Gly Val Trp Leu Val

100 105 110

Gly Arg Asp Pro Glu Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys

115 120 125

Thr Ala Gly Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Arg

130 135 140

Gln Ser Glu Thr Ser Ser Pro Gly

145 150

<210> 109

<211> 152

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 35

<400> 109

Val Ser Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys

1 5 10 15

Ala Met Thr Val Asp Glu Gly Cys Arg Pro Trp Asn Ile Phe Ser Val

20 25 30

Thr Pro Met Thr Leu Thr Thr Leu Glu Gly Gly Asn Leu Glu Ala Lys

35 40 45

Val Thr Met Ala Ile Asp Gly Pro Ala Gln Glu Val Arg Ala Val Leu

50 55 60

Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly Gly Lys His

65 70 75 80

Val Ala Tyr Ile Ile Arg Ser His Val Glu Asp His Tyr Ile Phe Tyr

85 90 95

Ser Glu Gly Val Cys Asp Gly Ser Pro Val Pro Gly Val Trp Leu Val

100 105 110

Gly Arg Asp Pro Glu Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys

115 120 125

Thr Ala Gly Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Arg

130 135 140

Gln Ser Glu Thr Ser Ser Pro Gly

145 150

<210> 110

<211> 152

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 36

<400> 110

Ala Ser Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys

1 5 10 15

Ala Met Thr Val Asp Glu Gly Cys Arg Pro Trp Asn Ile Phe Ser Val

20 25 30

Thr Pro Met Thr Leu Ser Thr Leu Glu Gly Gly Asn Leu Glu Ala Lys

35 40 45

Val Thr Met Ala Ile Asp Gly Pro Ala Gln Glu Val Lys Ala Val Leu

50 55 60

Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly Gly Lys His

65 70 75 80

Val Ala Tyr Ile Ile Arg Ser His Val Lys Asp His Tyr Ile Phe Tyr

85 90 95

Ser Glu Gly Val Cys Asp Gly Ser Pro Val Pro Gly Val Trp Leu Val

100 105 110

Gly Arg Asp Pro Lys Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys

115 120 125

Ala Ala Gly Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Arg

130 135 140

Gln Ile Glu Thr Ser Ser Pro Gly

145 150

<210> 111

<211> 152

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 37

<400> 111

Ala Ser Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys

1 5 10 15

Ala Met Thr Val Asp Glu Gly Cys Arg Pro Trp Asn Ile Phe Ser Val

20 25 30

Thr Pro Met Thr Leu Thr Thr Leu Glu Gly Gly Asn Leu Glu Ala Glu

35 40 45

Val Thr Met Ala Ile Asp Gly Pro Ala Gln Glu Val Lys Ala Val Leu

50 55 60

Glu Lys Ala Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly Gly Lys His

65 70 75 80

Val Ala Tyr Ile Ile Arg Ser His Val Lys Asp His Tyr Ile Phe Tyr

85 90 95

Ser Glu Gly Val Cys Asp Gly Ser Pro Val Pro Gly Val Trp Leu Val

100 105 110

Gly Arg Asp Pro Lys Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys

115 120 125

Thr Ala Gly Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Ser

130 135 140

Gln Ile Glu Thr Ser Ser Pro Gly

145 150

<210> 112

<211> 152

<212> PRT

<213> Artificial sequence

<220>

<223> Lipocalin mutein variant 38

<400> 112

Thr Ser Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys

1 5 10 15

Ala Met Thr Val Asp Glu Gly Cys Arg Pro Trp Asn Ile Phe Ser Val

20 25 30

Thr Pro Met Thr Leu Thr Thr Leu Glu Asp Gly Asn Leu Glu Ala Lys

35 40 45

Val Thr Met Ala Ile Asp Gly Pro Ala Gln Glu Val Lys Ala Val Leu

50 55 60

Glu Lys Ala Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly Gly Lys His

65 70 75 80

Val Ala Tyr Ile Ile Arg Ser His Val Lys Asp His Tyr Ile Phe Tyr

85 90 95

Ser Glu Gly Val Cys Asp Gly Ser Pro Val Pro Gly Val Trp Leu Val

100 105 110

Gly Arg Asp Pro Lys Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys

115 120 125

Ala Ala Gly Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Arg

130 135 140

Gln Ile Glu Thr Ser Ser Pro Gly

145 150

<210> 113

<211> 16

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 113

Pro Ser Thr Pro Pro Thr Asn Ser Ser Ser Thr Ile Pro Thr Pro Ser

1 5 10 15

<210> 114

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 114

Gly Gly Ser Gly Asn Ser Ser Gly Ser Gly Gly Ser Pro Val

1 5 10

<210> 115

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 115

Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro

1 5 10 15

Ala

<210> 116

<211> 66

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 116

Ala Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Pro Val Pro Ser

1 5 10 15

Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser

20 25 30

Gly Gly Ser Gly Asn Ser Ser Gly Ser Gly Gly Ser Pro Val Pro Ser

35 40 45

Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser

50 55 60

Ala Ser

65

<210> 117

<211> 32

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 117

Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr Pro Ser

1 5 10 15

Pro Ser Gly Gly Ser Gly Asn Ser Ser Gly Ser Gly Gly Ser Pro Val

20 25 30

<210> 118

<211> 74

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 118

Ala Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Pro Val Pro Ser

1 5 10 15

Thr Pro Pro Thr Asn Ser Ser Ser Thr Pro Pro Thr Pro Ser Pro Ser

20 25 30

Pro Val Pro Ser Thr Pro Pro Thr Asn Ser Ser Ser Thr Pro Pro Thr

35 40 45

Pro Ser Pro Ser Pro Val Pro Ser Thr Pro Pro Thr Asn Ser Ser Ser

50 55 60

Thr Pro Pro Thr Pro Ser Pro Ser Ala Ser

65 70

<210> 119

<211> 40

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 119

Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro

1 5 10 15

Ser Ala Pro Ala Ala Ser Pro Ala Ala Pro Ala Pro Ala Ser Pro Ala

20 25 30

Ala Pro Ala Pro Ser Ala Pro Ala

35 40

<210> 120

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 120

Val Asp Asp Ile Glu Gly Arg Met Asp Glu

1 5 10

<210> 121

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<400> 121

Glu Asn Leu Tyr Phe Gln Gly Arg Met Asp Glu

1 5 10

<210> 122

<211> 330

<212> PRT

<213> Intelligent people

<400> 122

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys

1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys

100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro

115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys

130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp

145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu

165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu

180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn

195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu

225 230 235 240

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn

290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr

305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

325 330

<210> 123

<211> 330

<212> PRT

<213> Intelligent people

<400> 123

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys

1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys

100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro

115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys

130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp

145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu

165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu

180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn

195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu

225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn

290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr

305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

325 330

<210> 124

<211> 326

<212> PRT

<213> Intelligent people

<400> 124

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg

1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr

65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro

100 105 110

Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp

115 120 125

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp

130 135 140

Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly

145 150 155 160

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn

165 170 175

Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp

180 185 190

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro

195 200 205

Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu

210 215 220

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn

225 230 235 240

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile

245 250 255

Ser Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr

260 265 270

Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys

275 280 285

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys

290 295 300

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu

305 310 315 320

Ser Leu Ser Pro Gly Lys

325

<210> 125

<211> 377

<212> PRT

<213> Intelligent people

<400> 125

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg

1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

65 70 75 80

Tyr Thr Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Arg Val Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro

100 105 110

Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg

115 120 125

Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys

130 135 140

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro

145 150 155 160

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys

165 170 175

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val

180 185 190

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Lys Trp Tyr

195 200 205

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

210 215 220

Gln Tyr Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu His

225 230 235 240

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys

245 250 255

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln

260 265 270

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met

275 280 285

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro

290 295 300

Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gln Pro Glu Asn Asn

305 310 315 320

Tyr Asn Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu

325 330 335

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Ile

340 345 350

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln

355 360 365

Lys Ser Leu Ser Leu Ser Pro Gly Lys

370 375

<210> 126

<211> 327

<212> PRT

<213> Intelligent people

<400> 126

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg

1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr

65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro

100 105 110

Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys

115 120 125

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val

130 135 140

Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp

145 150 155 160

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe

165 170 175

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp

180 185 190

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu

195 200 205

Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg

210 215 220

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys

225 230 235 240

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp

245 250 255

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys

260 265 270

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser

275 280 285

Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser

290 295 300

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser

305 310 315 320

Leu Ser Leu Ser Leu Gly Lys

325

<210> 127

<211> 327

<212> PRT

<213> Artificial sequence

<220>

<223> Fc huIgG4 SP

<400> 127

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg

1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr

65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro

100 105 110

Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys

115 120 125

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val

130 135 140

Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp

145 150 155 160

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe

165 170 175

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp

180 185 190

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu

195 200 205

Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg

210 215 220

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys

225 230 235 240

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp

245 250 255

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys

260 265 270

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser

275 280 285

Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser

290 295 300

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser

305 310 315 320

Leu Ser Leu Ser Leu Gly Lys

325

<210> 128

<211> 226

<212> PRT

<213> Artificial sequence

<220>

<223> Fc well hu IgG1

<400> 128

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly

225

<210> 129

<211> 226

<212> PRT

<213> Artificial sequence

<220>

<223> Fc protuberant hu IgG1

<400> 129

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly

225